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Abstract
Activation of extracellular signal-regulated protein kinases (ERK1&2) has 
emerged as a key signalling event in the modulation of presynaptic plasticity by 
neurotrophic factors. In this study, we investigated the cross-talk between presynaptic 
signalling pathways activating PKA or PKC and ERK signalling, underlying the 
modulation of neurotransmitter release. Purified, isolated cerebrocortical nerve 
terminals and phosphorylation state-specific antibodies were used to carry out this 
research. Stimulation of PKA by cAMP, produced in response to p-adrenoreceptor 
activation by isoproterenol, or direct stimulation of adenylyl cyclase by forskolin, 
resulted in a substantial increase in ERK phosphorylation/activity. Similarly, 
stimulation of PKC, by PDBu, also led to stimulation of ERK phosphorylation/activity. 
Metabotropic glutamate receptor activation by the Group I agonist DHPG, however, led
^ I
to ERK 1,2 phosphorylation which showed a Ca -dependency, though the role of PKC 
was less clearly defined. A key effector molecule for the regulation of neurotransmitter 
release by ERK activation is the small synaptic vesicle (SSV) protein synapsin I, which, 
through alteration in its phosphorylation-state, modulates SSV-actin cytoskeleton 
interactions and thereby controls the distribution of SSVs between release pools. 
Accordingly, with both PKA and PKC activation of ERKs, the downstream stimulation 
of synapsin phosphorylation at specific ERK-dependent sites was also detected. These 
results suggest that, together with the established roles of PKA and PKC acting on ion- 
channel targets to modulate of presynaptic excitability and/or voltage-dependent Ca- 
entry, downstream of these loci, the two kinase cascades may converge at the level of 
SSV mobilization to regulate the efficacy of glutamate release from cerebrocortical 
nerve terminals.
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Chapter 1
Introduction
1. Introduction
It was Ramon Y Cajal, in the early part of the twentieth century, who discovered that 
brain cells, or neurones, form junctions with each other. He observed that the junctions 
seemed to consist of three parts: the presynaptic terminal, the synaptic cleft (the space 
in-between), and the postsynaptic terminal. These junctions, or synapses, are now 
known to be crucial for regulating communication between neurones and for 
modulation of responses. Depolarising action potentials travel from the main body of
^  I
the cell to the presynaptic nerve terminal where they activate voltage-dependent Ca 
channels (VDCCs). The VDCCs are localised to membrane regions known as active
^  I
zones where they can result in an increase in local Ca concentration by up to as much 
as lOOpM through the N-, P/Q- and R-type channels (Dunlap et al., 1995; Wu et al., 
1998; Wu et al., 1999). This dramatic increase in the Ca levels can stimulate the 
release of neurotransmitter from the active zone by way of exocytosis (or emptying) of 
synaptic vesicles into the synaptic cleft (Heidelberger et al,, 1994). The 
neurotransmitter can then cross the cleft to act on receptors of the postsynaptic terminal 
in order to elicit all or nothing ionotropic responses, or modulatory metabotropic 
responses, from the neighbouring dendrite. The transmitter can also act on presynaptic 
receptors where it may have a modulatory role over further neurotransmitter release 
(Sanchez-Prieto et al., 1996).
A diverse array of signalling molecules can be released from cells to convey messages 
from one area to another, ranging from amino acids, to catecholamines, to fatty acids, to 
hormones. In the brain, the main excitatory neurotransmitter is the amino acid 
glutamate (Orrego and Villanueva, 1993). This thesis is concerned with the elucidation 
of the regulation/activation of extracellular-signal regulated protein kinases 1/2 
(ERK 1/2) phosphorylation, and their involvement in glutamatergic synaptic 
transmission. Accordingly, the subsequent focus of this introduction will be confined to 
glutamatergic neurotransmission, its regulation, and the cross-talk of kinase-mediated 
signalling pathways. Notwithstanding, glutamate release from nerve terminals can be 
regulated, through presynaptic receptors, by other neurotransmitters, such as 
noradrenaline and y-aniinobutyric acid (GABA), these aspects being discussed further in 
section 1.4.
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1.1 Glutamate Release
There are currently believed to be four stages involved in the exocytosis/endocytosis 
pathway that constitute neurotransmitter release. These stages follow the filling of the 
small synaptic vesicle with neurotransmitter and translocation to the active zone, the 
specialised area of the nerve terminal where transmitter release takes place (Landis, 
1988). The four stages are: docking of the synaptic vesicle to the release plasma 
membrane; priming of the vesicle; fusion of the vesicle with the release plasma 
membrane (including exocytosis); and, finally, recycling of the vesicle (endocytosis) 
(Brunger, 2000). Each stage in this cycle requires a great many proteins, which have 
specific, but sometimes overlapping, roles. Massive progress has recently been made in 
this field so that it is now possible to identify most of the proteins associated with 
vesicles, and to put forward hypotheses as to their potential involvements in release 
(Augustine, 2001). Central to the process are proteins known as SNAREs (soluble N- 
ethylmaleimide-sensitive factor [NSF]-attachment protein receptors), which are resident 
on the synaptic vesicle membrane (vesicular v-SNAREs) and plasma membrane (target 
t-SNAREs), and mediate the basic interaction between the two compartments (Sollner, 
1995). The docking process is thought to initiate when nSecl (also known as M uncl8) 
dissociates from the plasma membrane bound t-SNARE, syntaxin (Pevsner et al., 1994). 
This dissociation has been shown to involve another protein, known as Munc-13 (mouse 
homologue of the c. elegans protein Uncoordinated-13), which is thought to either 
directly displace nSecl, or to induce a conformational change in the syntaxin/nSecl 
complex leading to the dissociation of nSecl (Sassa et al., 1999; Brose et al., 2000; 
Misura et al., 2000). This effects a switch in the primary conformation of syntaxin, 
from a ‘closed’ state bound to nSecl (Dulubova et al., 1999), to an ‘open’ state enabling 
it to then bind to a partner t-SNARE, SNAP-25 (synaptosome-associated protein of 
25kDa). This interaction of syntaxin and SNAP-25 is known as the binary 
conformation of SNAREs (Fasshauer et al., 1997a). The interaction between syntaxin 
and SNAP-25 has recently been reported to be the slow, rate-limiting step in SNARE 
formation (Fasshauer, 2003). The ternary conformation of SNAREs occurs when the v- 
SNARE, synaptobrevin (also known as vesicle-associated membrane protein, or 
VAMP) binds to the binary conformation of syntaxin and SNAP-25 (Otto et al., 1997; 
Fasshauer, 2003). This is thought to result in the formation of four, tight, a-helices in a
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parallel arrangement (Fasshauer et al., 1997b; Pointer et al., 1998) which bring the 
synaptic vesicle within close proximity of the plasma membrane in a so called ‘zipper 
model’ of exocytosis (Hanson et al., 1997). The association of the three SNARE 
proteins is the docking phase of neurotransmitter release, which may be reversible to 
some extent. The next priming phase is where the vesicle is brought within close 
proximity of the plasma membrane in preparation for fusion and is a process that is 
putatively irreversible (Brunger, 2000). The protein Munc-13, is also believed to have a 
role central to vesicle priming, possibly through its interactions with RIM (Rab3- 
interacting molecule) (Betz et al., 2001).
The role of the SNARE proteins in the next stage of neurotransmitter release, the fusion 
of the vesicle with the plasma membrane, is the subject o f considerable debate. As, 
although SNARE complexes have been shown to form readily in vitro (Fasshauer et al., 
1997b; Sutton et al., 1998) and in vivo (Chen et al., 1999), their time course for enabling 
vesicle fusion in vitro is much slower than that in real life, probably as a result of the 
high energy barriers that need to be overcome. Other proteins are therefore believed to 
be involved at this stage of the cycle to facilitate the process, but Ca^-dependent roles 
for SNAREs are also beginning to be elucidated (Murthy and De Camilli, 2003, 
review). One protein that may well be involved in the Ca2+-dependent fusion stage of 
exocytosis is synaptotagmin. It is a vesicle-bound protein which has two cytosolic
I
domains known to interact with SNAREs (Schiavo et al., 1997), Ca channels (Brose et 
al., 1992), and proteins involved with endocytosis (Chapman et al., 1998). 
Synaptotagmin has been shown to interact with SNARE proteins such as syntaxin in the 
presence (Chapman et al., 1995) or absence of Ca2+ (Sutton et al., 1999), but binding to
a  I
lipid bilayers is greatly enhanced in the presence of Ca (Davis et al., 1999). 
Consequently, synaptotagmin has been proposed as a ‘clamp’ of ‘fusion-ready’ vesicles, 
which is released on Ca2+-influx, resulting in rapid exocytosis. Other proteins involved 
with vesicle fusion include the small G-protein, Rab3A, its effectors, rabphilin-3A and 
RIM, and its modulators, the GDP-dissociation inhibitor (GDI), and the GDI- 
displacement factor, GDF (Fischer von Mollard et al., 1990). Rab3 A is bound to GDI 
when in the cytosol, thus preventing the exchange of GDP for GTP on the molecule, but 
when Rab3 A associates with a synaptic vesicle, the GDI is replaced by GDF and GTP is 
allowed to bind and exchange for GDP (Geppert and Sudhof, 1998). The GTP-bound 
form of Rab3A can then interact with its effector proteins such as rabphilin-3 A, which
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binds to the synaptic vesicle, and RIM, which associates with the active zone of the 
plasma membrane (Stahl et al., 1996;Wang et al., 1997). RIM has also recently been 
shown to bind the novel cytomatrix at the active zone-associated protein, CAST, in 
association with the priming of vesicles (Takao-Rikitsu et al., 2004). The exact 
mechanisms by which these proteins elicit fusion and exocytosis are still not known. 
However, the rapid effect of Ca2+ on exocytosis suggests a conformational change in a 
component of the prefusion complex, rather than any indirect and likely slower, 
metabotropic effect (Murthy and De Camilli, 2003).
1.2 Endocytosis.
The final stage in the cycle on neurotransmitter release is endocytosis. The main 
proteins thought to be involved in the initial phase of this process are NSF (N- 
ethylmaleimide-sensitive factor) and a/p-SNAPs (soluble-NSF-attachment protein), all 
involved in the primary delineation and ultimately the nomenclatural definition of the 
SNAREs described above. Again, the exact mechanisms of action are not known but 
NSF, which as an ATPase binds and hydrolyses ATP, is key to providing the impetus 
necessary for SNARE dissociation (Whiteheart et al., 1994; Sumida et al., 1994). ot/p- 
SNAPs, in their association with NSF, may act to form rigid levers to help with SNARE 
dissociation (Rice and Brunger, 1999). Following this there are two main hypotheses 
relating to endocytosis, neither of which totally counter the other. One hypothesis 
revolves around slow vesicle cycling whereby the synaptic vesicle becomes totally 
incorporated with the plasma membrane before being endocytosed. This means that all 
the transmitter contained within the vesicle is released and the whole cycle can take 
about 20 seconds (Koenig and Ikeda, 1996). Endocytosis in this situation is thought to 
occur following the binding of AP2 (adaptor protein 2) to synaptotagmin (Cremona and 
De Camilli, 1997), which has recently been identified as having a crucial role in vesicle 
endocytosis, aside from its role in exocytosis (Poskanzer et al., 2003). This then allows 
clathrin triskelia to assemble into a lattice of pentagons and hexagons (Abe et al., 1999) 
with the help of interactions with membrane lipids (Martin, 1998; Corvera et al., 1999). 
The lysophosphatidic acid acyl transferase, endophilin, is believed to be crucial in this 
stage of invagination of the plasma membrane (Ringstad et al., 1999), as it recruits and 
stabilises the phosphoinositide phosphatase, synaptojanin (Song and Zinsmaier, 2003). 
Endophilin has also been found to interact with the voltage-gated calcium channels
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required for endocytosis (Chen et al., 2003). The size of the resulting clathrin coat, and 
so the synaptic vesicle, appears, at least in part, to be determined by the neuronal- 
specific protein API 80 (Zhang et al., 1998). Actin polymerisation, stimulated by 
GTPase or phosphoinositide pathways, seems to be involved in the narrowing of the 
neck region of the invagination (Merrifield et al., 1999; Gustafsson et al., 1998; 
Cremona et al., 1999), and cission seems to require the GTPase dynamin, amphiphysin, 
and endophilin (Abe et al., 1999; Ringstad et al., 1999; Graham et al., 2002; Holroyd et 
al., 2002). The second hypothesis relating to endocytosis is sometimes termed the ‘kiss 
and run’ theory, or ‘fast endocytosis’ (Koenig and Ikeda, 1996). This is where the 
synaptic vesicle does not become totally incorporated with the plasma membrane, so 
that not all neurotransmitter is released, but the whole cycle only takes about 6 seconds 
(Klingauf et al., 1998). Clathrin coating is also believed to be involved here but the 
exact mechanism remains to be elucidated (Takei et al., 1996). Also requiring 
elucidation are the signalling pathways involved in endocytosis but these have proved 
difficult to investigate due to the close coupling of endocytosis with exocytosis, 
however, calcium and the calcium-dependent phosphatase, calcineurin, are thought to 
be involved (Marks and McMahon, 1998), as well as cdk5 (Nguyen and Bibb, 2003).
1.3 Modulation of Glutamate Release
As discussed above, the processes involved in small synaptic vesicle exocytosis and 
endocytosis are highly regulated, but what about the trafficking of the synaptic vesicles 
preceding and following these events? It has been demonstrated that the distribution of 
vesicles in the presynaptic terminal is highly organised and consists of three distinct 
pools. In hippocampal neurones, the ‘ready-releasable pool’ is typically made up of 5-8 
vesicles which are already docked to the plasma membrane, and have been correlated 
with the release-ready neurotransmitter quanta (Schikorski and Stevens, 2001). 
Juxtaposed to this is the ‘reserve pool’ of 17-20 synaptic vesicles which are tethered, 
close to the active zone, by a matrix of fine filaments. The resting pool of vesicles is 
normally kept about 200nm away from the active zone by tethering to microfilaments 
by members of the synapsin family. The ‘resting pool’ typically contains 180 vesicles 
(Gamer et al., 2000; Sudhof, 2000, reviews).
From this description of glutamate release it is possible to postulate three distinct ways
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of regulating transmitter release. One would be to regulate the excitability of the 
plasma membrane, thereby affecting the VDCCs and so either decreasing or enhancing 
the fusion of vesicles to the active zone. For example protein kinase C (PKC)- 
dependent phosphorylation is able to destabilise the membrane potential by inhibiting 
K+ channels (Barrie et al., 1991). Protein kinase A (PKA) and PKC are also able to
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directly phosphorylate Ca T channels and so facilitate their opening (Dolphin, 1995; 
Shearman et al., 1989; Farago and Nishizuka, 1990). Other potential targets for 
regulation are the proteins involved in mediating exocytosis and endocytosis, such as 
the SNAREs. In the control of SNARE function, NSF has been shown to undergo a 
depolarisation-induced and Ca -dependent phosphorylation. This phosphorylation was 
believed to be mediated by PKC and to result in the inhibition of neurotransmitter 
release (Matveeva et al., 2001). The final potential target for modulation of transmitter 
release is the distribution of vesicles within the presynaptic terminal. The distribution 
could be altered either temporarily, or perhaps more permanently, as seen with some 
forms of long term potentiation (LTP) (Lynch et al., 1994). A key player in such a 
pathway could be synapsin I, one of a family of proteins involved in tethering small 
synaptic vesicles to the actin cytoskeleton in a phophorylation-dependent manner (Li et 
al., 1995; Hilfiker et al., 1998), which is known to have phosphorylation sites for 
several second messenger kinase cascades including the PKA (Huttner et al., 1981),
Ca /calmodulin-dependent protein kinases I and II (Choe and Wang, 2001b; Kennedy 
and Greengard, 1981) and extracellular signal-regulating kinases (ERK1/ERK2); also 
called p44 and p42 mitogen-activated protein (MAP) kinases (Jovanovic et al., 1996).
In fact a pathway has in part been identified involving synapsin I in the regulation of 
neurotransmitter release. Brain-derived neurotrophic factor (BDNF) has been shown to 
increase glutamate release from cerebrocortical synaptosomes (Jovanovic et al., 2000) 
and to enhance hippocampal LTP (Figurov et al., 1996). The increase in glutamate 
release results from BDNF acting on the TrkB receptor to induce a second messenger 
cascade including the phosphorylation/activation of ERK1/ERK2 which in turn 
phosphorylate synapsin I on sites 4 and 5 (Jovanovic et al., 2000). The phosphorylation
16
of synapsin I regulates its interaction with the small synaptic vesicles and actin 
cytoskeleton (Jovanovic et al., 1996), and so perhaps can regulate glutamate release by 
making more vesicles available for release, through changing the balance of the 
aforementioned pools of synaptic vesicles.
One of the objectives of this thesis is to investigate whether this type of regulation may 
also be under the control of G-protein coupled presynaptic receptors (Parmentier et al.,
2002) and whether these signalling pathways are able to cross-talk with ERK1 and 2 in 
nerve terminals, and if so, examine what the implications are for the regulation of 
glutamate release.
1.4 Regulation of Glutamatergic Nerve Terminals by Presynaptic Receptors
There are three main types of receptor shown to be involved in the regulation of 
glutamate release from nerve terminals: ionotropic, metabotropic G-protein coupled, 
and receptor tyrosine kinases (RTKs) (Jovanovic et al., 2000; Perkinton and Sihra,
1999; Sanchez-Prieto et al., 1996). Ionotropic receptors traverse the cell membrane and 
have a pore forming region, through which ions can flow into and out of the cells. The 
flow of ions can be regulated through phosphorylation of the receptor, which can induce 
conformational changes to mediate opening and closing of the pore region. In contrast 
to this, metabotropic G-protein coupled receptors and tyrosine receptor kinases 
transduce signals through coupling to intracellular molecules. Ligands will bind to 
external domains of the receptors, which can induce changes in the conformation or 
binding properties of the intracellular domains, resulting in stimulation of downstream 
effectors. Ionotropic receptors tend to be involved in rapid signalling processes, 
whereas metabotropic receptors tend to mediate slower, modulatory processes 
(Sugiyama et al., 1987; Schoepp et al., 1990; Nicoll et al., 1990; Kandel et al., 1991).
1.4.1 Ionotropic Receptors
There are three main ionotropic glutamate receptor subtypes; N-methyl-D-aspartate 
(NMDA) receptors, and two non-NMDA-type receptors known as kainate, and D-2- 
amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA). These receptors were 
originally distinguished by their differing pharmacology and sensitivities to kainate and
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AMPA (McLennan, 1983; Foster and Fagg, 1984; Monaghan et al., 1985; Sommer et 
al., 1992), however, more recent cloning experiments have also identified differences in 
the subunit composition of the receptors (Keinanen et al., 1990; Herb et al., 1992; 
Hollmann and Heinemann, 1994). The presence of AMPA and NMDA receptors in 
presynaptic locations is yet to be confirmed, despite a suggested role for the NMDA 
receptor in regulating the release of noradrenaline and dopamine, the majority of studies 
confine these two receptors to postsynaptic domains (Pittaluga and Raiteri, 1992; Wang, 
1991; Nicoll, 2003, review). However, presynaptic roles for the kainate receptor have 
been elucidated in several systems, including cerebrocortical synaptosomes (Perkinton 
and Sihra, 1999).
1.4.1.1 Kainate Receptors
Kainate receptors are ligand-gated tetrameric ion channels, whose unitary conductance 
and affinity for kainate can be determined by their subunit composition (Rosenmund et 
al., 1998; Bowie and Lange, 2002). The different channel subunits have been divided 
into two groups, depending on their affinity for kainate. The low affinity subunits 
include GluR5, GluR6, and GluR7, which are also able to form homomeric channels, 
whereas the high affinity subunits include KA1 and KA2 and are only able to exist as 
part of heteromeric channels (Lerma et al., 2001, review). A characteristic of kainate 
receptors is to undergo rapid desensitisation, the time course of which is also dependent 
on subunit composition, as well as the cell type that the receptor is expressed in. In 
contrast to this, the subsequent recovery of the receptor is dependent on the agonist 
used, with more rapid recovery occurring with glutamate, and slower recovery with 
kainate (Patemain et al., 1998).
Kainate receptors are non-specific cation channels and so are able to carry ions such as 
K+, Na+ and Ca2+ across the cell membrane, leading to neuronal membrane 
depolarisation (Seeburg, 1993, review). Many of their presynaptic effects reflect these 
properties of the receptor, such as increasing glutamate release from cerebrocortical and 
CA3 synaptosomes (Malva et al., 1995; Malva et al., 1996; Perkinton and Sihra, 1999), 
and an initial enhancement in synaptic transmission at the Schaffer collateral and mossy 
fibre synapses in brain slices (Vignes et al., 1998; Schmitz et al., 2000). However, 
kainate has also been shown to decrease the release of glutamate from hippocampal 
synaptosomes (Chittajallu et al., 1996), and the synaptic transmission between various
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hippocampal regions in rat brain slices (Kamiya and Ozawa, 1998; Vignes et al., 1998).
^  I *
The mechanism for this decrease has been proposed to occur at the level of Ca influx, 
where Ca2+-channels involved in the release process become inactivated following 
longer-term membrane depolarisation (Chittajallu et al., 1996; Kamiya and Ozawa, 
1998). As well as regulating the excitatory synaptic transmission of a number of 
neurones, kainate receptors are also believed to be present on a subset of inhibitory 
nerve terminals (Lerma et al., 2001), where they have been shown to decrease the 
amplitude of the evoked inhibitory post synaptic potential (IPSP) (Rodriguez-Moreno et 
al., 1997; Min etal., 1999).
1.4.2 G-Protein Coupled Receptors
G-protein-coupled receptors (Parmentier et al., 2002) transduce signals from the cell 
surface to intracellular proteins through the activation of heterotrimeric G-proteins.
They consist of seven a-helical transmembrane-spanning regions with an extracellular 
N-terminal domain and an intracellular C-terminal domain (Dohlman et al., 1987).
There are over 1000 members of the GPCR family, making them the largest group of 
cell surface receptors encoded by the mammalian genome (Gutkind, 2000).
Considering the size of the family, it is not surprising then, that they are responsible for 
mediating a diverse array of cellular signals stimulated by a wide range of agonists, 
including: hormones, phospholipids, neurotransmitters, vasoactive polypeptides, growth 
factors, odorants, photons, and taste ligands (Gutkind, 2000). Activation of GPCRs 
occurs following the binding of an extracellular ligand, which induces conformational 
changes in the a-helices and intracellular loops of the receptors. This results in the 
exposure of previously masked intracellular G protein binding sites. The interaction 
promotes the exchange of GDP on the G-protein for GTP, thereby effecting its 
activation (Wess, 1997;Boume, 1997). The heterotrimeric G proteins consist of a , p 
and y subunits. Binding of GTP to the a  subunit of the G protein (Ga) causes it to 
dissociate from the py subunits by inducing conformational changes in three flexible 
‘switch regions’ of Ga. This exposes the effector interaction sites on the Py subunits 
and allows the targeting of the a  subunits towards effector molecules such as adenylate 
cyclase (Lambright et al., 1994; Clapham and Neer, 1997).
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There are currently believed to be about 20 different G a subunits in existence, which 
have been divided into four families based on their sequence homology: Gs, Gi/o, Gq, 
and G n (Wilkie et al., 1992). The four families have also been found to regulate 
different downstream effector molecules. Gas, for example, stimulates adenylate 
cyclase resulting in the increase in intracellular levels of the second messenger, cAMP. 
Members of Gai/o family, however, inhibit adenylate cyclase and so decrease the 
intracellular levels of cAMP (Simonds, 1999). Members of the Gai/o family of a  
subunits have also been implicated in activating a variety of phospholipases and 
phosphodiesterases, as well as having direct interactions with some ion channels. They 
can directly increase K channel activity as well as decrease Ca channel activity 
(Hamm, 1998). Gaq family members have been linked with phospholipase C (PLC) 
activation, resulting in the increase in the production of the intracellular messengers: 
Ca2+ and diacylglycerol (DAG) (Rhee and Bae, 1997). The final family of Ga protein 
subunits, G12, are believed to provide a link between GPCRs and the Rho family of 
small GTP-binding protein which are also involved in stimulating the activation of 
MAPK (Fromm et al., 1997; Fukuhara et al., 1999).
In contrast to G a subunits, molecular cloning has so far only revealed the existence of 
12 Gy subunits and 6 Gp subunits. Nonetheless, this still results in a substantial number 
of Py dimers. It was originally thought that GPy subunits were passive in signalling 
terms, and that this was all carried out by the Ga subunit. Subsequent research is 
consistently finding more and more roles for the GPy subunit in signalling within cells; 
including activation of K+-channels, inhibition of Ca2+ channels, and regulation of 
adenlyate cyclases, phosphatidyl-inositol-3-kinases (PDKs), phospholipases and 
receptor kinases (Clapham and Neer, 1997). It is also possible that there are distinct 
pools of GPy subunits, which mediate different processes in signal transduction 
depending on cell-type and/or subcellular localisation (Hamm, 1998).
The heterotrimeric G proteins involved in signalling downstream of GPCRs can, in part, 
be distinguished by the treatment of cells with specific bacterial toxins. Pertussis toxin 
catalyses the ADP-ribosylation of Gi and Go a-subunits resulting in their inactivation, 
however, it has no effect on Gq or Gs family members (Katada and Ui, 1982; Codina et 
al., 1983; Moss et al., 1984). Opposed to this treatment with pertussis toxin, Gs-type a-
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subunits can be permanently activated by the toxin from Cholera vibrio (Kahn and 
Gilman, 1984b; Kahn and Gilman, 1984a).
1.4.2.1 Metabotropic Glutamate Receptors
Metabotropic glutamate receptors (mGluRs) were originally identified as a non- 
ionotropic component of glutamatergic signalling that could evoke phosphoinositide 
(PI) hydrolysis in rat brain slices (Nicoletti et al., 1986). The first mGluR to be 
identified, through expression cloning using a rat cerebellar library, was the receptor 
now known as rat mGluRla (Houamed et al., 1991; Masu et al., 1991). Subsequent 
cloning experiments, using homology screening, led to the identification of 8 different 
mGluRs, which can be divided into 3 subgroups based on sequence homology and 
signal transduction systems (Nakanishi, 1992).
Group I contains the receptors; mGluRl, and its splice variants a, b, c, and e, and 
mGluR5 and its splice variants a and b. These receptors are primarily coupled to 
increased PIP3 hydrolysis through Gq proteins (Pin and Duvoisin, 1995). 
Immunohistochemical evidence places these receptors at a post-synaptic location, 
however, there is more recent pharmacological evidence which suggests that these 
receptors may also be found presynaptically (Shigemoto et al., 1993; Herrero et al., 
1998). The localisation of these receptors appears to be determined by ‘homer’ 
proteins, which selectively bind to Group I mGluRs and regulate their positioning near 
to intracellular messengers (Ciruela et al., 1999; Ango et al., 2000). Stimulation of 
presynaptic Group I mGluRs has been shown to increase glutamate release from nerve 
terminals, though coapplication of arachidonic acid is required in some systems 
(Herrero et al., 1998).
The Group II subgroup of mGluRs consists of mGluR2 and mGluR3 and are generally 
negatively coupled to adenylate cyclase (AC) through Gi proteins (Pin and Duvoisin, 
1995). They have been located to perisynaptic areas, away from the site of transmitter 
release, in both pre- and post-synaptic neuronal locations (Petralia et al., 1997; 
Shigemoto et al., 1997). As well as this, mGluR3s have been found to be highly 
expressed in glial cells (Ohishi et al., 1993; Ohishi et al., 1994; Mineff and 
Valtschanoff, 1999). The perisynaptic localisation of mGluR2 on presynaptic terminals 
has been proposed to be important in the regulation of exocytotic cell death in
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hippocampal neurones. The activation of these receptors appears to only occur 
following substantial glutamate release and results in the inhibition of further glutamate 
release, thus preventing excitotoxicity (Scanziani et al., 1997; Cartmell and Schoepp,
2000).
Group III contains the receptors; mGluR4, mGluR6, mGluR7 and mGluR8 and their 
splice variants. mGluR6 was originally believed to be exclusively expressed in ON 
bipolar cells in the retina, where it was found to have an important role in the 
amplification of visual inputs (Laurie et al., 1997; Ueda et al., 1997). However, more 
recent studies have also found mGluR6 to be expressed in microglia, where it may be 
involved in protecting microglia from over-stimulation-induced apoptosis (Taylor et al.,
2003). mGluR4a, 7a, 7b and 8 have been identified in areas relating to presynaptic 
active zones in neurones (Shigemoto et al., 1997), with hippocampal mGluR7 being 
solely localised to glutamatergic neurones (Bradley et al., 1996). These receptors have 
been shown to be negatively coupled to AC, through Gi, and can reduce glutamate 
release from hippocampal neurones, as well as GABA release from striatal neurones 
(Lafon-Cazal et al., 1999) and cultured cortical neurones (Schaffhauser et al., 1998). 
Thus they are able to act both as autoreceptors and heteroceptors.
Not all the subtypes of mGluRs are found at every synapse, and their distribution can 
vary considerably even between terminals sharing the same axon. The presynaptic 
distribution of mGluRs appears to be heavily reliant on the postsynaptic identity 
(Scanziani et al., 1998; Shigemoto et al., 1996; Shigemoto et al., 1997). Despite these 
receptors being coupled to G-proteins and consisting of 7 transmembrane domains 
(7TMD), they have no sequence homology to the GPCRs mediated by ‘classical’ 
metabotropic neurotransmitters, such as muscarinic acetylcholine receptors. (Pin and 
Duvoisin, 1995). Rather mGluRs are members of the “Family 3” GPCRs, along with 
Ca -sensmg and GABAb receptors, and some putative olfactory, pheromone and taste 
receptors (De Blasi et al., 2001). These receptors have a large N-terminal extracellular 
domain (ECD) which consists of two lobes that are able to exist in an open or closed 
conformation. Agonist binding to the hinge region, located between the two lobes, is 
believed to stabilise the ECD in the closed conformation and bring about activation of 
the receptor. This mechanism for activation has become known as the ‘venus fly-trap’ 
model, as the opening and closing of the ECD in the absence and presence of agonists,
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is believed to resemble the opening and closing of a venus fly-trap (Kunishima et al., 
2000). The signal transduction downstream of glutamate binding to the ECD of 
mGluRs has been suggested to be conferred by the second intracellular loop of the 
7TMD. This loop is believed to be important in coupling to G-proteins and in 
determining the transduction mechanism for the receptor subtype (Pin and Duvoisin, 
1995; Gomeza et al., 1996). The third intracellular loop plays a crucial role in G-protein 
activation and controls the coupling efficacy in combination with the first intracellular 
loop and the C-terminal tail (De Blasi et al., 2001).
1.4.2.2 GABAb Receptors
GABA is believed to be the main inhibitory neurotransmitter found in the brain and is 
found to act at two different receptors, the ionotropic GABAa receptor and the 
metabotropic GABAb receptor (Stephenson, 1988; Bowery, 1989). It is the GABAb 
receptor which has been shown to be located presynaptically (as well as 
postsynaptically) and to regulate the release of neurotransmitters (Bowery et al., 1980; 
Hill and Bowery, 1981).
GABAb receptors have been found to be structurally related to the mGluR family and 
display the venus flytrap model of agonist binding (Kaupmann et al., 1997). Two 
distinct GABAb subunits have been identified; GABAbi and GABAb2, which, 
combined with pharmacological studies, has led to the suggestion that the differing 
properties of pre- and postsynaptic GABAb receptors may be mediated by different 
subunits (Enna, 2001; Yamada et al., 1999). However, an absolute requirement for both 
these subunits in the formation of functional GABAb receptors has been demonstrated 
in knock out mice (Schuler et al., 2001), which, unusually for GPCRs, form 
heterodimers (Enna, 2001). Notwithstanding, it remains possible that as yet 
unidentified proteins are responsible for the observed differences (Enna, 2001).
The first presynaptic effect, now attributed to GABAb receptors, was demonstrated in 
spinal cord, where a decrease in neurotransmitter release from excitatory nerve 
terminals was observed (Pierau and Zimmermann, 1973). Subsequent 
electrophysiological studies conducted in the CA1 region of the hippocampus have 
supported this role for GABAb receptors (Lanthom and Cotman, 1981; Potier and 
Dutar, 1993). As well as studies investigating the K+-evoked release from purified
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synaptosomes, which have found GABAb receptors to be involved in inhibiting GABA, 
glutamate and somatostatin release (Bonanno et al., 1991; Bonanno and Raiteri, 
1992;Pende et al., 1993). More recent studies have reported on the mechanisms 
involved in GABAe-mediated decreases in neurotransmitter release. Inhibition of 
glutamate release from cerebrocortical synaptosomes by the GABAb agonist, baclofen, 
was found to be dependent on the decreased conductance of the VDCCs linked to 
release (Perkinton and Sihra, 1998). These results have been supported by those 
obtained examining the calyx of held synapse, which also found that GABAb receptor 
activation led to inhibition of Ca2+-channels via Gi/o proteins (Takahashi et al., 1998; 
Isaacson, 1998). Interestingly, and in contrast to postsynaptic GABAb receptors, none 
of these studies identified a GABA-mediated enhancement of K+ conductance, which 
could, in theory, inhibit neurotransmitter release by reducing the nerve terminal 
excitability (Saint et al., 1990). As well as signalling through Gi/o to decrease 
adenylate cyclase activity, GABAb receptor signalling has also been shown to be 
regulated by PKC and to be able to activate ERK1/2 in the CA1 region of mouse 
hippocampus (Perkinton and Sihra, 1998; Vanhoose et al., 2002).
1.4.2.3 P-Adrenoceptors
There are currently believed to be three subtypes of p-adrenergic receptor, classified as 
pi, p2, and P3. The most prevalent subtype found in forebrain regions, including the 
cortex, hippocampus and striatum, has been identified as the Pi subtype, whereas P2- 
adrenoceptors are the more prevalent in the cerebellum (Minneman et al., 1979; Gamier 
et al., 1997). These receptors have been shown to exist in both high and low affinity 
states, depending on their G-protein coupling. Activated p-adrenoceptors are generally 
believed to be in their high affinity conformation when bound to Gs, which results in 
the activation of adenylate cyclase leading to increased levels of cAMP and stimulation 
of PKA (De Lean et al., 1980; Rasenick et al., 1994). The third intracellular loop of p- 
adrenoceptors is believed to confer their G-protein binding specificity (Strader et al., 
1994), with both the transmembrane segments 3 and 6 being involved in the activation 
of the G-protein (Ballesteros et al., 2001). Following activation, P-adrenoceptors have 
been demonstrated to undergo clathrin-coated endocytosis, possibly resulting in the 
stimulation of signalling cascades such as the ERK1/2 pathway (Daaka et al., 1998; 
Luttrell et al., 1999).
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Activation of p-adrenoceptors has, for a while, been shown to be required for long term 
potentiation (LTP) in the dentate gyrus (Stanton and Sarvey, 1985b; Stanton and 
Sarvey, 1985a), a form of synaptic plasticity believed to be involved in mnemonic 
processes. More recent evidence in slices has suggested that p-adrenoceptors may be 
acting presynaptically to increase neurotransmitter release (Chavez-Noriega and 
Stevens, 1994; Huang and Kandel, 1996). This phenomenon has been confirmed by 
work using purified cerebrocortical nerve terminals, which found activation of P- 
adrenoceptors could enhance the depolarisation-induced release of glutamate (Herrero 
and Sanchez-Prieto, 1996; Wang et al., 2002). These downstream signalling effects of 
p-adrenoceptors have been demonstrated to be mediated through Gs activation of 
adenylate cyclase leading to increased levels of intracellular cAMP and subsequent 
activation of PKA (Huang et al., 1996; Huang and Kandel, 1996; Herrero and Sanchez- 
Prieto, 1996; Wang et al., 2002).
Recent evidence has suggested that p-adrenoceptors are able to cross-talk with other 
receptors in the control of signalling pathways. For example, activation of these 
receptors has been shown to result in the ‘transactivation’ of the epidermal growth 
factor receptor (EGFR) (Kim et al., 2002). The p2-adrenoceptor has also been shown to 
be able to form heteromeric complexes with kappa opioid receptors, resulting in 
inhibition of P2-adrenoceptor endocytosis and activation of ERK1/2 (Jordan et al.,
2001).
1.4.2.4 Adenosine Receptors
Adenosine is a ubiquitous signalling molecule which appears to be released from all 
cells, including glia and neurones (Ribeiro et al., 2003). Intracellular adenosine is 
released through a nucleoside transporter which can also regulate reuptake, thus 
controlling the extracellular concentration of the nucleoside (Gu et al., 1995). As well 
as the intracellular synthesis of adenosine from 5’AMP, adenosine can also be 
synthesised in the extracellular space, from the breakdown of adenine nucleotides 
(Zimmermann and Braun, 1999). The location of adenosine production in cells may be 
of functional importance, as Ai receptors have been shown to be preferentially activated
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by released adenosine, whereas A2A receptors were preferentially activated by the 
adenosine formed from adenine nucleotides (Cunha et al., 1996).
There are currently believed to be three different subtypes of adenosine receptor in 
cells: Ai, A2, and A3, with the A2 subgroup further divisible into A2A and A2B (Klinger 
et al., 2002). Distribution studies have found Ai to be highly expressed in the cerebral 
cortex, cerebellum, hippocampus and the dorsal horn of the spinal cord, whereas the 
A2A receptors appear to be localised to striato-pallidal GABAergic neurones and the 
olfactory bulb, with lower levels of expression in the hippocampus, neocortex and 
thalamus (Reppert et al., 1991; Sebastiao and Ribeiro, 1996). This is in contrast to the 
A2B and A3 adenosine receptors which show low levels of expression throughout the 
brain (Dixon et al., 1996; Fredholm et al., 2001).
All the subtypes of adenosine receptor are asparagine-linked glycoproteins, which can 
couple to different G-proteins, with Ai and A3 found normally coupled to Gi/o, and A2A 
and A2B normally coupled to Gs (Feoktistov and Biaggioni, 1997; Linden, 2001;
Ribeiro et al., 2003). This differential coupling of the adenosine receptor subtypes 
provides mechanisms for the expression of the diverse cellular effects mediated by these 
receptors. It can explain why the activation of adenosine receptors can lead to 
presynaptic inhibition and postsynaptic hyperpolarisation, mediated by Ai and A3 
receptors, and to the potentiation of neurotransmitter release and postsynaptic 
depolarisation, following activation of A2A or A2B receptors (Klinger et al., 2002; 
Ribeiro et al., 2003). Ai receptors can inhibit N-type voltage-gated Ca channels, 
through a voltage-dependent and PTX-sensitive pathway (Park et al., 2001). A2 
receptors have been shown to increase levels of intracellular Ca2+ in some cells, and
• •  •  0 - i~inhibit L-type Ca channels in others (Gubitz et al., 1996; Goncalves et al., 1997; Stella 
et al., 2002). A2 receptors can also inhibit Na+ channels, through a mechanism possibly 
dependent on cAMP (Ribeiro and Sebastiao, 1987).
As well as a role in regulating general neuronal excitability, adenosine receptors have 
also been shown to directly modulate the activity of other cell surface receptors.
For example, the coupling of adenosine A3 receptors to Gq proteins, can lead to the 
stimulation of PKC, which in turn can lead to the inhibition of Group II and III mGluRs 
(Macek et al., 1998). Recent studies have found that neurotrophin TrkB receptors can
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be activated in the absence of neurotrophin, but only as long as A2A receptors are 
activated (Lee and Chao, 2001). A2A receptors can also enhance the desensitisation of 
the nicotinic ACh receptor, possibly through a cAMP/PKA-dependent mechanism 
(Correia-de-Sa and Ribeiro, 1994). The G-protein coupling of adenosine receptors can 
leave them open to regulation by kinase signalling cascades, as mGluRs have been 
shown to inhibit Ai activation through a mechanism dependent on PKC (de Mendonca 
and Ribeiro, 1997). The regulation of cell function by adenosine receptors is not 
limited to interactions between other types of receptor and the adenosine receptor, as 
A2A receptors can also attenuate the actions of Ai receptors through a PKC-dependent 
mechanism (Lopes et al., 1999).
Studies have suggested that adenosine is a molecule which has very important 
neuromodulatory roles in the CNS, and can both regulate the increase and decrease of 
neurotransmitter release from nerve terminals (Ribeiro et al., 2003).
1.4.3 Neurotrophin Receptors
There are five different neurotrophins: nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), and 
neurotrophin-6 (NT-6), which act at two different types of neurotrophin receptor: p75 
receptors, that belong to the tumour necrosis factor (TNF) receptor superfamily; and 
tropomyosin-related kinase (Trk) receptors from the receptor tyrosine kinase (RTK) 
family (Poo, 2001). There are three main subtypes of Trk receptor found in cells; TrkA, 
B and C, which have also been found to exist as several different functional splice 
variants. p75 and Trk receptors are not thought to directly bind to each other, but 
signalling complexes have been found to form between them. p75 appears to confer 
increased ligand selectivity upon the Trks, for example, TrkB becomes specific for 
BDNF and TrkA specific for NGF, when complexed with p75 (Benedetti et al., 1993; 
Bibel et al., 1999; Lee et al., 2001).
Ligand binding to Trk receptors induces receptor dimerisation and autophosphorylation 
on tyrosine residues. Of the 10 tyrosine phosphorylation sites localised on the 
intracellular domain of Trk receptors, the three found on the autoregulatory loop are 
responsible for further activation of the kinase, whereas the remaining seven sites 
mediate the docking of adaptor proteins (Patapoutian and Reichardt, 2001).
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Phosphorylation of tyrosine 490 has been shown to regulate the binding of the adaptor 
protein She, and tyrosine 785 can regulate interactions with PLC-yl (Obermeier et al., 
1993; Cunningham et al., 1997). Although Trk receptors can be remarkably similar in 
structure, they are able to signal through different downstream cascades by interacting 
with different adaptor proteins. The recruitment of adaptor proteins such as She, or 
growth factor receptor-bound protein 2 (Grb2), can lead to the binding of guanine 
nucleotide exchange factors (GEFs) with proline-rich SH3 domain-binding sites, such 
as Sosl/2 (son of sevenless) and Ras-GRF (Li et al., 1993). The GEFs then catalyse the 
exchange of GDP for GTP in small guanine nucleotide binding proteins such as Ras, 
which are acting as molecular ‘switches’ by cycling between GDP and GTP bound 
forms. Ras then goes on the activate Raf, a broad specificity serine/threonine kinase 
which, in turn, activates mitogen- and extracellular-signal regulated kinase kinase 
(MEK) and ERK1/2 (Moodie et al., 1993). In conjunction with this well characterised 
activation of the ERK1/2 signalling cascade, Trk receptors can also activate PI3K, 
through Ras-dependent and -independent mechanisms, and stimulate PKC8 through 
activation of PLC-yl, which can also lead to MEK activation (Burgering et al., 1993; 
Rodriguez-Viciana et al., 1994; Holgado-Madruga et al., 1997; Kaplan and Miller, 
2000).
Following receptor activation, Trks can undergo endocytosis, a process which is 
believed to be crucial for some aspects of neurotrophin signalling (Poo, 2001). 
Neurotrophin-mediated signalling is implicated in a wide range of processes in cells; 
including regulation of cell survival, mediation of synaptic contacts during 
development, activation of gene transcription, maintenance of synaptic structure, and 
the regulation of synaptic plasticity (Poo, 2001; Kaplan and Miller, 2000). Of particular 
note with respect to this thesis, is the finding that BDNF-mediated activation of TrkB 
receptors on adult rat presynaptic cerebrocortical nerve terminals leads to increases in 
glutamate neurotransmitter release. This signalling pathway was found to be dependent 
on ERK1/2 activation and the downstream phosphorylation of sites 4/5 of synapsin I, 
which is believed to result in greater availability of synaptic vesicles for release 
(Jovanovic et al., 2000). The diversity of upstream signals which are able to stimulate 
ERK1/2 (Gutkind, 2000) has led to the possibility of a general role for this kinase in 
mediating cross-talk between signalling cascades in the regulation of glutamate release.
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1.5 Signalling cascades downstream of Cell-Surface Receptors
Signalling cascades downstream of cell-surface receptors often involve the activation of 
protein kinases or phosphatases. Phosphorylation is an important means of 
posttranslational modification involving the transfer of a negatively charged phosphate 
group from ATP (or occasionally, GTP) to tyrosine or serine/threonine residues on 
substrate proteins (Engh and Bossemeyer, 2001). Modification by phosphorylation can 
induce substantial changes in proteins, resulting in alterations in their binding properties 
and/or conformation. In kinase signalling cascades, this can lead to activation, as in the 
case of extracellular signal-regulated kinase (ERK), or in some cases, can bring about 
deactivation, as with the phosphorylation by PKA on serine 259 of Raf-1 for instance 
(Dhillon et al., 2002), providing a very important means for regulating signalling in the 
cell. Enzymes that are able to mediate the addition of phosphate groups to substrates 
(phosphorylate) are termed protein kinases, whereas protein phosphatases catalyse the 
removal of phosphate groups (Sun et al., 1993).
1.6 Protein Kinases
There are believed to be over 1000 protein kinases in humans, with up to a third of all 
cytoplasmic proteins containing a covalently bound phosphate group at any one time. 
The catalytic domain structure of protein kinases is a highly conserved region (Hanks 
and Quinn, 1991) and all protein kinases require divalent metal ions, such as Mg2+, for 
activity (Engh and Bossemeyer, 2001). The disregulation of protein kinases, often 
through spontaneous genetic mutation, has wide ranging implications in the process of 
serious diseases, such as cancer (Sherr, 1996). This current study investigates the 
relationships between three families of protein kinases: protein kinases A, protein 
kinases C and mitogen-activated protein kinases with respect to presynaptic function.
1.6.1 Protein Kinase A
Protein kinase A (PKA) is a broad specificity kinase which phosphorylates proteins on 
serine or threonine residues contained in the consensus sequence RRxS/Tx (Kemp and 
Pearson, 1990). PKA, in the inactive state, consists of two regulatory subunits (R) and 
two catalytic subunits (C) (Francis and Corbin, 1994). So far, four different isoforms of 
R have been identified, along with 3 different isoforms o f C. The regulatory subunits 
have been shown to be able to form heterodimers, making it possible to have 24
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different isoforms of PKA. However, not all the isoforms of the subunits exist in the 
same tissue, meaning the number of different PKAs found in reality is a lot less than 
that predicted on theoretical grounds (Beebe, 1994; Tasken et al., 1997).
1.6.1.1 Activation of Protein Kinase A
The understanding of how protein kinases are activated has been helped dramatically by 
obtaining crystal structures of the conformation and construction of a fully active 
protein kinase (Bossemeyer et al., 1993). The structure of a PKA catalytic subunit was 
one of the first to be determined (Knighton et al., 1991). In the inactive state, PKA 
exists as a tetramer, where the catalytic subunits are stabilised by the binding of 
pseudosubstrate regions found on the regulatory subunits. The pseudosubstrate motif 
consists of RRxG/Ax, where non-phosphorylatable glycine or alanine residues have 
replaced the serine or threonine residues found on the genuine substrates (Soderling, 
1993). Each regulatory subunit also possesses two similar binding sites for 3 \5 ’-cyclic 
adenosine monophosphate (cAMP), meaning each PKA enzyme requires four cAMP 
molecules for activation. Upon binding of one cAMP molecule, the affinity of the other 
binding sites for cAMP is increased, showing that cAMP binding is cooperative. Upon 
complete occupancy of the cAMP binding sites, the stability of the R2C2 complex 
declines and the R subunits dissociate from the C subunits, allowing the C subunits to 
phosphorylate their target substrates. Following dissociation of the subunits the affinity 
of the R subunits for cAMP decreases, resulting in the release of cAMP back into the 
cytoplasm (Scott, 1991; Taylor et al., 1993; Tasken et al., 1997). As well as requiring 
cAMP-binding for activation, PKA also requires the phosphorylation of a threonine 
residue found in the activation loop (Thrl97) (Adams et al., 1995). Phosphorylation of 
this residue can either occur via phosphoinositide-dependent protein kinase (PDK1) 
(Cheng et al., 1998), or through autophosphorylation (Girod et al., 1996).
1.6.1.2 Roles of Protein Kinase A
PKA has been shown to be able to regulate gene transcription through phosphorylation 
of the cAMP response element binding protein (CREB). The increase in gene 
transcription mediated by CREB is thought to underlie the process of LTP and to 
regulate many of the longer term stimulus-induced post-synaptic changes (Bito et al.,
1996). PKA can also phosphorylate and inhibit Group II mGluRs in the dentate gyrus
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and CA3 area of the hippocampus, and Group III mGluRs in the dentate gyrus and CA1 
area of the hippocampus. This effectively decreases the inhibitory effects of these 
receptors on glutamate release (Kamiya and Yamamoto, 1997; Schaffhauser et al., 
2000).
1.6.1.3 Signalling Upstream of PKA: Cyclic Adenosine Monophosphate (cAMP) 
Second Messenger Production.
cAMP is synthesised from ATP (adenosine triphosphate), a common constituent of 
cells, by a reaction which is catalysed by the membrane bound adenylate cyclase (AC) 
(Tang and Hurley, 1998). The subsequent removal of cAMP is highly regulated by the 
action of phosphodiesterases which catalyse the conversion of cAMP into 5’-AMP 
(Drummond, 1973). cAMP was the first cellular second messenger to be identified, by 
Sutherland, following experiments looking at glycogenolysis in dogs (Berthet et al., 
1957). Work carried out since then has identified signalling roles for the second 
messenger throughout evolution, ranging from the prokaryotes: Eubacteria and Archaea, 
through to single cellular eukaryotes like yeast, and then on to multicellular plants, rats 
and humans (Botsford and Harman, 1992; Thomer, 1982; Bolwell, 1995; Castagna, 
1983; Scarpace et al., 1991). The diversity of systems in which cAMP is used as a 
messenger could perhaps be accounted for by its roles in mediating responses to 
starvation. cAMP is also able to regulate ion channels in some systems, such as in 
olfactory cells and in plants (Bradley et al., 1994; Li et al., 1994). More recent evidence 
has also implicated cAMP as having a direct signalling role to protein kinase cascades, 
other than PKA (de Rooij et al., 1998).
1.6.1.4 Signalling Upstream of Protein Kinase A: Adenylate Cyclase
Adenylate cyclase (AC) can be structurally divided into four main domains starting 
from the N-terminus; Mi, Ci, M2 and C2. Mi and M2 consist of six transmembrane a- 
helices each, whereas Ci and C2 are extensive cytoplasmic domains (Krupinski et al., 
1989). The catalytic site for synthesis of cAMP from ATP is located within the Ci and 
C2 domains, along with several important regulatory sites (Tang and Gilman, 1995; Yan 
et al., 1997). To date, nine different isoforms of adenylate cyclase (AC) have been 
cloned and identified in mammals. They are labelled I-IX and have been divided into 
classes depending on their activation properties. Class 1 includes AC II, IV and VII;
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Class 2 contains AC V and VI; and Class 3 consists of AC I, III, and VIII. All 
mammalian ACs identified so far can be activated by Gas subunits and inhibited by so- 
called P-site inhibitors such as deoxy-3’-AMP (Tang and Hurley, 1998; Hurley, 1999).
Table 1.6.1 Properties of the Different Adenylate Cyclases.
Adenylate
Cyclase
Localisation Activators Inhibitors
I
neural tissue Gas, forskolin, 
Ca2+.Calmodulin
py subunits, Gai
n
brain, lung Gas, forskolin, PKC, py 
(synergistically with Gas)
in mainly olfactory Gas, forskolin, 
Ca2+.Calmodulin
IV
broad distribution Gas, forskolin, py subunits 
(synergistically with Gas)
V
mainly heart, 
some brain
Gas, forskolin, PKC PKA, Gai, Ca2+
VI
mainly heart, brain, 
some other tissue
Gas, forskolin, PKA, Gai, Ca2+, 
PKC
vn
broad distribution Gas, forskolin, PKC, py 
(synergistically with Gas)
VIII
neural tissue Gas, forskolin, 
Ca2+. Calmodulin
EX Gas
It is possible that some types of AC may have the potential to act as coincidence 
detectors in some systems. For example, Py subunits do not appear to stimulate AC II, 
IV, and VII on their own, but their presence results in a synergistic activation by Gas. 
However, the concentration of Py subunits needed to produce this effect is greater than 
the number produced by Gs alone, suggesting a need for simultaneous Gi/o activation.
32
This means, to elicit activation of AC with py subunits, the simultaneous stimulation of 
two types of GPCR (Gi/o and Gs) with different effectors, would be required (Sunahara 
et al., 1996). This is an example of short term coincidence detection by AC, but longer 
lasting mechanisms can be induced by phosphorylation of the enzyme. PKC activation 
through Gq-mediated pathways can result in the phosphorylation of type II, V, and VII 
AC, which may prepare the enzyme for the transient stimulation by Gas (Summers and 
Cronin, 1986). Not all phosphorylations of AC are excitatory however, PKA has been 
shown to inhibit AC V and VI through a phosphorylation mediated by a negative 
feedback loop (Chen et al., 1997). PKC has also been shown to phosphorylate and 
inhibit AC VI (Lai et al., 1997).
1.6.2 Protein Kinase C
Protein kinase C (PKC) was initially identified as a cyclic nucleotide-independent 
protein kinase present in bovine cerebellum (Takai et al., 1977). Since then, molecular 
cloning has revealed the presence of a total of 12 different mammalian isoforms of PKC 
(Parker et al., 1986; Coussens et al., 1986). These isoforms have been split into three 
subgroups depending on their activation properties and sequence homology (Way et al., 
2000). The first subgroup of PKCs has become known as the conventional PKCs 
(cPKC), these require Ca2+, DAG and a phospholipid, such as phosphatidylserine, for 
activation. Included in this subgroup are the a , p i, p2 and y isoforms of PKC. The 
second subgroup of PKCs are known as the novel PKCs (nPKC) and, like cPKCs, they 
also require DAG and phospholipid for activation, but are Ca2+-independent. Four 
isoforms are included in this subgroup; 5, s, r|, and 0. The remaining subgroup of PKCs
•  "7 -4-contains PKCX, i, and p, these require phospholipid but are not activated by Ca or 
D AG, which has led their being labelled as atypical PKCs (aPKC) (Majewski and 
Iannazzo, 1998).
1.6.2.1 Activation of Protein Kinase C
PKC proteins consist of 4 domains (with the exception of aPKC), identified as C l, C2, 
C3 and C4 when starting from the N-terminus, with Cl and C2 acting as regulatory 
domains and C3 and C4 as catalytic domains (Newton, 1995). Activation of cPKCs and 
nPKC occurs in four stages. The first stage involves the phosphorylation of the C4 
domain at Thr-500 by a PKC kinase, such as PDK1. This subsequently allows
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autophosphorylation to occur at sites Thr-641 and Ser-660, which are also found on the 
C4 domain (Keranen et al., 1995). These phosphorylations render the kinase 
catalytically competent but still inactive due to the proximity of a pseudosubstrate 
region found on the N-terminus of the protein. The third stage of activation occurs with 
DAG binding to the Cl domain, combined with Ca2+ binding to the C2 domain (when 
present). This renders the regulatory domain less hydrophilic, and in doing so, 
encourages interactions between the C2 domain and the phospholipid membrane of 
cells. The final stage of activation occurs when the pseudosubstrate region is distanced 
from the catalytic domain by the conformational change in the protein resulting from 
binding of the C2 domain to phospholipids. This exposes the catalytic domain of the 
PKC to intracellular substrates, so rendering the kinase active (Newton, 1997).
1.6.2.2 Signalling upstream of Protein Kinase C: Lipids
All PKCs require the binding of a phospholipid for activation (Bell and Bums, 1991). 
Phospholipids are common constituents of the membrane bilayer in cells. They all 
consist of a glycerol backbone which is esterified at its first and second hydroxyl groups 
to fatty acids. The third hydroxyl group contains a diester of phosphoric acid and an 
alcohol (Folch and Lebaron, 1956; Lebaron and Folch, 1957). The name given to the 
phospholipid is determined by the alcohol attached to the third hydroxyl group:
Table 1.6.2 Phopholipids
ALCOHOL PHOSPHOLIPID
Choline Phosphatidylcholine (PC)
Serine Phosphatidylserine (PS)
Ethanolamine Phosphatidylethanolamine (PE)
Inositol Phosphatidylinositol (PI)
The most common phospholipid involved in the activation of PKCs is 
phosphatidylserine (PS), occurring when PKC interacts with the cell membrane, 
however, products of phospholipid metabolism can also be involved in regulating the 
activation of PKCs (Bell and Bums, 1991). Phosphoinositide (PI) can undergo two 
further phosphorylations by phosphatidylinositol 4-kinase (PI4K) and then 
phosphatidylinositol-4-phosphate 5-kinase (PI5K) to become phosphatidylinositol-4,5-
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bisphosphate (PIP2) (Fruman et al., 1998). PIP2 is a major substrate for phospholipase 
C (PLC), which cleaves the phospholipid into diacylglycerol (DAG) and inositol-1,4,5- 
triphosphate (IP3) (Rhee and Bae, 1997). DAG is hydrophobic and, because of its 
relatively small size, it is able to travel laterally along the lipid membrane and go on to 
activate novel and conventional PKCs (Newton, 1997). However, DAG is rapidly 
metabolised, either into glycerol and fatty acids by DAG lipase, or into phosphatidate 
by DAG kinase, thus resulting in a transient activation of n and cPKCs (Topham and 
Prescott, 1999). IP3, in contrast to DAG, is a water-soluble second messenger which 
combines with specific receptors on membrane organelles (endoplasmic reticulum and 
mitochondria) to release calcium (Ca2+) from endogenous stores (Berridge, 1993). This 
rise in intracellular Ca -levels can also increase the activation of cPKCs, as well as 
modulating many other signalling pathways (Hug and Sarre, 1993; Verkhratsky and 
Petersen, 1998). As well as PIP2 being an important source of DAG and IP3, it can 
itself be further phosphorylated by phosphoinositide-3-kinase (PI3K) to form the 
product phosphoinositol-3,4,5-triphosphate (PI3,4 ,5P3). PI(4)P can also be 
phosphorylated by PI3K to form phosphoinositol-3,4-bisphosphate (PI(3 ,4)P2) 
(Anderson et al., 1999). Both PI3,4,5P3 and PI3,4 ,P2 are able to increase the activation 
of the nPKCs, 8,6, and 0, and of the aPKC, £ (Toker et al., 1994).
Another phospholipid that can be metabolised into products which regulate PKC 
activation is phosphatidylcholine. This can be cleaved by phospholipase A2 (PLA2) to 
release the unsaturated fatty acid, arachidonic acid (AA). The effect of DAG upon 
cPKCs and nPKCs is believed to be potentiated by AA, negating the need for increases
•  •  2+in intracellular Ca concentrations. Lysophosphatidic acid and lyso- 
phosphatidylcholine can also enhance the activities of nPKCs and cPKCs (Sando and 
Chertihin, 1996). Phospholipase D (Pastorino et al., 2000) is also able to hydrolyse 
phosphatidylcholine to produce phosphatidate and choline. Subsequent removal of the 
phosphate group of phosphatidate by phosphatidate phosphohydrolase results in the 
production of DAG. The synthesis of DAG in this manner provides a less transient 
source of this second messenger (Martin, 1988).
1.6.2.3 Phospholipase C
There are currently believed to be three main classes of PLC: PLCp, y and 8 . All these
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PLCs possess a PH domain, EF-hand motifs, a C2 domain, and two catalytic 
subdomains known as X and Y. The PH domain is possibly involved in tethering the 
enzyme to the phospholipids membrane and the EF-hands may bind Ca2+ (Rebecchi and 
Pentyala, 2000). PLC8 is believed to be an ancestral form of PLC as it is simpler than 
the other enzymes and does not require receptor activation, though it does require Ca 
(Essen et al., 1996; Singer et al., 1997). PLCp isoforms have been linked with 
signalling downstream of Gq and Gi/o-coupled GPCRs (Zhu and Bimbaumer, 1996). 
The a-subunit from Gq-coupled receptors has been shown to interact with the extended 
C-terminal region of PLCp, resulting in the activation of the enzyme (Smrcka et al., 
1991). In contrast to this, it is the Py subunit that activates PLCp from Gi/o-coupled 
receptors, by binding to a site inbetween the X and Y subdomains (Kuang et al., 1996). 
Activation of the y isoforms of PLC can be mediated by receptor tyrosine kinases 
(RTKs), due to extra SH3 and SH2 domains located in between the X and Y catalytic 
regions. The binding of a stimulatory ligand to RTKs results in the phosphorylation of 
a tyrosine residue found within the intracellular domain of the receptor. The SH2 
domains of PLCy enable it to bind to these phosphorylated intracellular domains and in 
doing so, become phosphorylated and activated (Meisenhelder et al., 1989; Anderson et 
al., 1990; Nishibe et al., 1990). PLCy can also be phosphorylated and activated by 
accessory, non-receptor tyrosine kinases (Park et al., 1991b; Park et al., 1991a).
1.6.3 Mitogen-Activated Protein Kinase Family
The mitogen-activated protein kinases (Baldassa et al., 2003) are a specialised family of 
serine/threonine phosphorylating kinases which show a high degree of evolutionary 
conservation (Camps et al., 2000). Their signalling cascades are believed to have a 
major role in cells in providing a link between cell-surface receptors and important 
regulatory processes within the cell, such as gene transcription (Pages et al., 1993). The 
first members of the MAPK family to be identified were the extracellular signal- 
regulated protein kinases 1 and 2 (ERK1/2). These were found to be phosphoproteins 
that were stimulated by mitogen and, as a consequence of this, are also known as p42 
and p44 MAPK (Cooper and Hunter, 1983). Subsequent studies in the late 1980’s 
further identified ERK1/2 as enzymes which phosphorylated myelin basic protein 
(MBP) and microtubule-associated protein 2 (MAP2) (Ray and Sturgill, 1987; Hoshi et 
al., 1988). Advances in drug development and gene cloning have led to the
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identification of at least a further 3 major subgroups of MAPKs in mammals (Chang 
and Karin, 2001). These are the c-Jun N-terminal kinases/stress-activated protein 
kinases (JNK/SAPK 1, 2, and 3), p38 proteins (p38a, p, y (also known as ERK6 or 
SAPK3) and 8), and ERK5 (or big mitogen-activated protein kinase 1, BMK-1, or 
SAPK5). These kinases are activated by a wide range of stimuli and, as a result, are 
involved in a wide range of cellular processes such as regulating cell morphology, 
survival and neurotransmitter release (Seger and Krebs, 1995;Jovanovic et al., 2000). A 
group consisting of ERK3 and ERK 7 has also recently been identified, but their roles in 
cells remain to be determined.
MAPKs are activated by a dual phosphorylation of a threonine and a tyrosine residue 
found within the activation loop of the kinase subdomain VIII (with the exception of 
ERK3) (Cobb and Goldsmith, 1995). The phosphorylations are not processive, but 
rather occur through a two-collision distributive mechanism, despite this, the tyrosine is 
most commonly phosphorylated first (Ferrell and Bhatt, 1997a; Burack and Sturgill,
1997). Removal of either phosphate group will inactivate the kinase, showing that the 
phosphorylation of both the threonine and the tyrosine residue is required for the 
activation of the kinases (Payne et al., 1991). The tyrosine and threonine residues are 
found in a TxY motif that is characteristic of MAPKs. The residue labelled x refers to 
glutamate in ERKs, proline in JNKs, and glycine in p38 MAPKs. When activated, 
these kinases in turn phosphorylate serine or threonine residues preceding a proline 
residue on their target proteins, with specificity being conferred by additional docking 
sites (Kallunki et al., 1996; Tanoue et al., 2000).
The dual specificity kinases responsible for the phosphorylation of MAPKs are termed 
mitogen activated protein kinase kinases (MKKs or MEKs). MKKs are also activated 
by phosphorylation, which is brought about by the serine/threonine MAPK kinase 
kinases (MAPKKK or MKKK), thus forming a three kinase cascade, characteristic of 
MAPK signalling. The reasons behind having a three tier kinase cascade are still under 
debate but one possibility is, in this case at least, that it results in an amplification of the 
original signal. The finding that cells contain higher levels of MKK compared to 
MKKK supports the idea of signal amplification. The levels of MKKs and MAPKs, 
however, have been found to be similar in cells, a property thought to provide a
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mechanism for creating a threshold to filter out noise from subthreshold levels (Ferrell, 
1997b). Cells have also been found to contain many more different types of MKKKs 
than MKKs, which is perhaps why such a diversity of signals is able to feed into the 
MAPK signalling cascades.
1.6.3.1 c-Jun N-Terminal Kinases
The JNKs were initially discovered in 1990 as a cycloheximide-activated proline- 
directed kinase and in 1993, as a protein which phosphorylated the N-terminal of c-Jun 
in response to UV light (Kyriakis and Avruch, 1990; Hibi et al., 1993). The activation 
of JNK1, 2 and 3 is regulated by just two MKKs; JNK kinase 1 and 2. JNKK1 is also 
known as SEK1, MKK4, or SKK1 whereas JNKK2 has also been named MKK7 and 
SKK4. These proteins kinases have been found to be activated following trophic factor 
deprivation, treatment with inflammatory cytokines and factors stimulating cell stress, 
such as heat and osmotic shock, UV light, oxidants and DNA damaging agents. 
Downstream of activation, the JNKs are involved in pathways controlling T-cell 
differentiation, apoptotic cell death, and in the production of inflammatory cytokines 
and eicosanoids (English et al., 1999; Gutkind, 2000). This can include the 
phosphorylation of Jun proteins to enhance the activation of transcription, without 
affecting DNA binding (Kallunki et al., 1996) and, mediating the stabilisation of IL-2 
messenger RNA in T cells (Chen et al., 2000).
1.6.3.2 p38 Proteins
These proteins were initially discovered as a lipopolysaccharide-induced tyrosine 
phosphoprotein and as a target of a drug which had been developed to inhibit LPS- 
induced tumour necrosis factor-a biosynthesis (Han et al., 1994; Lee et al., 1994; 
Stawowy et al., 2003). The phosphorylation and activation of the four isotopes of p38, 
(a,p,y and 8) is regulated by two upstream kinases: MKK3, also known as SKK2, and 
MKK6, which is also termed MEK6 and SKK3. Like JNKs these enzymes have been 
found to be activated by trophic factor deprivation, inflammatory cytokines and a 
number of cell stresses, such as heat and osmotic shock, UV light, oxidants and DNA 
damaging agents. As a result, they are also involved in pathways controlling T-cell 
differentiation, apoptotic cell death, and in the production of inflammatory cytokines 
and eicosanoids. As well as these roles, studies have also implicated the p38 proteins in
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B cell proliferation and muscle cell differentiation, following the phosphorylation of 
MEF2 transcription factors (Craxton et al., 1998; Zhao et al., 1999).
1.6.3.3 Extracellular Signal-Regulated Kinases 3, 5 and 7
ERK3 is the enzyme in the MAPK family whose catalytic region shares the most 
sequence homology with ERK2. Unlike ERK2 and the other MAPKs, ERK3 contains a 
phosphorylation motif consisting of a serine and a glycine residue, rather than the 
standard threonine-tyrosine dual motif (Boulton et al., 1991). ERK3 is also 
constitutively localised to the nucleus, whereas ERK2 only translocates to the nucleus 
upon activation (Cheng et al., 1996). The spatial localisation of ERK3 is believed to be 
conferred by its C-terminal tail (Robinson et al., 2002). ERK3 mRNA is upregulated in 
a p3 8-dependent manner following treatment of cells with proteasome inhibitors and 
may also be involved in cell cycle arrest (Zimmermann et al., 2001), though 
downstream substrates are yet to be identified.
ERK 5 was first identified, through cloning, as a homologue of ERK1/2 and as a protein 
that interacted with MEK5 (Lee et al., 1995; Zhou et al., 1995). It has been reported to 
respond to both growth factors and stressful stimuli, but less is known about this kinase 
compared to the rest of the MAPK family. Studies have shown a requirement for ERK5 
in cell proliferation induced by epidermal growth factor and an ability of the kinase to 
phosphorylate the transcriptional regulators, MEF2 and Myc (Kato et al., 1998; English 
et al., 1998). Like ERK3, ERK5 also possesses a long C-terminal tail, though its 
function remains to be determined.
ERK7 was first cloned in 1999, where it was identified as a novel, 61kDa, member of 
the MAPK family of proteins. It was not found to be activated by stimulators of the 
other members of the MAPK family, such as growth factors or stress, but was found to 
be constitutively active in serum-starved cells. This kinase was also found to contain a 
C-terminal tail domain, which is in contrast to the other MAPK family members (Abe et 
al., 1999). The purpose of the C-terminal domain is still under investigation but it is, so 
far, believed to convey localisation of ERK7 to the nucleus and to regulate its kinase 
activity through multiple interactions. ERK7 has also been shown to undergo 
autophosphorylation as a form of activation, in the absence of an upstream MEK (Abe 
et al., 2001)
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1.6.3.4 Extracellular Signal-Regulated Protein Kinase 1 and 2
ERK1 and 2 are the main focus of this study, and hence shall be discussed in more 
detail than the other members of the MAPK family. The three dimensional structure of 
ERK1 and 2 consists of a larger C-terminal domain and a smaller N-tenninal domain, 
linked by a crossover region (Zhang et al., 1994). ATP is found to bind at a site deep 
within the region formed between the interface of the two domains, termed the catalytic 
cleft. Protein substrates bind to the surface of the kinases (Zhang et al., 1994). The 
tyrosine and threonine residues phorphorylated by MEK1/2 are 185 and 183 
respectively, on human ERK1 and 204 and 202 respectively, on mouse ERK2 (Ray and 
Sturgill, 1988; Payne et al., 1991). Phosphorylation is believed to provoke both local 
and global conformational changes in the enzyme, to bring about activation. In the low 
activity state, the position of the Thr-183 and Tyr-185 residue-containing 
phosphorylation lip of ERK2, reduces the accessibility of the active site to substrates. 
Phosphorylation of these residues changes the conformation of ERK2 and allows the 
exposure of the active site to downstream substrates. MEK1 and 2 are the protein 
kinases which mediate the phosphorylation of these residues in ERK1 and 2 (Zhang et 
al., 1994; Cobb and Goldsmith, 1995).
ERK1 and 2 were originally identified by their roles in developmental and 
differentiation processes, downstream of neurotrophin receptor activation. They were 
found to be involved in cell cycle progression and mitogenesis, and neuronal 
differentiation and survival, with constitutively active Ras/RafZERK pathways taking on 
oncogenic properties (Gutkind, 2000). However, high levels of ERK1 and 2 persist in 
the post-mitotic, adult nervous system, implicating a post-developmental role for the 
kinases (Thomas and Hunt, 1993). A substantial amount of work has been carried out 
investigating the role of ERK1/2 signalling in long term potentiation (LTP) and long 
term depression (LTD) in the CA1 region of the hippocampus (English and Sweatt,
1997; Norman et al., 2000). LTP and LTD are used as a cellular model of learning and 
memory as they refer to the ability of various signals to modulate synaptic strength over 
long periods of time (Bear and Malenka, 1994). The involvement of ERK1 and 2 in the 
postsynaptic changes associated with LTP and LTD have been well documented, where 
they have been found to mediate the transcription of immediate early genes (Adams et 
al., 2000). ERK1/2 have been shown to be stimulated downsteam of receptor activation
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and of increases in intracellular Ca2+ concentration, as well as being involved in cross­
talk with the PKA and PKC signalling cascades, amongst others (Roberson et al., 1999, 
Sweatt, 2001). It is only recently that ERK1 and 2 have become associated with 
signalling pathways that are independent of nuclear translocation and regulation of gene 
transcription. The abundant presynaptic protein, synapsin I, has been identified as a 
substrate of ERK1/2 in nerve terminals, where it is believed to regulate the interactions 
of synapsin I with actin (Jovanovic et al., 1996). The synapsins are proteins which 
tether neurotransmitter-containing vesicles to the actin cytoskeleton, away from the 
plasma membrane (Hilfiker et al., 1999). Phosphorylation of synapsin by ERK1,2 has 
been suggested to be a mechanism for increasing glutamate release from presynaptic 
nerve terminals (Jovanovic et al., 2000). Figure 1.1 illustrates the established 
trkB/ERKl,2/synapsin pathway which has been identified in nerve terminals, along 
with possibilities for further interactions of this pathway with other signalling cascades, 
as discussed later in this introduction.
1.7 Signalling Upstream of ERK 1,2
The kinases involved in phosphorylating, and hence activating, ERK 1,2 are MEK1 and 
MEK2 (Seger et al., 1992). These are, in turn, activated by the phosphorylation of 
serine or threonine residues, generally brought about by Raf-1 or B-Raf (MKKKs) 
(Kyriakis et al., 1992; Dent et al., 1992). The MKKKs are quite a diverse family of 
protein kinases. Structurally, they can contain Pleckstrin homology (PH) domains, 
binding sites for GTP-binding proteins, leucine-zipper dimerisation sequences, proline- 
rich sequences for binding Src homology-3 domains (Ringstad et al., 1999), and 
phosphorylation sites for tyrosine and serine/threonine kinases (Garrington and 
Johnson, 1999). The three main types of Raf kinases that have been identified are c- 
Raf-1 (Raf-1), B-Raf, and A-Raf. Raf-1 is ubiquitously expressed in mouse, whereas B- 
Raf and A-Raf have much more restricted distributions, with B-Raf being localised to 
the brain and testis and A-raf to urogenital tissue (Hagemann and Rapp, 1999). As well 
as different distributions, these Raf kinases are also subject to differential regulation by 
upstream Ras family proteins. For example, the activity of Raf-1, downstream of Ras 
activation has been shown to be antagonised by the competitive binding of Rap 1 to the 
Raf-1 site normally activated by Ras. This is in contrast to B-Raf, which was found to 
be activated by Rap-1 (Hagemann and Rapp, 1999). More recent studies have
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Figure 1.1 Schematic Diagram Illustrating the Mechanisms for Receptor-Tyrosine 
Kinase Activation of ERK 1,2 in Nerve Terminals.
BDNF has been shown to stimulate trkB receptors leading to the downstream activation 
of ERK 1,2 and synapsin I, and the enhancement of depolarisation-induced glutamate 
release. The specific roles for Raf-1 and B-Raf remain to be clarified. The large ovals 
indicate the potential for signalling cascades to cross-talk with this pathway at multiple 
loci. Abbreviations: BDNF = brain-derived neurotrophic factor, GDP = guanosine 
diphosphate, GTP = guanosine triphosphate, RTK = receptor tyrosine kinase, MEK = 
mitogen activated protein kinase kinase, ERK = extracellular signal-regulated protein 
kinase.
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uncovered functional roles for these different signalling pathways within neuronal cells, 
where it has been suggested that activation of Raf-1 mediates transient signalling 
pathways, and that activation of B-Raf leads to a more sustained enhancement in ERK
1,2 phosphorylation (York et al., 1998). Both these pathways have also been shown to 
be regulated by cAMP/PKA signalling, whereby phosphorylation of Raf-1 by PKA 
leads to inhibition of ERK 1,2 activation, and stimulation by cAMP or PKA of a B-Raf- 
mediated pathway leads to enhanced activation of ERK 1,2 (Gutkind, 2000; Dhillon et 
al., 2002).
In contrast to Raf kinases, the Ras family of small GTP-binding proteins are highly 
conserved and are able to bind the same effectors and upstream GEFs. However, they 
do contain a 24 residue C-terminal hypervariable region which is believed to regulate 
the membrane microlocalisation of the protein, leading to biological differences in 
signalling (Prior and Hancock, 2001). As well as targeting Raf activation, Ras proteins 
also have the capacity to bind to and activate at least two other families of downstream 
effectors, including PI3K and Ral-specific GEFs (Ral-GEFs) (Shields et al., 2000). The 
Ras/Ral-GEF pathway has been shown to be involved in promoting cell cycle arrest 
following treatment with nerve growth factor, a complete opposite to the Ras/Raf 
pathway, which was found to promote cell proliferation. The Ras/Raf pathway has also 
been known to be stimulated for hours at a time, whereas Ras/Ral-GEF stimulation 
occurs as a short lived activation which is terminated within minutes by a PKC- 
dependent mechanism (Rusanescu et al., 2001).
1.8 Factors Determining Signalling Specificity of MAPKs
Considering the diversity of signals which are able to feed into the MAPK signalling 
cascades there must be some mechanisms in place which are able to regulate the 
specificity of the signalling, to ensure the correct pathways are followed for each 
stimulation. There are currently believed to be three mechanisms through which 
signalling specificity can be determined: through scaffolding proteins, sequential 
physical interactions, and through spatial localisation.
Scaffolding proteins have been found to be involved in both positive and negative 
regulatory mechanisms. They can bring proteins closer together for interaction, or they 
keep proteins apart, preventing interaction. For example, the scaffolding protein, MEK
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partner 1 (Schaeffer et al., 1998), has been shown to bind specifically to MEK1 and 
ERK 1, leading to the facilitation of their activation (Schaeffer et al., 1998), and the 
kinase suppressor of Ras (Morrison, 2001) scaffold seems to localise MEK to the 
plasma membrane in a manner dependent on Ras activation, where it promotes the 
assembly of a multiprotein signalling complex to bring MEK into close proximity with 
its activators and substrates (Morrison, 2001). The differential expression of 
scaffolding proteins can also contribute to the control of subcellular localisation of some 
proteins and, like protein kinases, scaffolding proteins can also be controlled by post 
translational modification (Garrington and Johnson, 1999).
As well as scaffolding proteins, highly specific sequential physical interactions can also 
regulate the specificity of MAPK signalling cascades, as for example, MEKs have been 
found to be extremely specific for their MAPK substrates. This results in minimum 
variability in MAPK/MEK interactions, conferring specificity of the pathway 
(Garrington and Johnson, 1999). The sequential nature of the signalling cascades also 
help to confer specificity, where each interaction is disrupted on the activation of the 
downstream kinase (Xia et al., 1998).
The final mechanism for conferring the specificity of MAPK signalling cascades is 
through spatial localisation. Different MKKKs can be localised to different areas of 
cells. For example, cytoskeletal rearrangements may stimulate MEKK1 activity when 
MEKK1 is colocalised with elements of the cytoskeleton, leading to modulation of cell 
motility (Yujiri et al., 1998; English et al., 1999; Xia et al., 2000). Ras and Rap have 
also been shown to have different subcellular distributions, with Ras being mainly 
localised in the plasma membrane whereas Rap has also been found in the mid-Golgi, 
endocytic vesicles and lysosomes distribution, depending on cell type (Zwartkruis and 
Bos, 1999).
1.9 Phosphatases
Phosphatases are proteins that mediate the removal of a phosphate group from their 
substrates. This can result in changes in the binding properties or conformation of the 
substrate, leading to activation or deactivation. In the past, protein kinases have been 
maintained as the focus for regulating cell signalling, however, the finding of 
increasingly complicated mechanisms for the regulation of phosphatases, implies that
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Phosphatases that Utilise Phosphoproteins as their Substrates
Protein Ser/Thr Phosphatases
• Remove phosphoryl group 
from Ser/Thr residues. 
Two-metal-ion metalloenzymes that 
affect catalysis by direct attack of an 
activated water molecule at the 
phosphorus atom of the substrate, 
e.g. PP1, PP2A, PP2B.
Protein Tyrosine Phosphatases
• Dephosphorylate tyrosine 
residues.
Non-metalloenzymes that proceed 
through a covalent phosphocysteine 
intermediate during catalytic turnover.
3 Subfamilies.
Low-Molecular Weight 
Phosphatases (LMW)
• Strictly target 
pTyr residues
Dual-Specific Phosphatases
• Cleave phosphodiester 
bonds in substrates 
containing pTyr as well as 
pSer and pThr. 
e.g. MAPK phosphatases
Tyrosine-Specific
Phosphatases
• Strictly target 
pTyr-residues
Receptor-like
Extracellular, putative ligand 
binding domain, single 
transmembrane region, one or 
two cytoplasmic PTP 
domains.
e.g. PTPa, CD45, PTPg
Intracellular
Single catalytic domain 
and various amino or 
carboxyl terminal 
extensions such as SH2 
domains, which may have 
targeting or regulatory 
functions, 
e.g. PTP IB, SHP2, 
PTPH1.
Figure 1.2 Different Families of Protein Phosphatases. Information collated from 
(Zhang et al., 2002).
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they may be more important than originally thought. Figure 1.2 describes the different 
families of phosphatases that have so far been identified, as well as their target 
substrates (Zhang et al., 2002). The phosphatases involved in regulating the above 
signalling pathways are discussed in more detail in the following section.
1.9.1 Protein Phosphatase 1
Protein phosphatase 1 (PP1) is a widely expressed enzyme which is able to remove the 
phosphate from phosphorylated serine and threonine residues (Price and Mumby, 1999). 
The catalytic subunit of PP1 exists in multiple isoforms which are differentially 
distributed, with the a, (3, yl and y2 being expressed in brain and yl being located to 
presynaptic terminals in cortical pyramidal cells (Strack et al., 1999). Regulation of 
PP1 activity can occur through several mechanisms, including: direct inhibition of PP1, 
subcellular compartmentalisation, and direct protein-protein interactions (Winder and 
Sweatt, 2001). Several proteins have been identified in neurones, which are able to bind 
to and inhibit PP1 activity, such as Inhibitor 1 (1-1) and DARPP-32 (Walaas et al.,
1983; Gustafson et al., 1991). Phosphorylation of DARPP-32, by PKA, promotes 
binding to PP1 resulting in PP1 inhibition, a process which can be reversed by the 
dephosphorylation of DARPP-32 by PP2B (Winder and Sweatt, 2001). As well as 
indirect inhibition of PP1, PKA can also indirectly activate PP1, by decreasing the 
binding of the inhibitory regulatory protein neurabin through mediating its 
phosphorylation (McAvoy T et al., 1999). This not only suggests that the activity of 
PP1 is highly regulated in cells, but also that regulation of its activity can be the point of 
cross-talk of some signalling pathways.
The regulatory proteins which bind to PP1 are also able to determine the subcellular 
localisation of the enzymes, for example, spinophilin can localise PP1 to actin, post­
synaptic densities and D2 dopamine receptors (Allen et al., 1997; Smith et al., 1999). 
PP1 has been shown to be involved in dephosphorylating many proteins, including 
CREB, GluRl subunits and membrane bound CaMKIIa (Bito et al., 1996; Strack et al., 
1997; Lee et al., 2000). ERK1/2 phosphorylation has also been shown to be sensitive to 
PP1/2A inhibitors in the hippocampus (Runden et al., 1998). The ability of PP1 to 
dephosphorylate protein kinases has led to roles for the phosphatase in enhancing the 
induction hippocampal LTP and in increasing synaptic transmission. These
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experiments have led to the suggestion that PP1 is transiently involved in synaptic 
plasticity (Winder and Sweatt, 2001).
1.9.2 Protein Phosphatase 2A
Protein phosphatase 2A (PP2A) is an amazingly ubiquitous and evolutionarily 
conserved family of enzymes. They can account for as much as 1% of total cellular 
proteins and form the majority of serine/threonine phosphatase activity in most cells and 
tissues (Cohen, 1997). PP2As can be differentially regulated, show distinct distribution 
patterns and have restricted substrate specificity, depending on their subunit 
composition. All PP2As consist of a scaffolding subunit (A), a regulatory subunit (B), 
and a catalytic subunit (C), however different forms of these subunits exist, which is 
what determines the different regulatory properties of the enzymes. As well as this, the 
different subunits can be regulated by phosphorylation. The C subunit contains two 
phosphorylation sites (Thr304, Tyr307), the first of which can be phosphorylated by 
“autophosphorylation-activated protein kinase”, and the second by downstream of 
epidermal growth factor or insulin receptors (Guo and Damuni, 1993; Brautigan, 1995). 
Phosphorylation of these sites results in inactivation of the enzyme, a process that can 
be reversed by its unique ability to catalyse intramolecular autodephosphorylation (Guo 
and Damuni, 1993; Brautigan, 1995). In contrast to this, phosphorylation of the B 
subunit by PKA can result in the activation of PP2A (Usui et al., 1998). These studies 
have provided evidence for the dynamic regulation of phosphatase activation in cells, a 
property which was previously confined to protein kinases (Sontag, 2001). The 
dephosphorylation of downstream substrates, induced by activation of PP2A, can also 
have bidirectional effects on signalling pathways. For example, inhibitory 
phosphorylation of Raf-1 by PKB/Akt can be reversed by PP2A, resulting in Raf-1 
activation. However, dephosphorylation by PP2A can also inactivate a diversity of 
kinases in vitro, including PKB (Andjelkovic et al., 1996), PKCs (Keranen et al., 1995), 
MEK and ERK (Sontag et al., 1993). Roles have been identified for PP2A in cell cycle 
regulation, cytoskeletal regulation and gene expression. This has led to an involvement 
of PP2A signalling regulation in diseases such as cancer, Alzheimer’s disease and AEDs 
(Sontag, 2001).
1.9.3 Protein Phosphatase 2B/Calcineurin
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PP2B is a eukaryotic Ca2+- and calmodulin-dependent serine/threonine protein 
phosphatase. Wang and Desai were the first to detect PP2B, as a column fraction that 
inhibited the calmodulin-dependent cyclic nucleotide phosphodiesterase, through a 
mechanism which is now believed to be due to Ca2+-dependent competition for 
calmodulin (Wang and Desai, 1977). PP2B is heterodimeric in structure and, in 
mammals, consists of a 57-59kDa catalytic subunit (A) and a 19-20kDa regulatory 
subunit (B). The calmodulin binding site is located within the catalytic subunit, 
whereas the regulatory subunit contains four Ca2+-binding EF-hand motifs. As well as 
requiring Ca2+ and calmodulin for activation, PP2B also requires the cofactors Fe3+ and 
Zn2+ to catalyse the removal of phosphate groups from substrates (Rusnak and Mertz, 
2000).
PP2B is widely distributed in mammals, with the highest levels identified in brain 
(Anthony et al., 1988). Elucidation of the subcellular localisation of PP2B has found it 
to be enriched in the cytoplasm and in nerve terminals, although it can also be localised 
to the nucleus (Jiang et al., 1997; Pujol et al., 1993). PP2B is tonically inhibited in cells 
through an a-helical autoinhibitory domain which binds to the active site cleft.
I
Activation is mediated by pathways which lead to increases in intracellular Ca
^  I
concentrations, resulting in Ca binding-induced conformational changes in 
calmodulin, thereby allowing the binding of calmodulin to PP2B. The binding of 
calmodulin to PP2B is likely to involve a conformational change in the enzyme which
•  « o  |exposes the active site. The binding of Ca to the regulatory subunit of PP2B is also 
believed to have a role in mediating the activation of the phosphatase activity of the 
enzyme (Rusnak and Mertz, 2000; Winder and Sweatt, 2001).
The localisation of PP2B to nerve terminals has led to the elucidation of several roles of 
this enzyme in the regulation of intercellular signalling and neurotransmitter release. 
This phosphatase has been shown to dephosphorylate sites 4, 5 and 6 on the synaptic 
vesicle tethering protein, synapsin, leading to the suggestions of an involvement in 
regulating vesicle availability for release (Jovanovic et al., 2001). PP2B has also been 
implicated in the regulation of endocytosis, through relieving the ERK2 
phosphorylation-mediated inhibition of the dynamin-microtubule association (Earnest et 
al., 1996; Cousin et al., 2001). Numerous studies have also found a requirement for
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PP2B activity in the regulation of memory processes and synaptic plasticity, and in the 
regulation of ion channel function (Winder and Sweatt, 2001).
1.9.4 Mitogen Activated Protein Kinase Phosphatases
Mitogen activated protein kinase phosphatases (MKPs) are members of the dual­
specificity phosphatases, which means they are able to dephosphorylate both the 
phospho-tyrosine and the phospho-serine/threonine residues. Despite the broad 
function of the MKPs, they demonstrate greater substrate specificity than the other 
groups of phosphatases and individual MKPs have been shown to differentially 
recognise MAPK family members in vitro. To date, nine members of the dual­
specificity phosphatases have been cloned and found to be effective in mediating the 
inactivation of MAPKs. They are: MKP-1, PAC1, MKP-2 or hVH-2, B23, M3/6 or 
hVH-5, MKP-3, B59, MKP-4 and MKP-5 (Camps et al., 2000).
Out of all the dual-specificity phosphatases to be identified, only hVH-5, MKP-1, B59, 
MKP-3, and B23 have been found in the brain, with MKP-1 and B23 expression being 
confined to the nucleus, and only MKP-3 being found in the cytosol (Muda et al.,
1996a). It is believed that specific sequences within the amino-terminal region of the 
phosphatases could be responsible for their subcellular localisation, as well as their 
substrate specificity (Camps et al., 2000). MKP-3 is able to completely inactivate 
ERK1/2 at low concentrations, but not JNK or p38, whereas M3/6 is able to completely 
inactivate JNK and p38, but not ERK1/2 (Muda et al., 1996b). Other MKPs also show 
preference for one MAPK or another, with MKP-4 being more proficient at inactivating 
ERKs and MKP-1, despite being originally identified as an ERK1/2 phosphatase, has 
been shown to prefer JNK and p38s (Muda et al., 1997; Sun et al., 1993; Franklin and 
Kraft, 1997).
The first MKP to be identified was MKP-1, as an immediate early gene in mice 
(Charles et al., 1992). Further investigation has since found that other members of the 
MKPs, such as MKP-2 and PAC-1, are also immediate early genes, whose expression 
can be induced by activation of MAPKs (Brondello et al., 1997; Grumont et al., 1996; 
Bokemeyer et al., 1996). This suggests a mechanism for negative feedback of MAPK 
signalling cascades, and a way of inhibiting pools of MAPKs which have not yet been
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activated, adding evidence to the hypothesis that the activation of these kinase cascades 
is highly regulated (Camps et al., 2000).
1.10 Phosphoprotein Substrates and Synaptic Plasticity.
As research into neurotransmitter release progresses, it is becoming evident that many 
of the proteins involved in regulating synaptic vesicle exocytosis and endocytosis are 
themselves subject to regulation by phosphorylation. For example, the t-SNARE, 
SNAP-25, has been shown to be phosphorylated by PKA (Risinger and Bennett, 1999; 
Hepp et al., 2002) which, in chromaffin cells at least, results in an increased number of 
primed synaptic vesicles ready for release (Nagy et al., 2004). The active zone protein 
Rim la  has also been shown to be phosphorylated by PKA, resulting in the induction of 
LTP in cerebellar parallel fibre synapses (Lonart et al., 2003). As well as this, the 
dephosphins, a family of proteins involved the endocytosis of synaptic vesicles, are 
known to be regulated by phosphorylation. However, they tend to be highly 
phosphorylated in resting states and undergo rapid dephosphorylation following nerve 
terminal depolarisation (Cousin and Robinson, 2001b). An example of a dephosphin is 
dynamin, which is phosphorylated by PKC (Cousin et al., 2001a; Powell et al., 2000) 
and following rapid dephosphorylation, mediates vesicle fission (Cousin and Robinson, 
2001b). Many more components of the synaptic vesicle cycle are beginning to be seen 
to undergo phosphorylation, such as cysteine string protein, rabphilin, and snapin 
(Chheda et al., 2001; Evans et al., 2001b; Lonart and Sudhof, 2001), though the exact 
roles for these phosphorylations are awaiting further elucidation. The synaptic vesicle 
tethering protein, synapsin, is also a phosphoprotein whose phosphorylation state is 
known to be regulated by several protein kinases and phosphatases, including ERK 1,2 
(Jovanovic et al., 2001). As a result of the regulation by ERK 1,2, this family of 
phosphoproteins, and their role in regulating neurotransmitter release, is described in 
more detail in the following section.
1.10.1 Synapsins
Synapsins were initially identified as proteins found in the brain which could act as 
substrates for multiple protein kinases (Johnson et al., 1971; Krueger et al., 1977). 
Synapsins were subsequently found to be abundant presynaptic proteins, accounting for 
up to 6% of the total vesicular protein present. There are three separate genes which 
can encode for synapsin in vertebrates (I, II and II), which can be alternatively spliced
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to produce a, b and b-like isoforms (Sudhof et al., 1989; Hosaka and Sudhof, 1998; Kao 
et al., 1998). Invertebrates seem to only have one gene for the encoding of synapsin, 
but are able to produce multiple isoforms through alternative splicing (Klagges et al., 
1996). The synapsin isoforms found in mammals have been shown to be differentially 
distributed, but the physiological relevance of this has yet to be determined.
Further investigations into the roles of synapsin have identified binding interactions 
with synaptic vesicles, actin, microtubules, neurofilaments and brain spectrin. Binding 
to vesicles occurs with high affinity in a two stage process, involving both protein and 
phospholipid interactions. The polar head region of synapsin first contacts with the 
surface of the vesicle membrane through electrostatic interactions. This is followed by 
a conformational change in the protein which leads to the penetration of specific regions 
within the C-terminal domain into the hydrophobic core of the vesicle lipid membrane 
bilayer. It is estimated that each vesicle can bind between 20 and 30 synapsin 
molecules at any one time (Hilfiker et al., 1999). These binding properties of synapsin 
have led to suggestions of the involvement of these proteins in the tethering of synaptic 
vesicles to the actin cytoskeleton, in the formation of the reserve pool of vesicles 
(Hilfiker et al., 1999). Further studies, involving genetic modification and localisation, 
have provided evidence for a causal link between synapsin-mediated regulation of the 
reserve pool of vesicles and regulation of neurotransmitter release (Jovanovic et al., 
2000). The interaction between synapsin and actin has been shown to be dependent on 
the phosphorylation state of synapsin. Thus it has been suggested that, upon 
phosphorylation of synapsin, vesicles can be untethered from the reserve pool and 
migrate to the readily releasable pool where they act to increase neurotransmitter release 
(Jovanovic et al., 1996). Fairly recent experiments have finally provided some direct 
physiological evidence for the role of synapsin I as a phosphorylation-state-dependent 
regulator of synaptic vesicle mobilisation. Results obtained using green fluorescent 
protein-labelled synapsin la in hippocampal cell cultures, confirmed that synapsin I can 
indeed dissociate from synaptic vesicles during action potential firing. Synapsin I was 
found to disperse into axons, which correlated with vesicle pool mobilisation, and then 
recluster to synapses following cessation of the stimulation (Chi et al., 2001).
The interactions of synapsin I with actin are regulated by the phosphorylation of 
multiple sites on synapsin. Phosphorylation of synapsin can be induced following
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depolarisation or by extracellular stimuli, and can decrease the affinity of the phospho­
protein for actin. There are currently believed to be seven different phosphorylation 
sites found on synapsin I, which can be regulated by different protein kinases and 
phosphatases, as well as by Ca2+, and have been summarised in the following table 
(Jovanovic et al., 2001; Sakurada et al., 2002).
Table 1.10: Regulation of Synapsin I Phosphorylation Sites.
Phosphorylation
Site
Site
Terminology
Kinases Phosphatase
Response to 
Ca2+ influx
Serine-9 1
PKA
CaMKI/IV
PP2A 4
Serine-566 2 CaMKII
PAK1
PP2A 4Serine-603 3
Serine-62 4
ERK1,2 PP2B 4Serine-67 5
Serine-549 6
ERK1,2
Cdkl,5
PP2B 4
Serine-511 7 Cdk5
Data obtained from (Jovanovic et al., 2001) and (Sakurada et al., 2002).
PI3-K has also been shown to associate with synapsin in intact nerve terminals, though 
its exact site is yet to be identified. Disruption of either PI3-K activity or its interaction 
with synapsin was found to inhibit replenishment of the readily releasable pool of 
vesicles from the reserve pool (Cousin et al., 2003).
The phosphorylation of synapsin I by ERK1/2 is particularly relevant to this thesis. 
BDNF has been shown to increase depolarisation-induced glutamate release from 
cerebrocortical nerve terminals. It is believed to do this through increasing vesicle 
availability following synapsin site 4/5 phosphorylation mediated by ERK1/2, which is 
activated downstream of trkB stimulation (Jovanovic et al., 2000). Phosphorylation of 
synapsin I by ERK 1/2 has been shown to regulate interactions with the actin 
cytoskeleton (Jovanovic et al., 1996) and more recently, to regulate interactions with
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synaptic vesicles following a range of electrical stimuli (5-20Hz) in vitro (Chi et al., 
2003). ERK1/2 has also been shown to mediate synapsin site 4/5 phosphorylation in 
vivo (Yamagata et al., 2002), adding increasing evidence to the suggestion that ERK1/2 
activation is able to increase glutamate release from nerve terminals through increasing 
vesicle availability following the phosphorylation of synasin I. This thesis is 
investigating other pathways, which can also increase glutamate release, to see if they 
could be stimulating ERK 1/2 and synapsin site 4/5 phosphorylation as a mechanism for 
this modulation.
The identification of the role of synapsins in the regulation of neurotransmitter release 
has led to a plethora of studies investigating the participation of synapsin in human 
diseases of the central nervous system. Specific decreases in the levels of synapsin 
expression have been associated with Alzheimer’s disease, schizophrenia, bipolar 
disorders and amyotrophic lateral sclerosis (Qin et al., 2004; Vawter et al., 2002; 
Ikemoto et al., 2002). Other diseases have been associated with abnormalities in 
synapsin phosphorylation, including Huntington’s disease and schizophrenia (Lievens et 
al., 2002; Porton et al., 2004).
As well as a fairly well documented role in regulating vesicle availability in the 
modulation of neurotransmitter release, synapsin has also been linked with the 
regulation of endocytosis. In a study using the giant synapse in lamprey to examine 
synapsin distribution during synaptic activity, synapsin was found to migrate from the 
vesicle cluster to the endocytic zones, where it appeared to be involved in vesicle 
recycling (Bloom et al., 2003).
There is also a growing body of evidence to suggest that synapsins have a broad role in 
neuronal development. They have been found to participate in the formation and 
maintenance of synaptic contacts between central neurones, as well as having specific 
roles in the elongation of undifferentiated processes and their consequent differentiation 
into axons and dendrites (Ferreira and Paganoni, 2002). In addition, the role in neuronal 
development may not be limited solely to young, developing nervous systems. The 
location of synapsin III to the cell bodies and processes of ‘plastic’ neurones in mouse 
adult hippocampi and olfactory bulbs, suggests an involvement of synapsin III in adult 
neurogenesis (Pieribone et al., 2002). Synapsin I may also be involved in the
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translocation of vesicles, by fast axonal transport, to the elongated membranes in 
regenerating sprouts following ligation crush injury of sciatic nerves in rats (Kwon et 
al., 2000).
1.11 Multiple Mechanisms of ERK 1,2 Activation Downstream of GPCR Signalling
Ligands that act at GPCRs can regulate signalling to ERK1/2 in many different ways. 
The mechanisms involved seem to be determined by the composition of the G-protein 
subunits coupled to the receptor and by the subcellular localisation of the receptors 
(English et al., 1999).
1.11.1 Gs-Coupled Receptors
These receptors are linked to adenylate cyclase activation upon agonist binding. The 
resulting increase in cAMP levels has been shown to decrease, increase, or have no 
effect on ERK1/2 phosphorylation levels. The differences in effects on ERK1/2 
activation appear to be dependent on the cell type being investigated, though other 
factors may also be involved.
In rat lhER fibroblasts, forskolin-stimulated increases in cAMP levels were found to 
block EGF-induced stimulation of MAPK phosphorylation. Further investigation found 
that PKA was phosphorylating Raf-1 on serine 43 in the regulatory domain, which 
reduced the apparent affinity of Raf-1 for Ras (Wu et al., 1993). Subsequent studies 
have identified further inhibitory PKA phosphorylation sites on Raf-1, including serine 
621, which appears to be essential for catalytic activity and can interfere with Ras 
binding (Mischak et al., 1996), and serine 259. It has recently been confirmed that PKA 
is able to phosphorylate all these sites on Raf-1 in vivo, with Raf-1 inhibition mainly 
being mediated through serine 259 (Dhillon et al., 2002).
In neuroendocrine cells, the increase in cAMP levels produced by Gas stimulation of 
adenylate cyclase has been found to enhance ERK1/2 activation. This signalling 
pathway is believed to involve the recruitment of Rap-1 and B-Raf, rather than Ras-1 
and Raf-1, in the stimulation of ERK1/2. Guanine nucleotide-exchange factors have 
been identified for Rap-1 which can be stimulated directly by cAMP, such as Epac (de 
Rooij et al., 1998). Rap-l-GTP then goes on to activate B-Raf, which can feed into the
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ERK1/2 cascade at the level of MEK1/2. PKA has also been found to directly 
phosphorylate Rap-1, leading to sequential B-Raf/MEK/ERKl ,2 activation (Lerosey et 
al., 1991; English et al., 1999). However, in some systems Rap-1 has been shown to 
inhibit Ras signalling to Raf-1 by sequestering Raf-1, thus inhibiting the activation of 
ERK1/2 (English et al., 1999). Some studies have suggested that the nature of the 
signalling through Rap-1, whether through B-Raf leading to stimulation of ERK1/2, or 
through Raf-1 leading to inhibition of ERKl/2, is determined by the expression levels 
of B-Raf (Erhardt et al., 1995). Another mechanism for mediating Gas stimulation of 
ERKl/2 is just recently beginning to be elucidated. Signalling through Gas has been 
shown to enhance ERKl/2 phosphorylation through activation of Raf-1 via Src. This 
has been shown to be through a direct interaction between Gas and Src in vitro, though 
its physiological relevance is yet to be determined (English et al., 1999).
1.11.2 Gi-Coupled Receptors
Evidence for the phosphorylation of ERKl/2 following Gi/o receptor activation 
suggests it is the py subunit of the heterotrimeric G-protein complex that is involved in 
mediating the ERKl/2 activation (Koch et al., 1994). This process is believed to 
involve Src, but it is not known whether this is through a direct interaction, or through a 
PI3K intermediary (Luttrell et al., 1996; Lopez-Ilasaca et al., 1997). G-protein py 
subunits have also been shown to activate the MAP kinase pathway at the level of GEFs 
(Crespo et al., 1994), calmodulin can also do this but only via an increase in 
intracellular calcium (Farnsworth et al., 1995).
1.11.3 Gq-Coupled Receptors
These receptors are known to stimulate the activity of phospholipase Cp (PLCP), thus 
producing the second messengers DAG and IP3, which can lead to the activation of 
some PKC isoforms (as described in section 1.6.2). PKC was originally shown to 
directly phosphorylate Raf-1 in a manner which enables it to go on to stimulate 
MEK1/2 activation, thus providing a Ras-independent mechanism for PKC-mediated 
activation of the ERKl/2 signalling cascade (Kolch et al., 1993). However, other 
studies found that phosphorylation of Raf-1 by PKC was not sufficient in itself to 
increase Raf-1 phosphorylation of MEK (Macdonald et al., 1993). More recent studies 
suggest that PKC can stimulate ERKl/2 activation through a mechanism distinct from
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that of the receptor tyrosine kinases, by phosphorylating Raf-1 to facilitate its full 
activation upon binding to Ras (Marais et al., 1998). It should be noted that the Ras- 
dependency of PKC signalling to ERKl/2 could be dependent upon cell type and so 
further studies need to be conducted to clarify this.
Gaq-coupled receptors have also been found to stimulate the ERKl/2 cascade in a 
PKC-independent manner. Ras-GEFs have been identified which are directly
2_j_
stimulated by the binding of the second messenger, DAG, such as CalDAG. Ca - 
dependent Ras-GEFs, such as Ras-GRF (Ras-guanine-nucleotide-releasing factor) are 
also found in neurones. These can be stimulated by the rises in intracellular Ca levels 
brought about by the other product of PLC-mediated hydrolysis of PIP2, IP3. IP3 can act
9+on intracellular receptors to mediate the release of Ca from intracellular stores 
(English et al., 1999).
1.12 Preparations Used to Study Presynaptic Function
This thesis focuses on the cross-talk of signalling cascades in the modulation of 
presynaptic function. There are several preparations that could be used to examine this 
phenomenon, namely: brain slices, primary neuronal cultures, and isolated nerve 
terminals (synaptosomes). Brain slices contain mixed poopulations of neurones with 
some in situ neuronal connections remaining intact. This makes it a particularly good 
preparation for examining postsynaptic changes brought on by presynaptic electrical 
stimulation. Although it is possible to examine transmitter release with this preparation, 
the presence of the postsynaptic cell makes it difficult to establish whether the 
activation of signalling cascades is brought about by pre- or postsynaptic receptor 
modulation. The same problem is encountered when using primary neuronal cell 
cultures which, although can provide a purer population of neurones, does not lend itself 
to the examination of the presynaptic nerve terminal in complete isolation from the 
postsynaptic nerve terminal. The isolated nerve terminals preparation, however, is an 
acute procedure which results in the production of isolated presynaptic nerve terminals, 
thus making it possible to examine the presynaptic signalling cascades without the 
ambiguity of signalling from receptors on the cell body. It is for this reason that the 
preparation chosen here, to examine the cross-talk of signalling pathways in the 
modulation of presynaptic function, is the isolated nerve terminal preparation.
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1.12.1 The Isolated Nerve Terminal (Synaptosome)
Synaptosomes are small (0.5-1.0pm) plasma membrane delimited nerve terminals 
which have been pinched off from axons during homogenisation and isolated using 
differential centrifugation. Electron microscopy has shown the synaptosomes to contain
1-2 mitochondria and a high density of small synaptic vesicle (SSVs), clustered around 
the active zone (Surchev, 1987; Dunkley et al., 1988). These nerve terminals are 
metabolically active, being able to produce ATP, and can maintain a resting membrane 
potential of between -60 and -70mV (Nicholls, 1989). They are also able to control 
intracellular Ca2+ concentrations, by way of a Ca2+-ATPase, with 0.1-0.3mM levels 
being maintained within polarised synaptosomes (Nicholls et al., 1987). The
• •  2 " badvantages for using synaptosomes are that signalling cascades and the Ca -dependent 
release of multiple transmitters can be examined in isolation form the cell body. 
However, it should be noted that these preparations contain a heterogenous population 
of neurones, making it difficult to measure responses of a particul subset of nerve 
terminals in isolation. Although synaptosomes are metabolically active, the absence of 
a nucleus means they can only be used as an acute preparation, lasting 4-6 hours, and so 
cannot be used to examine long term changes in transmitter release, or to examine the 
effects of changes in gene or protein expression.
Electrical stimulation can be used to evoke transmitter release from synaptosomes but 
this results in a Ca2+-independent release and so biochemical methods are usually 
favoured (Bradford, 1970b; Bradford, 1970a; Bradford et al., 1973; De Belleroche and 
Bradford, 1977). KC1 is often used to cause depolarisation of isolated nerve terminals 
and neurotransmitter release, through clamping of the membrane potential, however this 
is not thought to be particularly physiological as it is not sensitive to the Na+ channel 
blocker tetrodotoxin (Tibbs et al., 1989). 4-aminopyridine (White et al., 2003) is a K+ 
channel blocker which elicits nerve terminals depolarisation through destabilising the 
membrane potential. This method for evoking release is sensitive to tetrodotoxin, but 
will result in random depolarising events, rather than the global depolarisation obtained 
with KC1 (Tibbs et al., 1989). Ionophores, such as ionomycin and A23187, can also be 
used to examine neurotransmitter release. Application of ionomycin or A23187 results 
in random Ca2+ influx into the nerve terminals, allowing for the examination of release 
downstream of Ca2+ channel modulation. However, this is not quite the same as the
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stimulation of release following Ca2+ influx through voltage-dependent Ca2+ channels, 
which leads to very localised increases in Ca2+ at the active zone, rather than the 
"delocalised" increases in Ca2+ concentration resulting from the treatment with 
ionophores (McMahon and Nicholls, 1990; Sihra et al., 1992; Verhage et al., 1991).
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1.13 PhD Aims
The above discussion has highlighted the importance of ERK 1,2 as post-mitotic 
signalling molecules, that are not only activated through the traditional 
trk. Ras/RafTMEK/ERK pathway but are also open to regulation via cross-talk with the 
cAMP/PKA and PKC signalling cascades. This evidence, combined with studies 
implicating all three of these signalling cascades in the regulation of glutamate 
neurotransmitter release, has led me to examine the hypothesis of whether cAMP/PKA 
and PKC signalling cascades could be cross-talking with ERK in the regulation of 
presynaptic function. More specifically, I aim:
• To investigate the cross-talk of presynaptic signalling cascades in the regulation 
of ERK 1,2 activation in cerebrocortical nerve terminals.
• To identify the involvement of upstream presynaptic receptors in regulating the 
cross-talk of signalling cascades with ERK 1,2 in cerebrocortical nerve 
terminals.
• To elucidate the possible roles of signalling cross-talk with the ERK 1,2 cascade 
in the modulation of presynaptic function, through the examination of the 
activation of the downstream effector, synapsin I, and the regulation of 
glutamate release.
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Chapter 2
Materials and Methods
2. Materials and Methods
2.1 Preparation of Rat Brain Synaptosomes
Isolated nerve terminals were prepared from the cerebrocortices of 150-200g male 
Sprague-Dawley rats using the previously described methods of differential 
centrifugation and Percoll gradient purification (Dunkley et al., 1986; Sihra, 1997). A 
Percoll purified preparation was used, rather than the P2 level of isolation, as this 
process removes the majority of the free mitochondria, myelin and broken postsynaptic 
membranes that contaminate the P2 preparation (Dunkley et al., 1986; Dunkley et al., 
1988). All steps in this section were carried out at 4°C.
Percoll gradients were prepared in advance consisting of a lower layer of a solution 
containing 23% Percoll, a middle layer solution containing 10% Percoll, and an upper 
layer consisting of a 3% Percoll solution. As well as containing 3,10, or 23% Percoll, 
these solutions also contained 320mM sucrose, ImM EDTA, and 250pM DTT and had 
a pH of 7.4 (Dunkley et al., 1986; Sihra, 1997).
Animals were killed by stunning followed by decapitation according to Schedule 1 
procedures under the Home Office Animals (Scientific Procedures) Act of 1986. The 
brains were removed rapidly onto ice and the cerebrocortices dissected out. Each 
hemisphere was homogenised in 30ml of 320mM sucrose solution (pH 7.4) using a 
Potter-Elvehjem tissue grinder and Teflon pestle with 0.1-.015mm clearance (spinning 
at 900rpm). The homogenate was then centrifuged at 3,000 x g for two minutes and the 
resulting supernatant (SI) transferred to a fresh tube and recentrifuged at 14,500 x g for 
11 minutes. Following this centrifugation the supernatant (S2) was discarded and the 
remaining crude synaptosomal pellet (P2) was resuspended in the sucrose solution and 
homogenised using a loose, glass-to-glass, Dounce homogeniser to disperse the nerve 
terminals. The resuspension of crude synaptosomes from two P2 pellets (equivalent to 
one brain) was diluted to 8ml with sucrose solution and 2ml carefully layered onto the 
top, 3%, layer of each of the Percoll gradients. The gradients were resolved by 
centrifugation at 32,500 x g for 6 minutes. The synaptosomal fraction, found between 
the 23% and 10% layers, was harvested into 40ml HBM (Hepes-buffered medium 
containing: 20mM Hepes, pH7.4, 140mM NaCl, 5mM KC1, 5mM NaHCOs, 1.2mM
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Na2HP04 , ImM MgC^, lOmM Glucose) and centrifuged at 27,000 x g for 10 minutes 
as a wash step. The resulting pellet was resuspended to 2-3ml using HBM before 
duplicate aliquots of 5 and lOpl were assayed for protein concentration using the 
Bradford method (Bradford, 1976). Aliquots of synaptosomal resuspension were placed 
into tubes containing 8ml of HBM, as a final wash before centrifugation at 3,000 x g for 
10 minutes to obtain the final pellets. Pellets were stored on ice (4°C), until required 
and all synaptosome pellets were used within four hours of purification. All 
centrifugation steps were carried out using a Beckman J2-21M/E centrifuge with a JA- 
20 rotor (or JA-20.1 rotor for the final pelleting step) (Dunkley et al., 1986; Sihra,
1997).
2.2 Measurement of Glutamate Release
A direct cumulative measurement of glutamate release was conducted using an 
enzymatic assay system whereby glutamate was metabolised to 2 -oxoglutarate by 
exogenous glutamate dehydrogenase with exogenous NADP as a cofactor. This process 
of oxidative deamination resulted in the reduction of NADP to the fluorescent NADPH. 
By measuring the level of fluorescence increase of the system, the amount of released 
and metabolised glutamate could be thereby be ascertained assuming a direct 1:1 
correlation between the NADPH produced and the glutamate released (see Figure 2.1).
Figure 2.1 Glutamate Release Assay
To calibrate this fluorescence response, 5nmol of exogenous glutamate standard was 
routinely added at the end of each incubation, and the steady-state fluorescence 
response induced by this addition used to carry out a point-by-point calculation of the
glutamate
glutamate
dehydrogenase
NADP
NADPH
2-oxoglutarate
A,Ex340
A,Em460
62
foregoing glutamate release as nmol/mg synaptosomal protein. This assay for 
measuring glutamate release was originally developed using synaptosomes purified 
from guinea-pig cerebral cortices (Nicholls and Sihra, 1986). Subsequent studies have 
also found this protocol useful for measuring glutamate release from synaptosomes 
purified from the cerebral cortices of rats and mice, as well as from other brain regions 
such as the hippocampus (Sanchez-Prieto et al., 1987; Jovanovic et al., 2000; 
Rodriguez-Moreno and Sihra, 2004).
2.2.1 Measurement of Glutamate Release from Synaptosomes
Synaptosomes were stored on ice as 0.3 mg pellets and resuspended in HBM 
containinglmg/ml bovine serum albumin (BSA), to give a final synaptosomal protein 
concentration of 0.2mg/ml. The resuspension was transferred to a magnetically stirred 
cuvette in a Perkin-Elmer LS3B Spectrofluorometer (Perkin-Elmer, Emeryville, CA) 
and maintained at 37°C. Excitation and emission wavelengths were 340nm and 460nm 
respectively. Glutamate dehydrogenase (GDH, 50U/ml) and nicotinamide adenine 
dinucleotide phosphate (NADP, 2mM) were added after 2 minutes, followed by the 
addition of ImM CaCh after 5 minutes, as a standard procedure. Either ImM 4- 
aminopyridine (White et al., 2003) or 5pM ionomycin was used to stimulate glutamate 
release after 13 minutes of incubation, which was calibrated and measured using 5nmol 
exogenous glutamate standards applied 18 minutes after commencing the 37°C 
incubation (see Scheme 2.1). To allow direct comparisons of effects on depolarisation- 
induced release to be made, release traces were aligned horizontally and vertically at the 
point of secretogogue addition and initiation of glutamate release. Data was analysed 
using Lotus 1,2,3 spreadsheet and Origin (Microcal) graphical software. This protocol 
has been adapted from others which have been previously published (Nicholls and 
Sihra, 1986; Perkinton and Sihra, 1999).
Scheme 2.1 Standard Protocol for Measuring Glutamate Release.
Omins 2mins 5mins 13mins 18mins 20mins
Add to GDH/ CaCL 4-AP/ Glutamate End
• fluorimeter NADP Ionomycin Standard
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The drugs whose effects were to be tested on glutamate release were applied prior to the 
addition of the secretogogue, with times and concentrations specified in the relevant 
chapter.
2.3 Measuring Intracellular Calcium Concentration (Fura-2-AM)
Fura-2 is a fluorescent Ca2+-chelating agent which has been used to study intracellular
9-4- 9-4-Ca concentrations in many tissues. It is a ratiometric dye and, upon Ca -chelation,
♦ •  2 " hexhibits an excitation shift from 380nm to 340nm, making it possible to measure Ca 
concentrations through examining the ratio between the two excitation values.
Emission values are measured at a wavelength of 510nm. Ratiometric dyes are
* 9-j- •advantageous compared to single wavelength dyes, as the resultant evaluation of Ca is 
rendered independent of differences in dye loading and thereby unaffected by factors 
such as cell/preparation thickness/depth. The addition of an acetoxymethyl ester group 
to Fura-2 enables it to cross cell membranes into the cell, where the acetoxymethyl ester 
group is removed from the ester by cytosolic esterases, thereby trapping the charged 
(Foster and Fagg, 1984) indicator within the synaptosome (Grynkiewicz et al., 1985).
2.3.1 Fura-2-AM Loading of Synaptosomes
Pellets of synaptosomes (0.5mg) were resuspended at 4°C using 1ml of HBM 
containing lmg of BSA. The synaptosomes were then put to preincubate at 37°C for 20 
minutes, with magnetic stirring. Fura-2-AM (5pM) was added immediately after 
transferring the synaptosomes to the waterbath and CaCh (O.lmM) was added 
following 3 minutes of incubation. A 20 minute preincubation protocol was used to 
ensure adequate incorporation of the Fura-2 into the nerve terminals, to achieve 
reproducible measurements of cytosolic Ca2+. Following this preincubation, the 
synaptosomes were spun at 10,000 x g for 30 seconds using a microcentrifuge, to 
remove the unincorporated Fura-2 from the extracellular medium. Pellets were 
resuspended using 1.5ml of HBM and the washing procedure repeated once more to 
remove any residual indicator (Perkinton and Sihra, 1999).
2.3.2 Intracellular Ca Measurements
Synaptosomal pellets loaded with Fura-2 were resuspended in 1.5ml HBM and 
incubated in a Perkin-Elmer LS3B Spectrofluorometer (Perkin-Elmer, Emeryville, CA)
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at 37°C with magnetic stirring, for a total of 15mins, with the following additions being 
made: (see Scheme 2.2)
Scheme 2.2 Standard Protocol for Measuring Intracellular Calcium.
Omins 3mins lOmins 13mins 14mins 15mins
Add to CaCl2 4-AP SDS EGTA/Tris End
fluorimeter (ImM) (ImM) (0.2%) (lOmM/lmM)
Excitation wavelengths were cycled between 340nm and 380nm with fluorescent values 
being taken at the emission wavelength of 505nm, every 3.5secs and recorded digitally 
on a computer. Internal calibrations were made for every synaptosome incubation, 
defining the maximum and minimum Fura-2 fluorescence levels. Maximum 
fluorescence levels were obtained by the addition of 0.2% SDS to lyse the nerve 
terminals and thereby allow the complete saturation of Fura-2 in the incubation with the
0*4*excess ImM Ca present in the lysate. Minimum levels were measured following the 
subsequent chelation of this Ca2+ by 5mM Na-EGTA buffered with 1M tris. The Tris 
buffer was added in conjunction with EGTA to neutralise the increase in [H^] resulting 
from chelation of Ca2+ by EGTA, which would otherwise affect the fluorescent
0-4*response of the Fura-2/Ca adduct. This method for internal calibration in
synaptosomes has been previously described (Sihra et al., 1993). Free cytosolic
2 +
Ca concentration was subsequently calculated using the following equation 
(Grynkiewicz et al., 1985):
[Ca2+]c = Kj X (R' Rnm) X
(Rmax- R )  F maxX2
Kd = 224nM at 37°C
R = Experimental fluorescence ratio value (340/380)
Rmm = Minimum fluorescence ratio value 
Rmax = Maximum fluorescence ratio value 
FminX2 = Minimum fluorescence value at 380nm
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FmaxA2 = Maximum fluorescence value at 380nm
2.4 Identification of Downstream Effectors
Synaptosomal pellets were resuspended at 4°C to a concentration of 1 mg/ml using 
HBM containing lmg/ml BSA. CaCh (ImM) was added immediately before transfer of 
the resuspended synaptosomes to the 37°C waterbath. The exact incubation protocols 
used varied in detail depending on the aim of the individual experiment and are 
described in more detail below. Following the 37°C incubation, samples were stopped 
using 5x SDS-PAGE STOP buffer (1% (w/v) sodium dodecyl sulphate, 6.25mM Tris, 
pH 6 .8, 5% 2-mercaptoethanol, 10% (v/v) glycerol, and 0.001% (w/v) bromophenol 
blue) before being boiled for 5 minutes, in preparation for protein separation using 
SDS-PAGE (PolyAcrylamide Gel Electrophoresis) (Laemmli, 1970).
2.4.1 Standard Incubation Protocol
Following synaptosomal resuspension and addition of ImM CaCl2, synaptosomes were 
split into individual incubation tubes for each condition being tested. The tubes were 
transferred to the 37°C waterbath for a total of 10 minutes with the maximum possible 
time in the presence of a drug also being 10 minutes. Specific drug incubations are 
described in the methods section of each chapter. Each incubation was terminated with 
the addition of 5x SDS-PAGE STOP buffer (Jovanovic et al., 2000).
2.4.2 Preincubation Protocol
Resuspended synaptosomes containing ImM CaCl2 were divided into two preincubation 
tubes (control and test) before both tubes were put to incubate at 37°C, with stirring, for 
20 minutes. Drugs were added at different stages during this preincubation, depending 
on the specific drug used (as described in each chapter). Following this preincubation, 
both tubes were removed from the waterbath and centrifuged using a benchtop 
microcentrifuge (10,000 x g, 30 seconds) to pellet the synaptosomes. At this stage the 
supernatant was removed and either kept, or discarded as specified in each chapter. The 
synaptosome pellet was cooled to 4°C for 10 minutes before following the standard 10 
minute incubation protocol. The aim of this preincubation protocol was to introduce 
drugs into the synaptosomes which would normally take longer than 10 minutes to cross 
the plasma membrane in sufficient quantity to be effective.
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2.4.3 SDS-Polyacrylamide Gel Electrophoresis
A Hoeffer gel system was used with gels consisting of separate stacking and resolving 
dimensions. Resolving gel mixture routinely contained 7.5% acrylamide, 0.2% bis- 
acrylamide, 0.1% SDS and 325mM tris (pH 8 .8), and were polymerised using 75pl of 
10% ammonium persulphate (APS) and 50pl TEMED (N,N,N’,N’- 
tetramethylethylenediamine) per 30ml of resolving gel mix. Stacking gel mixture 
routinely contained 3.75% acrylamide, 0.1% bis-acrylamide, 0.1% SDS and 125mM tris 
(pH 6.8) and were polymerised using 50pl of 10% APS and IOjj.1 of TEMED per 10ml 
of stacking gel mix. Sample wells were formed using combs inserted during the 
polymerisation of the stacking gel, ensuring a minimum of 1cm migration for samples 
in the stacking phase. Gels were loaded with either lOpg or 20pg of synaptosomal 
protein (according to Bradford protein quantification), depending on the antibody used 
for immuoblotting and electrophoretic progress determined using visibly labelled 
molecular weight markers (Rainbow Markers, Amersham Pharmacia Biotech) ranging 
between 14.3KDa and 220KDa and including a marker at 46KDa. Gels were run in a 
buffer containing 25mM tris (pH 7.2), 192mM glycine and 0.1% SDS at a setting of 
80V through the stacking gel and 150V through the resolving gel (Laemmli, 1970).
2.4.4 Immunoblotting
Following separation using gel electrophoresis the synaptosomal proteins were 
transferred onto nitrocellulose membrane (Schleicher and Schuell) by electroblotting at 
200mA overnight. The transfer buffer contained 25mM tris (pH 7.2), 192mM glycine 
and 20% methanol to fix the proteins. The nitrocellulose was then dried before being 
labelled with Ponceau S (0.2% Ponceau Red, 3% TCA and 3% sulfosalicyclic acid) to 
verify even protein loading and transfer. Procedures for immunolabelling of the 
proteins varied for each antibody as detailed below (Burnette, 1981).
2.4.4.1 Phospho-p44/p42 MAP Kinase (Thr202/Tyr204) Antibody (NEB)
The nitrocellulose membranes used for labelling with this antibody had been obtained 
from gels loaded with 20pg of synaptosomal protein per lane. The nitrocellulose was 
first washed to remove any traces of Ponceau S, using three 10 minute incubations with 
tris-buffered saline (TBS: 20mM tris, pH 7.6, and 137mM NaCl) containing 0.1% 
Tween-20 (TBST). All incubations occurred at room temperature, unless otherwise
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specified, with constant agitation provided by a rocking platform (Stuart Scientific). 
Following washing, the membranes were incubated for 1 hour in blocking buffer 
containing lx  TBST and 5% w/v nonfat dry milk (Marvel Foods) to minimise non­
specific binding of the antibody. Blocked membranes were then labelled with the 
primary phospho-p42/p44 MAP kinase antibody (NEB) diluted 1:1000 in blocking 
buffer, by overnight incubation at 4°C. Following primary incubation, excess, unbound, 
antibody was washed off using one 5 minute incubation, proceeded by two 15 minute
incubations, in blocking buffer. In order to detect and quantitate levels of primary
1antibody binding, membranes were secondarily labelled by incubation with I-labelled 
protein A diluted in blocking buffer (18500dps/10ml of buffer) for one hour. Following 
secondary incubation, excess 125I-protein A was removed using one 5 minute wash step, 
proceeded by one 15 minute incubation in blocking buffer. In a final wash, milk protein 
was removed from the nitrocellulose membrane using one 5 minute incubation and a 
subsequent 15 minute incubation in TBST. The labelled membranes were then allowed 
to dry for 30 minutes before being exposed to a phosphorimager screen for radiolabel 
detection (Dai et al., 2001; Jovanovic et al., 2000).
2.4.4.2 Phospho-Synapsin I Site 1, Site 2/3, and Site 4/5
From herein the various synapsin antibodies are assigned a terminology relating to the 
original immunoglobulin production batch number. Thus, the synapsin antibody 
specific for site 1 phosphorylation is termed G257, site 2/3 termed RU19, and site 4/5 
termed G526 (Czemik et al., 1991; Jovanovic et al., 1996).
A similar protocol was followed for labelling nitrocellulose membranes with these 
phospho-synapsin antibodies, as for the phospho-p42/p44 MAP kinase antibody. The 
major differences included the composition of the tris-buffered saline (50mM tris (pH 
7.5) and 200mM NaCl, with 0.05% Tween-20 added to make TBST), the blocking 
buffer (lx  TBST with 2.5% w/v nonfat dried milk), and the length of the antibody 
incubation. Both RU19 and G526 were used at a dilution of 1:500 in an incubation 
lasting for 90 minutes at room temperature, whereas G257 was diluted to 1:200 for an 
incubation also lasting 90 minutes. Also, the nitrocellulose membranes used were 
obtained from gels resolving lOpg of synaptosomal protein per lane when labelling with 
RU19 and G257, and 20pg per lane when labelling with G526. These loadings have
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been characterised as producing linear antibody responses to increasing protein 
concentrations of the antibody in synaptosomal lysates (Czemik et al., 1991; Jovanovic 
et al., 1996).
The phospho-state specific antibodies used in this study were created using synthetic 
peptides containing permanently phosphorylated residues at positions corresponding to 
the phosphorylatable residues in the native protein. These synthetic phosphor-peptides 
were used to immunise rabbits and the resulting antibodies were harvested and purified 
using Protein A-Sepharose affinity chromatography to obtain IgG fractions based on Fc 
binding (Czemik et al., 1991). All such antibodies used in this study were either kind 
donations or purchased from companies, the details of which can be found in section 
2.7.3.
2.4.4.3 B-Raf Antibody
A similar protocol was used for labelling nitrocellulose membranes with this B-Raf 
antibody as for the phospho-synapsin I antibodies. TBST solution was standard, as 
described above, but the blocking buffer contained higher nonfat dried milk (5% w/v 
rather than 2.5%). The B-Raf primary antibody was used at a dilution of 1:250, with the 
incubation being conducted overnight at 4°C. Because this commercially acquired B- 
Raf antibody was raised in sheep, it binds poorly to Protein A (Harlow and Lane, 1988), 
and so 1251-labelled protein G (37000dps per 10ml of buffer) was used to probe for 
primary antibody binding instead (Moodie et al., 1994).
Following labelling all membranes were allowed to dry before being exposed to a 
phosphorimager screen either overnight or for 48 hours. Phosphorimage data was 
collected using Imagequant (Molecular Dynamics) and analysed using Origin 
(Microcal) graphical software.
2.5 Immunoblot Analysis
Radioactive Western blots were analysed by exposing a phosphorimager screen (Kodak) 
overnight and developed using a Typhoon 7100 phosphorimager/scanner (Molecular 
Dynamics or BioRad) to retrieve the images. Densitometric evaluation of the bands 
from the images was carried out using Imagequant software (Molecular Dynamics). 
Definitions of bands as “regions of interest” for evaluation was carried out using
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uniform-sized boxes to reduce band-to-band error due to differential contribution of 
background levels of radioactivity. The same sized region/box was also used to sample 
the background level of radioactivity on each blot, this being subtracted from each 
sample reading prior to further analysis. Following subtraction of background, the 
densitometry reading for each band was normalised to the 37°C control reading for that 
blot using the equation:
Normalised value =
(0,
100
(37°C control -  background)
X (sample -  background)
The data were normalised to obviate the inevitable blot-to-blot variability in absolute 
levels of blotting response. This normalisation also accounted for changes in reading 
levels due to changes in phosphorimager efficiency and, indeed, the use of different 
phosphorimager instruments, as was necessitated during the course of this work.
2.6 Statistical Analysis
All statistical analysis was carried out on data normalised as described in the previous 
section, with the exception of release data. Although analysis should ideally be carried 
out on raw data, it was not possible in this case due to large variability in the sensitivity 
of different phosphoimagers resulting in type II statistical errors. In order to try and 
prevent any reduction in validity, efforts were made to normalise the data in such a way 
so as to remove variation in the basal signalling levels obtained between blots, but to 
leave intact the differences between samples on any one blot.
The test used for assessing the confidence levels of any significant differences between 
two data sets was the Student’s paired t-test. An analysis of variance (ANOVA), 
followed by post hoc analysis with Duncan’s test, was used for assessing the confidence 
levels of differences between multiple data sets. Calculations were carried out using 
Excel spreadsheets (Microsoft) and WinStat (Microsoft).
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2.7 Reagents List
All reagents, with the exception of those listed below, were obtained from BDH 
Chemicals Ltd, Poole, Dorset and were of AnalaR grade.
2.7.1 Glutamate Release/Fura-2-AM Reagents
Glutamate dehydrogenase (GDH) type II from bovine liver (catalogue number G-2626), 
nicotinamide adenine dinucleotide (NADP), ionomycin (from Streptomyces 
conglobatus), L-glutamic acid, and ethylene glycol-bis(b-aminoethyl ether)-N,N,N’,N’,- 
tetraacetic acid (EGTA) were all obtained from Sigma-Aldrich Company, Gillingham, 
Dorset. 4-aminopyridine (White et al., 2003) was purchased from Tocris Cookson Ltd, 
Avonmouth, Bristol and Fura-2-AM was acquired from Molecular Probes c/o 
Cambridge BioScience, Cambridge.
2.7.2 Synaptosomal Preparation Reagents
Sucrose and purified water were obtained from BDH Chemicals Ltd, Poole, Dorset, but 
were of molecular biology grade and HPLC grade, respectively. Percoll, bovine serum 
albumin (BSA) and ethylenediaminetetraacetic acid (EDTA) were purchased from 
Sigma-Aldrich Company, Gillingham, Dorset.
2.7.3 Gel Electrophoresis/Immunoblotting Reagents
Phospho-p44/p42 MAP kinase (Thr202/Tyr204) antibody (phospho-ERKl,2 antibody), 
catalogue number 91 OIL, was purchased from New England Biolabs, Hitchin, 
Hertfordshire. This polyclonal antibody was produced by immunizing rabbits with a 
human phosphor-peptide containing the Thr202/Tyr204 region, and cross-reacts with rat 
forms of the protein. The B-Raf antibody, catalogue number 07-453, was purchased 
from Upstate Biotechnology, Milton Keynes. This antibody was raised in sheep using a 
peptide derived from the human form of B-Raf, and cross-reacts with the rat form of the 
kinase. The phospho-specific synapsin I antibodies were raised in rabbits at the 
Rockefeller University, New York, and were a kind gift from Professor Paul Greengard 
(Rockefeller University, New York), Dr. Andrew Czemik (Rockefeller University, New 
York) and Dr. Jasmina Jovanovic (London School of Pharmacy). 125I-labelled protein 
A and protein G were obtained from Amersham Pharmacia Biotech, Buckinghamshire. 
Acrylamide and bis-acrylamide were purchased as ready-made solutions (30% and 2%, 
respectively) from (National Diagnostic, Hull, UK).
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Chapter 3
Forskolin/IBMX-Mediated Modulation of Presynaptic Function: 
Cross-Talk of cAMP and ERK 1,2 Signalling Cascades.
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3.1 Introduction
The strength of synaptic connections within the brain has been shown to be a highly 
regulated phenomenon, in which both pre- and post-synaptic nerve terminals can play a 
part. Changes occur which can both enhance or diminish the transduction of signals 
across synapses, resulting in either short-term or long-term modifications. This process 
of synaptic plasticity has been shown to be regulated by numerous different modulators, 
including protein kinase A (PKA) (Roche et al., 1994; Greengard, 2001; Sheng and 
Kim, 2002; Waltereit and Weller, 2003).
Roles for cAMP/PKA have been described for short-term plastic phenomena, such as 
temporary decreases or increases in neurotransmitter release from presynaptic nerve 
terminals. For example, activation of the cAMP/PKA pathway in Lymnaea neurones 
has been shown to result in reduced synaptic efficacy during early synaptogenesis and 
plasticity (Munno et al., 2003), and increases in cAMP in the hippocampus have been 
shown to result in the depression of excitatory post synaptic potentials (EPSPs). This 
depression was believed to be due to adenosine receptor activation, following cAMP 
metabolism to adenosine (Gereau and Conn, 1994). However, increases in cAMP/PKA 
activation have also been linked with the enhancement of neurotransmission (in the 
form of glutamate release) in the CA3 region of the hippocampus (Lonart et al., 1998), 
at granule cell to Purkinje cells synapses in the cerebellum (Chen and Regehr, 1997), 
and in layer V of the entorhinal cortex (Evans et al., 2001a). In addition to glutamate, 
cAMP/PKA activation has been shown to increase the release of other 
neurotransmitters, for instance, Sciancalepore et al., found that the metabotropic 
glutamate receptor agonist, trans-ACPD, increased GABA release from hippocampal 
intemeurones in a PKA-dependent manner (Sciancalepore et al., 1995).
Long-term changes in synaptic strength can also be dependent on cAMP/PKA 
activation and roles for PKA have been described in the regulation of long-term 
depression (LTD) and in long-term potentiation (LTP). In the nucleus accumbens, 
activation of the PKA signalling cascade was shown to result in LTD, mediated by a 
PKA-dependent long-term reduction in Ca2+ influx through P/Q-type channels (Robbe 
et al., 2002). Activation of PKA and PKC was also found to be required for the
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induction of LTD in the medial perforant path of the dentate gyrus (Huang et al., 1999), 
whereas the CA3-CA1 synapse in the hippocampus was found to undergo cAMP/PKA- 
mediated LTP and LTD (Yu et al., 2001). An involvement of PKA in mossy fibre LTP
•  04 -was first identified in 1994, where Ca -influx was believed to activate type I adenylate 
cyclase, resulting in the downstream activation of PKA and a persistent enhancement in 
evoked glutamate release (Weisskopf et al., 1994). Since then, PKA activation has been 
shown to be required for the induction of cerebellar LTP (Salin et al., 1996; Linden and 
Ahn, 1999) and for corticothalamic LTP (Castro-Alamancos and Calcagnotto, 1999). 
PKA activation has also been shown to be able to increase the number of functional 
release sites in cultured neurones from the hippocampal region (Ma et al., 1999; Kohara 
et al., 2001).
cAMP/PKA-dependent signalling has been shown to regulate the enhancement of 
release from presynaptic nerve terminals through four different mechanisms. The first 
mechanism is through PKA-mediated regulation of membrane excitability, through the 
modification of ion channels. This form of regulation results in an increased 
excitability of the membrane leading to an increase in the propensity towards vesicle 
release (Dunwiddie et al., 1992; Herrero and Sanchez-Prieto, 1996). Secondly, direct 
PKA-regulation of Ca2+ channels could lead to increases in Ca2+ influx, and thus 
enhancement of Ca2+/exocytosis coupling (Catterall, 2000; Lonart et al., 1998). The 
third mechanism through which cAMP/PKA could increase glutamate release is via the 
regulation of the coupling of exocytotic machinery (Chen and Regehr, 1997; Lonart and 
Sudhof, 1998). PKA phosphorylation of components of the release machinery can lead
2~bto enhanced Ca -sensitivity and so increased probability of vesicle release (Trudeau et 
al., 1996). Consistent with this, some of the key members of the secretory apparatus 
and associated proteins have been shown to be substrates for PKA. These include the t- 
SNARE, SNAP-25 (Nagy et al., 2004), as well as Rab3A and RIM la, two proteins 
implicated in mossy fibre LTP (Lonart et al., 1998; Castillo et al., 2002). The fourth, 
and final, mechanism through which cAMP/PKA activation could result in the 
enhancement of glutamate release would be through increasing the availability of 
synaptic vesicles for exocytosis. PKA can phosphorylate the synaptic vesicle tethering 
protein, synapsin I, to decrease its interactions with actin thus allowing increased 
numbers of vesicles to migrate to the proximity of the active zone (Chi et al., 2001).
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Indeed, cAMP/PKA has been shown to increase the number of vesicles available for 
release during mossy fibre LTP (Lonart et al., 1998).
As research better defines the plastic changes occurring at synapses it is becoming 
evident that the specific involvement of PKA may vary between different synapses. For 
example, increases in cAMP levels were found to increase release at granule cell to 
purkinje cell synapses in rat cerebellum. The increase in cAMP was not found to alter 
Ca2+ influx, or change the presynaptic action potential, but it was found to increase the 
probability of release from existing active zones (Chen and Regehr, 1997). In contrast 
to this, the increase in cAMP/PKA activation in the CA3 region of the hippocampus has 
been shown to increase glutamate release through three separate mechanisms: through 
increasing the size of the readily releasable pool, through increasing Ca2+ influx and 
through enhancing Ca2+ action on the secretory apparatus (Lonart et al., 1998). This 
chapter focuses on the downstream pathways of cAMP/PKA signalling from 
synaptosomes purified from the rat cerebrocortex. Research to date, using this 
preparation, has identified several possible roles for PKA in the enhancement of 
depolarisation-induced glutamate release. It is possible that PKA may be regulating 
membrane excitability in this system, though this is yet to be confirmed (Herrero and 
Sanchez-Prieto, 1996). A more recent study, however, has shown that activation of 
PKA enhanced glutamate release from this system through increased Ca2+ influx from
^  I ^  I
Ca -channels, as well as through mechanisms occurring downstream of Ca entry, but 
not via regulation of membrane excitability (Wang and Sihra, 2003). This chapter 
aims to focus on the possible mechanisms of the cAMP/PKA mediated enhancement of
04-glutamate release that is occurring downstream of Ca entry, and whether the cross-talk 
of protein kinase signalling cascades could be involved in this regulation.
The neurotrophin, BDNF has been proposed to enhance glutamate release from purified 
cerebrocortical nerve terminals through ERKl,2-mediated phosphorylation of synapsin 
I (Jovanovic et al., 2000). This represents a mechanism for increasing glutamate release
^  I
downstream of Ca channel regulation. It is possible that direct and/or indirect 
phosphorylation of synapsin I by PKA represents a major modulatory contribution to 
enhanced release downstream of Ca entry. However, given the examples of 
cAMP/PKA signalling cross-talk with the ERK1,2 cascade in many other systems
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devoid of the synapsins as substrates, this is unlikely to be the sole mechanism, even in 
nerve terminals.
PKA has been shown to both stimulate and inhibit ERK1,2 phosphorylation in several 
systems. Inhibition of ERK1,2 activation can result from PKA-mediated inhibition of 
kinases shown to be upstream of ERK1,2 in signalling cascades. For example, PKA has 
been shown to inhibit Raf-1 through phosphorylation of several different serine 
residues, including Ser-259 and Ser-621 (Mischak et al., 1996; Dhillon et al., 2002), and 
also to inhibit B-Raf signalling (Sidovar et al., 2000; Konig et al., 2001). However, 
PKA has also been shown to stimulate ERK1,2 signalling through activation of the 
small GTPase proteins Ras-1 and Rap-1 (Schmitt and Stork, 2002; Norum et al., 2003), 
as well as through direct activation of B-Raf (Yamaguchi et al., 2003). The effect of 
PKA on ERK1,2 signalling has been found to be dependent on cell type and on serum 
conditions (Stork and Schmitt, 2002; Dhillon et al., 2002). As well as cAMP-dependent 
activation of PKA leading to the regulation of the ERK1,2 signalling cascade, cAMP 
has also been shown to stimulate ERK1,2 signalling in a manner independent of PKA. 
cAMP can directly activate a Rap-1 GEF known as Epac, leading to the formation of 
GTP-bound Rap-1 and activation of B-Raf/MEK/Erkl,2, a pathway which has been 
found to exist in several different systems (Laroche-Joubert et al., 2002; Fujita et al., 
2002; Berruti, 2003). cAMP can also directly stimulate Ras in melanocytes, which also 
results in the activation of B-RafrMEK and ERK1,2 (Busca et al., 2000). More 
recently, roles have been identified for the coupling of cAMP signalling to Rap-1, 
including an involvement in the control of early and late LTP in pyramidal cells in the 
hippocampus (Morozov et al., 2003).
This chapter focuses on the presynaptic roles of the cAMP/PKA signalling cascade in 
the regulation of glutamate release, and on its cross-talk with the ERK1,2 cascade. It 
aims to investigate whether cAMP/PKA could be stimulating ERK1,2 phosphorylation 
in cerebrocortical nerve terminals, and whether this could lead to downstream synapsin 
I phosphorylation. If so, this could provide a basis for cAMP/PKA modulation of 
glutamate release through increasing the availability of synaptic vesicles in 
cerebrocortical nerve terminals. This would not only suggest an alternative mechanism 
for cAMP/PKA modulation of glutamate release downstream of Ca2+ entry, but would 
also imply that distinct receptor-mediated signalling pathways coupled to protein
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phosphorylation could crosstalk with each other, to produce a convergent mechanism 
for the modulation of glutamate release.
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3.2 Method
Synaptosomes were prepared as described in section 2.1 (Sihra, 1997)
3.2.1. Glutamate Release
The standard glutamate release protocol was followed, as described in section 2.2 
(Nicholls and Sihra, 1986; Perkinton and Sihra, 1999). When used, forskolin (lOOpM) 
was added 4 minutes prior, IBMX (50pM) 2 minutes prior, as described by Wang et al., 
2003 (Wang and Sihra, 2003) and U0126 (IOjjM) 30 minutes prior (Brogley et al., 
1999), to the addition of the secretogogue. The secretogogues used were 4-AP (ImM) 
or ionomycin (5pM). All incubations took place in the presence of ImM CaCh.
3.2.2 Fura-2-AM
Synaptosomes were loaded with Fura-2-AM using established protocols, as described in 
chapter 2 in section 2.3, adapted from Perkinton et al., 1999 (Perkinton and Sihra,
94*1999). The protocol for measuring intracellular Ca levels was followed, with U0126 
(20pM) or DMSO (0.2%) being added to the synaptosomes after 3mins 30secs of 
incubation, 6mins and 3secs prior to the addition of 4-AP (ImM). Ratios were
•  •  O xconverted into cytosolic Ca concentrations using calibration procedures and formulae 
given in more detail in section 2.3.2 and described previously (Grynkiewicz et al., 1985; 
Sihra etal., 1993).
3.2.3 Standard Incubation for ERK 1,2 Phosphorylation/Activation
The synaptosomes were kept at 4°C whilst being resuspended to a final synaptosomal 
concentration of lmg/ml using HBM containing BSA. A final concentration of ImM 
CaCh was added prior to splitting the synaptosomes into individual incubation tubes. 
Forskolin (lOOpM), IBMX (50pM), H-89 (10pM), KT-5720 (lpM ) or Rp-cAMPS 
(50pM or lOOpM) were added immediately before transferring the incubation tubes to 
the 37°C waterbath. Incubations lasted for a standard time of 10 minutes before being 
terminated through addition of 5X SDS-PAGE sample stop buffer. This incubation 
protocol for measuring ERK 1,2 phosphorylation has previously been described by 
Jovanovic et al., 2000 (Jovanovic et al., 2000).
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3.2.4 Preincubation
Synaptosomes were resuspended at 4°C to a concentration of 1 mg/ml using HBM 
containing lmg/ml of BSA. CaCh (ImM) was added to the test tube containing the 
synaptosomes immediately prior to die transfer of the tube to the 37°C waterbath. The 
incubation lasted 20 minutes before the synaptosomes were recentrifuged using a 
microcentrifuge (10,000 x g for 30 seconds). The supernatant was discarded and the 
pellet cooled back to 4°C for 5 minutes. The standard incubation protocol was then 
utilised with the exception of forskolin (100pM) and IBMX (50pM) being added 6 
minutes and 30 seconds prior to the termination of the reactions, instead of 10 minutes 
prior.
Samples were processed for ERK 1,2, B-Raf and synapsin phosphorylation levels as 
described in the main methods in chapter 2, section 2.4, following previously published 
methods (Dai et al., 2001; Moodie et al., 1994; Jovanovic et al., 1996).
3.2.5 Reagents
Forskolin: Adenylate cyclase activator ([3R-(3a,4aP,5p,6p,6aa,10a,10a(3,10ba)]-5- 
(Acetyloxy)-3 -ethenyldodecahydro-6 ,10,10b-trihydroxy-3,4a,7,7,1 Oa-pentamethyl-1H- 
naphtho[2,l-b]pyran-l-one) (Seamon and Daly, 1981).
Dissolved in DMSO to a concentration of lOOmM to form the stock solution. This was 
further diluted with water to a concentration of lOmM, immediately prior to use.
IBMX: Phosphodiesterase inhibitor with antagonistic properties at adenosine receptors 
(3-isobutyl-1-methylxanthine) (Smellie et al., 1979; Dunwiddie et al., 1981).
This was dissolved in DMSO to give a lOOmM stock solution, which was diluted with 
water immediately prior to use to give a 5mM working solution.
U0126: MEK 1,2 inhibitor (l,4-diamino-2,3-dicyano-l,4-bis[2- 
aminophenylthiojbutadiene) (Favata et al., 1998).
20mM stock solutions were obtained by dissolving in DMSO, the 2mM working 
solution was obtained through addition of water to the stock solution.
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Fura-2-AM: Cell permeable Ca2+ fluorophore (l-[2-(5-Carboxyoxazol-2-yl)-6- 
aminobenzofxiran-5-oxy]-2-(2,-amino-5,-methyl-phenoxy)ethane-N,N,N’,N,-tetraacetic 
acid, pentaacetoxymethyl ester) (Grynkiewicz et al., 1985).
Dissolved in DMSO to give a stock solution of ImM, which was further diluted with 
water to a concentration of 500pM immediately prior to use.
H-89: PKA inhibitor acting at the catalytic site (N-[2-(p-Bromocinnamylamino)ethyl]- 
5-isoquinolinesulfonamide dihydrochloride) (Chijiwa et al., 1990).
This was dissolved with DMSO to give a stock concentration of lOmM, which was 
further diluted with water prior to use to give a concentration of ImM.
KT-5720: PKA inhibitor acting at the catalytic site ((9R,10S,12S)-2,3,9,10,11,12- 
Hexahydro-10-hydroxy-9-methyl-1 -oxo-9,12-epoxy-1 H-diindolo[ 1,2,3-fg: 3 ’ ,2 ’, 1’ - 
Kl]pyrrolo[3,4-i][l,6]benxodiazocine-10-carboxylic acid, hexyl ester) (Kase et al.,
1987; Gadbois et al., 1992).
This was dissolved to a concentration of ImM in DMSO and was further diluted before 
use to lOOpM with water.
Rp-cAMPS: PKA inhibitor acting at the regulatory site (Rp-adenosine 3’,5’-cyclic 
monophosphorothioate triethylammonium salt) (Botelho et al., 1988).
This was dissolved in water to a concentration of lOmM.
All the above drugs were purchased from the Sigma-Aldrich Company, Gillingham, 
Dorset, with the exception of U0126, which was obtained from Promega, Southampton, 
and Fura-2-AM, which was purchased from Molecular Probes, c/o Cambridge 
BioScience, Cambridge.
Unless stated, all drugs were added using lOOx stock solutions to minimise volume 
changes and only final concentrations are quoted in the text forthwith.
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3.3 Results
This chapter aimed to investigate whether the PKA and ERK1,2 signal transduction 
pathways could be cross-talking in the regulation of glutamate release from 
cerebrocortical nerve terminals. The first step towards this aim was to investigate 
whether stimulation of PKA could result in increased glutamate release and, perhaps
• 0 4 -  •more importantly, whether this could occur downstream of Ca channel regulation.
Two drugs were used in combination, both of which increase PKA activation through 
increasing intracellular levels of cAMP. Forskolin is a membrane permeable 
diterpenoid, which activates adenylyl cyclase to increase levels of cAMP (de Souza et 
al., 1983). IBMX increases cAMP levels through inhibiting the phosphodiesterase 
which would otherwise catalyse the breakdown of cAMP into 5’-AMP (Corbin and 
Francis, 2002). Addition of forskolin and IBMX prior to the secretogogue, 4-AP, 
elicited significantly higher cumulative levels of glutamate release than observed in the 
presence of the secretogogue alone (Figure 3.1) (mean ± s.e.m. cumulative glutamate 
release calculated from 8 independent experiments: control = 14.10 ± 1.3 nmol/mg; 
forskolin/lBMX = 25.04 ±3.0 nmol/mg). This is in complete agreement with previous 
studies examining the role of PKA in neurotransmitter regulation, which have also 
found increases in release following PKA stimulation (Herrero and Sanchez-Prieto, 
1996; Wang and Sihra, 2003). One of these previous studies has also shown that PKA
•  04 -can mcrease glutamate release through the modulation of Ca channel activation 
(Wang and Sihra, 2003). The following experiment was used to identify whether PKA 
could also be acting via an alternative mechanism, downstream of Ca2+-channel 
regulation, to increase glutamate release from cerebrocortical nerve terminals.
Ionomycin is an ionophore, which allows the influx of Ca2+ ions into nerve terminals
* 9.1independently of Ca channels. Effects of agents that would normally modulate 
synaptic excitability and/or Ca2+ channel function to regulate glutamate release would 
be obviated under these circumstances, making it possible to look for alternative 
mechanisms of release modulation downstream of Ca2+ influx. Under these conditions, 
with ionomycin used as the secretogogue, forskolin and IBMX were still able to 
significantly enhance glutamate release from cerebrocortical nerve terminals (Figure
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Figure 3.1 Forskolin/IBMX Enhances 4-AP-Evoked Glutamate Release.
Synaptosomes were incubated in the presence of ImM CaCh as indicated in section
3.2.1. Glutamate release was evoked with the addition of 4-AP (ImM, arrow) in the 
absence (control), or presence (+Forskolin/IBMX) of 1 OOpM and 50pM forskolin and 
IBMX, respectively, with forskolin added 2 min prior, and IBMX added 4 min prior to 
the addition of the secretogogue. The mean traces from eight independent experiments, 
measuring accumulative release at 2 sec intervals, are shown. Mean ± s.e.m. release 
was calculated at each time point, but the cumulative glutamate release values following 
4 min of incubation with the secretogogue were used for statistical analysis **P<0.01; 
different from control (Student’s paired t-test; n=8).
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Figure 3.2 Forskolin/IBMX Enhances Ionomycin-Elicited Glutamate Release.
Synaptosomes were incubated in the presence of ImM CaCb as described in section
3.2.1. 100pM forskolin and 50pM IBMX were added 4 min and 2 min, respectively, 
prior to the addition of the secretogogue. Glutamate release was elicited by addition of 
ionomycin (5pM, arrow) in the absence (control) or presence (+Forskolin/IBMX) of 
forskolin/IBMX. The mean traces from four independent experiments, measuring 
accumulative release at 2 sec intervals, are shown. Mean ± s.e.m. release was 
calculated at each time point, but the cumulative glutamate release values following 4 
min of incubation with the secretogogue were used for statistical analysis *P<0.05; 
different from control (Student’s paired t-test; n=4).
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3.2) (mean ± s.e.m. cumulative glutamate release calculated from 4 independent 
experiments: control = 8.86 ±1.3 nmol/mg; forskolin/IBMX = 13.56 ±1.3 
nmol/mg). This suggests that, as well as modulating Ca2+ channels, the cAMP/PKA
^ I
signalling cascade is also able to act at an alternative locus, downstream of Ca entry, 
to increase glutamate release from cerebrocortical nerve terminals.
The ERK1,2 signalling pathway was examined as potentially being the downstream site 
of action of cAMP and PKA signalling in nerve terminals. This pathway was 
specifically chosen as it has previously been shown to be involved in modulating 
glutamate release from nerve terminals (Jovanovic et al., 2000), as well as being open to 
regulation by PKA in some systems (Schmitt and Stork, 2002; Norum et al., 2003). 
Specific ERK1,2 inhibitors are not currently commercially available, but there are 
inhibitors of MEK1/2, the activating kinase directly upstream of ERK1,2. The next 
experiment in this chapter therefore looked at the effect of a MEK inhibitor, U0126 
(Favata et al., 1998), on glutamate release from nexve terminals. The ultimate aim of 
this approach was to test whether the inhibition of the ERK 1,2 cascade could attenuate, 
or abrogate the forskolin/IBMX enhancement of glutamate release and thereby directly 
implicate ERK1,2 activation downstream of cAMP production.
Synaptosomes were incubated at 37°C for 30 min with lOpM U0126, prior to the 
addition of the secretogogue, 4-AP. As can be seen from the graph in Figure 3.3, 
treatment with U0126 alone was able to significanttly enhance the glutamate release 
elicited by 4-AP. This unexpected finding could b*e explained through one of two 
mechanisms; either that U0126 is acting non-speciJically to increase glutamate release, 
or that the ERK1,2 signalling pathway has an inhibitory influence on glutamate release 
under the incubation protocols used herein. Although studies conducted in other labs 
have found U0126 to be relatively specific with respect to other kinases (Davies et al.,
2000), several irregularities have been noted wilh iits use in nerve terminals. For
2+example, U0126 was found to non-specifically joteentiate depolarisation-induced Ca - 
independent glutamate release from hippocampd synaptosomes (Pereira et al., 2002). 
Use of this MEK inhibitor has also resulted in slifits in the activation of dendritic K+ 
channels to more hyperpolarized potentials (Walaniabe et al., 2002), an effect that would 
also be expected to lead to enhanced excitability Fn order to obviate
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Figure 3.3 U0126 Enhances 4-AP-Evoked Glutamate Release.
Synaptosomes were incubated in the presence of ImM CaCh as indicated in section
3.2.1. Glutamate release was evoked using 4-AP (ImM, arrow) either in the absence 
(control) or presence (Pereira et al., 2002) of lOpM U0126, added 30 min prior to the 
addition of 4-AP. The mean traces from three independent experiments, measuring 
accumulative glutamate release at 2 sec intervals, are shown. Mean ± s.e.m. release was 
calculated at each time point, but the cumulative glutamate release values following 4 
min of incubation with the secretogogue were used for statistical analysis **P<0.05; 
different from control (Student’s paired t-test; n=3).
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the possible non-specific effects of U0126 on glutamate release, PD98059, the first 
established MEK inhibitor, (Dudley et al., 1995), could be considered as an alternative. 
Unfortunately however, although PD98059 has had obvious utility and value as a 
relatively specific inhibitor of MAP kinase pathways in many systems, the high intrinsic 
fluorescence and quenching properties of this compound makes it impossible to use 
with this enzyme-linked fluorescence assay for measuring cumulative glutamate release 
(Jovanovic et al., 2000). Additionally, PD98059 has also been shown to non-
 ^i
specifically regulate N and P/Q-type voltage-dependent Ca channels (Pereira et al.,
2002), complicating its relevance for use in examining the involvement of the ERK1,2 
signalling cascade in the regulation of glutamate release. Similarly, in control 
experiments looking at intracellular Ca concentrations in synaptosomes, an effect of 
U0126 in increasing basal Ca2+ levels (Figure 3.4) was also indicated, which could 
potentially suggest a locus for the unexpected facilitation of glutamate release seen with 
the use of this compound. Given the individual and overlapping problems encountered 
with the available MEK inhibitors, alternative approaches for investigating the roles of 
the MAPK signalling pathway were warranted. To most directly invoke a role for the 
kinase cascade in presynaptic modulation, in the following experiments we correlated 
actual levels of ERK 1,2 activation in response to the application of upstream regulators.
ERK1 and ERK2 are believed to be activated when they undergo dual phosphorylation 
of threonine and tyrosine residues (Payne et al., 1991). Antibodies have now been 
developed which are able to specifically detect the dually phosphorylated forms of these 
kinases, making it possible to detect levels of ERK1,2 activation in cells (Dai et al.,
2001). Thus, as an alternative to the foregoing problematic inhibitor studies, this 
antibody could be used to determine whether ERK1,2 activation/phosphorylation levels 
are enhanced when synaptosomes are treated with forskolin/IBMX. This would identify 
whether elements of the cAMP/PKA signalling cascade could be cross talking with the 
MAPK signalling cascade.
Figure 3.5 shows the results obtained using the phospho-specific ERK1,2 antibody 
when synaptosomes were incubated with forskolin and IBMX. As forskolin has been 
shown to inhibit ERK in some systems, albeit through a PKC-dependent mechanism 
(Siddhanti et al., 1995), both the combined and individual effects of forskolin and
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Figure 3.4 U0126 Can Increase Intracellular Ca2+ Concentration in Synaptosomes.
Synaptosomes were loaded with Fura-2-AM as described in chapter 2.3 and then 
incubated with ImM CaCE either in the presence (Pereira et al., 2002) or absence 
(control) of 20pM U0126. The arrow indicates the addition of 4-AP (ImM) to the 
nerve terminals. Excitation wavelengths of 340nm and 380nm were used, with 
fluorescence readings collected every 3.5sec at 505nm using a fluorimeter (Perkin- 
Elmer). Maximum and minimum Ca2+ levels were obtained and cytosolic Ca2+ 
concentrations were calculated. The graph shows representative synaptosomal cytosolic 
Ca2+ concentrations obtained in the presence and absence of the MEK inhibitor, U0126.
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IBMX on ERK1,2 phosphorylation levels were examined. No significant differences 
were found between the changes in phosphorylation levels of ERK1 compared to ERK2 
(data not shown), therefore henceforth, data are presented in terms of combined total 
ERK phosphorylation/activation levels.
The results show that both the treatments with IBMX alone, and IBMX combined with 
forskolin, were able to significantly increase ERK phosphorylation levels (mean ± 
s.e.m. in % compared to 100% 37°C control levels of total ERK phosphorylation:
IBMX = 122 ± 2; Forskolin/IBMX = 144 ± 13). The increase in ERK activation in the 
presence of forskolin was not found to be significantly different from control levels 
(mean ± s.e.m. in % compared to 100% 37°C control: Forskolin = 116 ± 4), however, it 
did not mediate the decrease in phosphorylation levels that has been observed in other 
systems. Of note from these experiments was the observation that when forskolin and 
IBMX were added in conjunction with each other, ERK1,2 phosphorylation levels were 
significantly higher than when either drug was added alone (P<0.05, ANOVA followed 
by Duncan’s post hoc analysis). This implies an aspect of additivity to their signalling 
pathways, suggesting that the two drugs were working together to increase levels of 
ERK1,2 activation in nerve terminals. These results are in complete agreement with 
other studies looking at forskolin/IBMX-mediated enhancement of glutamate release 
from cerebrocortical nerve terminals. The studies examining the properties of glutamate 
release found that application of forskolin on its own was unable to enhance 4-AP- 
elicited release, and IBMX was only able to cause a minimal increase in 4-AP-evoked 
release. However, combined application of both drugs induced a substantial increase in 
4-AP-elicited glutamate release from these nerve terminals (Wang and Sihra, 2003). As 
well as inhibiting phosphodiesterase activity, IBMX has also been shown to inhibit 
adenosine Ai receptor activation in synaptosomes (Wang and Sihra, 2003). Ai 
receptors, in turn, have been shown to have inhibitory influences in the central nervous 
system and are believed to be able to suppress signalling pathways (Lorenzen et al., 
1998; Park et al., 2001; Linden, 2001). Accordingly, in the aforementioned glutamate 
release studies, specific inhibitors of both Ai receptors and phosphodiesterase activity 
were able to enhance forskolin effects in the same manner as EBMX. This suggests that 
forskolin-mediated effects on glutamate release can be pharmacologically enhanced 
through two different means; via reduced catabolism of cAMP levels, and by
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Figure 3.5 Forskolin and IBMX-Mediated Stimulation of ERK 1,2 
Phosphorylation. Synaptosomes were incubated at 37°C with ImM CaC^ for 10 min 
either in the absence (control) or presence of lOOpM forskolin and/or 50pM IBMX 
(+forskolin and/or +IBMX). 7.5% polyacrylamide gels were run. Immunoblots were 
probed using phospho-MAPK antibody (1:1000, NEB) and reported using 125I-labelled 
protein A. Levels o f 1251-labelling were detected and analysed using phosphorimager 
spectroscopy (Molecular Dynamics). Mean ± s.e.m. ERK 1,2 phosphorylation levels 
were obtained from four separate experiments and normalised to individual 37°C 
controls. *P<0.05, **P<0.01 compared to 37°C control (ANOVA followed by 
Duncan’s post hoc analysis, n=4). A. Phosphorimage of forskolin/IBMX effect. B. 
Quantification of ERK 1,2 phosphorylation levels.
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the relief of inhibitory adenosine tone (Wang and Sihra, 2003). These effects of 
forskolin and IBMX on glutamate release have made it possible to invoke three possible 
pathways leading to the increases seen in ERK1,2 phosphorylation in nerve terminals. 
The first pathway would involve increased levels of cAMP resulting in greater 
activation of PKA, and therefore greater PKA-mediated activation of ERK1,2 (Lerosey 
et al., 1991; English et al., 1999). The second pathway would involve a PKA- 
independent mechanism, where increased levels of cAMP lead to direct activation of a 
Rap-GEF, such as Epac, and subsequent stimulation of an ERK1,2 signalling cascade 
(de Rooij et al., 1998). The third mechanism by which forskolin and IBMX could be 
increasing nerve terminal ERK1,2 phosphorylation could be through the lifting of an 
Ai-mediated inhibitory influence, such as removing the inhibition of a Ca channel 
(Park et al., 2001). These pathways are illustrated in Figure 3.6, wherein it is notable 
that, given the additivity of the forskolin and IBMX effects on ERK1,2 phosphorylation, 
it is highly likely that multiple influences acting in conjunction elicit the observed effect 
on ERK 1,2 phosphorylation/activation.
The next series of experiments conducted in this chapter investigated the involvement 
of pathway 1 (Figure 3.6) in the enhancement of ERK 1,2 activation, focussing on 
whether the forskolin/IBMX mediated increases in ERK1,2 phosphorylation were 
occurring in a PKA-dependent or -independent manner. This was done through 
introducing PKA inhibitors to the incubation medium and examining the ERK1,2 
phosphorylation levels in the absence and presence of forskolin/IBMX stimulation.
The first PKA-inhibitor used was H-89, a compound which binds competitively, with 
respect to ATP, to the catalytic subunit of PKA (Chijiwa et al., 1990). The ERK1,2 
phosphorylation levels obtained in the presence of this inhibitor are shown in Figure 
3.7. As can be seen from this figure, treatment of synaptosomes with H-89 alone 
induced a significant decrease in basal ERK1,2 phosphorylation levels (mean ± s.e.m. in 
% compared to 100% 37°C controls: H-89 = 60 ± 1). The effect of forskolin/IBMX 
treatment on ERK1,2 phosphorylation levels switched from a significant increase in the 
presence of forskolin/IBMX alone, to a significant decrease when H-89 was also added 
(mean ± s.e.m. in % compared to 100% 37°C control: forskolin/IBMX = 128 ± 6;
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Figure 3.6 Possible Pathways Involved in the Forskolin/IBMX Mediated Increases 
in ERK1,2 Phosphorylation. 1) Increased levels of cAMP, through activation of AC 
by forskolin and inhibition of PDE by IBMX, could be leading to increased activation 
of PKA and subsequent phosphorylation of ERK1,2. 2) Increased levels of cAMP 
through activation of AC by forskolin and inhibition of PDE by IBMX could be leading 
to direct activation of the ERK 1,2 signalling cascade through cAMP interactions with 
Rap-GEFs. 3) IBMX-mediated inhibition of the Ai receptor could be leading to the 
lifting of an inhibitory influence on the ERK 1,2 signalling cascade. Blue arrows 
indicate an inhibitory pathway, whereas pink arrows indicate a stimulatory effect. 
Abbreviations: AC = adenylate cyclase; ATP = adenosine triphosphate; cyclicAMP = 
cyclic adenosine monophosphate; PKA = protein kinase A; PDE = phosphodiesterase;
5 AM P = 5’-adenosine monophosphate; Ai = inhibitory adenosine receptor type I;
ERK 1,2 = extracellular regulated protein kinase 1,2.
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Figure 3.7 H-89 Decreased Basal Levels of ERK1,2 Phosphorylation But Not 
Forskolin/IBMX-Mediated Phosphorylation. Synaptosomes were incubated at 37°C 
with ImM CaCh, for 10 min either in the absence (control) or presence o f  lOpM H-89 
(+H-89), and/or lOOpM forskolin and 50pM IBMX (+forsk/IBMX). 7.5% 
polyacrylamide gels were run. Immunoblots were labelled with phospho-MAPK 
primary antibody (1:1000, NEB) and probed using 125I-labelled protein A. Levels o f  
251 from several independent experiments were detected and analysed using 
phosphorimager spectroscopy (Molecular Dynamics) *P<0.05, **P<0.01 compared to 
100% 37°C controls (ANOVA followed by Duncan’s post hoc analysis, n=6). A. 
Phosphorimage o f H-89 and/or forskolin/IBMX effect. B. Quantification o f ERK1,2 
phosphorylation levels.
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forskolin/IBMX/H-89 = 81 ± 8). Notably however, forskolin/IBMX in the presence of 
H-89 was still able to significantly enhance ERK1,2 phosphorylation (compared to 
activation in the presence of H-89 alone, P<0.01, ANOVA with Duncan’s post hoc 
analysis). Judging from this evidence therefore, the reduced activation of ERK 1,2 with 
forskolin/IBMX in the presence of H-89 may simply reflect the basal effects of H-89 on 
ERK 1,2 activation, rather than inhibition of a forskolin/IBMX-mediated pathway. If 
this is true, the implication would be that while there may be a PKA-dependent 
component to basal ERK1,2 phosphorylation levels (H-89 inhibited), the actions 
forskolin/IBMX may be occurring through a PKA-independent route to increase ERK
1,2 activation in nerve terminals. Alternatively, the apparent differential activity of H- 
89 under basal conditions compared to the effect in the presence of forskolin/IBMX 
may reflect on the specificity of action of the inhibitor. It is known that H-89 is not an 
entirely specific inhibitor of PKA, having been shown, in vitro, to inhibit at least three 
other kinases, sometimes with a potency similar to or greater than that for PKA, 
including mitogen and stress activated protein kinase 1 (MSK1), p70 ribosomal protein 
S6 kinase (S6K1) and Rho-dependent protein kinase (ROCKII) (Davies et al., 2000). 
While these alternative targets may not be present in nerve terminal, the possibility that 
the reduction in basal levels of ERK1,2 activation by H-89 could be mediated through 
the inhibition of a kinase other than PKA remains tenable. The relative lack of effect of 
the inhibitor on forkolin/IBMX-stimulated PKA activity may reflect the fact that, H-89, 
as a competitive inhibitor of the ATP-binding site on PKA, can be displaced under 
conditions of high cAMP production as might be postulated to occur in the presence of 
forskolin/IBMX. In order to try and clarify the roles of PKA in mediating ERK1,2 
phosphorylation levels in cerebrocortical nerve terminals, the effects of a second PKA 
inhibitor were examined.
KT-5720 has been described as a cell permeable, potent and specific inhibitor of PKA 
and, like H-89, also appears to work at the catalytic site of PKA (Kase et al., 1987; 
Gadbois et al., 1992). The results obtained with this inhibitor, in the presence and 
absence of forskolin/EBMX, are shown in Figure 3.8. Like H-89, KT-5720 also 
significantly decreased basal levels of ERK1,2 phosphorylation (mean ± s.e.m. in % 
compared to 100% 37°C control values: KT-5720 = 74 ± 4). KT-5720 also appeared to 
inhibit forskolin/EBMX induced increases in ERK 1,2 activation, when compared to the
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Figure 3.8 KT-5720 Decreased Basal Levels of ERK 1,2 Phosphorylation But Not 
Forskolin/IBMX-Mediated Phosphorylation. Synaptosomes were incubated for 10 
mins with ImM CaCE, either in the absence (control) or presence o f  lpM  KT-5720 
(+KT-5720) and/or lOOpM forskolin and 50pM IBMX (+Forskolin/IBMX). 7.5% 
polyacrylamide gels were run. Immunoblots were labelled with phospho-MAPK
195primary antibody (1:1000, NEB) and probed using I-labelled protein A. Levels o f  
25I from several separate blots were detected and analysed using phosphorimager 
spectroscopy (Molecular Dynamics). **P<0.01 compared to 100% 37°C controls 
(ANOVA followed by Duncan’s post hoc analysis, n=5). A. Phosphorimage o f KT- 
5720 and forskolin/IBMX effects on ERK 1,2 phosphorylation. B. Quantification o f  
ERK 1,2 phosphorylation levels.
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100% 37°C control values (mean ± s.e.m. in %: forskolin/IBMX = 123 ± 5; 
forskolin/IBMX/KT-5720 = 103 ± 8). However, again, because treatment of 
synaptosomes with forskolin/IBMX in the presence of KT-5720 was found to still 
significantly increase ERK1,2 phosphorylation levels when compared to the KT-5720 
control (P<0.01, ANOVA with Duncan’s post hoc analysis), the data would suggest that 
the lack of net change in ERK1,2 phosphorylation levels reflects a simple additivity of 
the negative effects of KT-5720 and the positive effects of forskolin/IBMX. These 
results are congruent with those obtained using H-89 and indeed, like H-89, KT-5720 
has also been recently shown to inhibit other protein kinases, these notably being MEK1 
and ERK2, members of the signalling cascade being addressed (Davies et al., 2000). 
Thus, notwithstanding the fact that the concentrations of inhibitor used in the latter 
studies were lOx higher than those used here, it is possible that the inhibitory effects of 
KT-5720 on basal ERK1,2 phosphorylation levels are due to a direct interaction with 
the ERK signalling cascade, rather than through PKA inhibition (Davies et al., 2000).
Both the PKA inhibitors used so far have utilised binding of the catalytic site of PKA to 
mediate their inhibition, and both were found to decrease basal levels of ERK1,2 
phosphorylation. It is possible that these effects of the inhibitors on the ERK1,2 
signalling cascade are as a result of non-specific binding, conducive to the design of the 
inhibitors as interactors with the ATP binding site of the catalytic domain of PKA.
Other PKA inhibitors are available which have been designed to act at the regulatory 
subunit of PKA, and so should not have the same non-specific effects as H-89 and KT- 
5720 (Davies et al., 2000). The following experiments conducted in this chapter 
investigated the effects of one such inhibitor, Rp-cAMPS, on ERK1,2 phosphorylation 
levels in the presence and absence of forskolin/IBMX.
Rp-cAMPS binds to the regulatory subunit of PKA in the place of cAMP, and in doing 
so prevents cAMP-mediated dissociation of the regulatory subunits from the catalytic 
subunits, thus resulting in the inhibition of PKA catalytic activity (Botelho et al., 1988). 
Figure 3.9 shows the measure of ERK 1,2 activation obtained when synaptosomes were 
incubated in the presence and absence of Rp-cAMPS (50pM) and/or forskolin/IBMX. 
ERK1,2 phosphorylation levels were found to be significantly increased both in the 
presence of forskolin/IBMX and when Rp-cAMPS was added in conjunction
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Figure 3.9 Rp-cAMPS (50pM) Does Not Inhibit Forskolin/IBMX Stimulation of 
ERK 1,2 Phosphorylation. Synaptosomes were incubated for 10 min with ImM CaCh 
either in the absence (control) or presence o f  50pM Rp-cAMPS (+Rp-cAMPS) and/or 
lOOpM forskolin and 50pM IBMX (+forskolin/IBMX). 7.5% polyacylamide gels were 
run. Immunoblots were labelled with phospho-MAPK primary antibody (1:1000, NEB)
1 1 ' J C
and probed using I-labelled protein A. Levels o f I from several separate blots were 
detected and analysed using phosphorimager spectroscopy (Molecular Dynamics). 
*P<0.05 compared to 100% 37°C controls (ANOVA followed by Duncan’s post hoc 
analysis, n=4). A. Phosphorimage o f  Rp-cAMPS and forskolin/IBMX effects on ERK
1,2 phosphorylation. B. Quantification o f ERK 1,2 phosphorylation levels.
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with forskolin/IBMX (mean ± s.e.m. in % compared to 100% 37°C controls levels: 
forskolin/IBMX = 138 ± 14; forskolin/IBMX/Rp-cAMPS = 149 ± 16). These results 
are in agreement with those obtained with the other PKA inhibitors, with the finding 
that forskolin/IBMX-mediated increases in ERK1,2 phosphorylation levels were not 
decreased by PKA inhibition. In contrast to the experiments conducted with H-89 and 
KT-5720, Rp-cAMPS by itself was not found to significantly decrease basal levels of 
ERK1,2 phosphorylation (mean ± s.e.m. in % compared to 100% 37°C control: Rp- 
cAMPS = 104 + 3). As it is possible that the lack of inhibitory effects seen here with 
Rp-cAMPS are due to competitive displacement of Rp-cAMPS by high levels of cAMP, 
a higher concentration of this inhibitor was also tested.
Figure 3.10 illustrates the effects found on ERK1,2 activation following treatment with 
the higher concentration of Rp-cAMPS (100pM). Both forskolin/IBMX and 
forskolin/IBMX/Rp-cAMP treatments were found to significantly enhance ERK 1,2 
phosphorylation levels with respect to control levels (mean ± s.e.m. in % compared to 
100% 37°C control: forskolin/IBMX = 132 ± 8; forskolin/IBMX/Rp-cAMPS = 136 ±
6). They were also found to be significantly different from the levels of ERK1,2 
phosphorylation obtained in the presence of Rp-cAMP on its own (mean ± s.e.m. in % 
compared to 100% 37°C control: Rp-cAMPS (lOOpM) = 112 ± 3) (*P<0.05, ANOVA 
followed by Duncan’s post hoc analysis). However, no significant difference was found 
between ERK 1,2 activation in the presence of Rp-cAMP and the levels obtained in 
control conditions.
Rp-cAMPS is not a very membrane soluble compound so it is possible that a 10 minute 
incubation is not long enough for this PKA inhibitor to be incorporated into the 
synaptosomes. Although this compound has been shown to be active in isolated nerve 
terminals, and to inhibit forskolin/IBMX-mediated enhancement of glutamate release, 
long (30 minute) preincubation times were used (Wang and Sihra, 2003). Likewise, 
recently developed and very specific PKA inhibitor peptides with membrane-permeable 
acetoxymethyl ester groups have also been shown to require a 30 minute preincubation, 
to allow incorporation into synaptosomes. As a view to these paradigms, a 
preincubation protocol was devised which would allow substantial loading of nucleotide 
inhibitor into synaptosomes, with the aim of clarifying the involvement of PKA in
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Figure 3.10 Raising the Concentration of Rp-cAMPS Does Not Change its Effect 
on Forskolin/IBMX-Mediated ERK 1,2 Phosphorylation. Synaptosomes were 
incubated with ImM CaCl2 for 10 min either in the absence (control) or presence of 
lOOpM Rp-cAMPS (+Rp-cAMPS) and/or lOOpM forskolin and 50pM IBMX 
(+forskolin/IBMX). 7.5% polyacrylamide gels were run. Immunoblots were labelled 
with phospho-MAPK antibody and probed using I25I-labelled protein A. 
Phosphorimager spectroscopy (Molecular Dynamics) was used to measure and analyse 
levels of 125I labelling. **P<0.01 compared to 100% 37°C controls (ANOVA followed 
by Duncan’s post hoc analysis, n=5). A. Phosphorimage of Rp-cAMPS and 
forskolin/IBMX effects on ERK 1,2 phosphorylation. B. Quantification of ERK 1,2 
phosphorylation levels.
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forskolin/IBMX-mediated enhancement of ERK1,2 phosphorylation.
Synaptosomes were incubated at 37°C for 20 minutes with ImM CaCl2 before being 
pelleted and cooled back to 4°C. Upon resuspension, a standard 10 minute incubation 
protocol was used. The results are shown in Figure 3.11 and, as can be seen from the 
graphs, forskolin/IBMX was no longer found to enhance ERK1,2 phosphorylation 
levels following the preincubation protocol. Instead, treatment of the synaptosomes 
with forskolin/IBMX resulted in a significant decrease in ERK1,2 activation, the 
complete opposite to the increase observed with the short incubation protocol (mean ± 
s.e.m. in % compared to 100% 37°C controls: preincubation = 77 ± 8; short incubation 
= 143 ± 8). These results suggests a bidirectional effect of forskolin/IBMX treatment 
on ERK1,2 activation, which is dependent upon incubation conditions. This could 
possibly help explain why some studies have identified an inhibitory effect of forskolin 
application on ERK1,2 phosphorylation, whereas others have found stimulatory effects 
(Siddhanti et al., 1995; Dhillon et al., 2002; Kanterewicz et al., 2000).
The results so far gleaned from putative PKA inhibitor studies appear to suggest that 
activation of ERK1,2, following the enhancement of cAMP levels and Ai receptor 
inhibition, could be occurring independently of PKA. To begin to examine this 
possibility, the next experiment investigated the possible presence of a key player 
putatively involved in pathways which, directly through cAMP action, potentially lead 
to the stimulation of ERK1,2 phosphorylation/activation. cAMP has been shown to 
directly activate the ERK1,2 signalling cascade in other systems, namely in spennatid- 
enriched cell cultures and in kidney cortical collecting duct cells, through the activation 
of a guanine nucleotide exchange factor (GEF) known as Epac (Laroche-Joubert et al., 
2002; Berruti, 2003), with more recent studies suggesting that this pathway may also 
exist in neurones (Lin et al., 2003). This cAMP-dependent GEF catalyses the 
transformation of Rap-1 from its GDP-bound form to its GTP-bound form, which 
results in the subsequent activation of an isoform of Raf known as B-Raf, and the 
sequestering of MEK (de Rooij et al., 1998; York et al., 1998). Synaptosomes were 
immunoblotted for B-Raf in order to investigate whether or not this pathway could 
possibly be leading to cAMP-mediated ERK1,2 activation in cerebrocortical nerve 
terminals. Figure 3.12 illustrates that B-Raf isoforms are indeed present in 
cerebrocortical nerve terminals, leading to the possibility that this pathway could be
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Figure 3.11 Forskolin/IBMX-Mediated Regulation of ERK 1,2 Activation is 
Bidirectional. Short Incubation: synaptosomes were incubated for a total o f  10 min 
with 6 min in the absence (control) or presence o f  lOOpM forskolin/50pM IBMX 
(+forskolin/IBMX). Preincubation: synaptosomes were preincubated for 20 min, 
pelleted and cooled, upon resuspension the short incubation protocol was followed. All 
incubations contained ImM CaC^. 7.5% gels were run. Immunoblots were labelled19 Swith phospho-MAPK antibody (1:1000, NEB) and reported using I-labelled protein 
A, and detected using phosphorimager spectroscopy (Molecular Dynamics). *P<0.05 
compared to 100% 37°C controls (Student’s paired t-test, Short Incubation n=3, 
Preincubation n=5). A. Phosphorimage o f effects. B. & C. Quantification o f  ERK 1,2 
phosphorylation levels.
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Figure 3.12 B-Raf Isoforms are Present in Cerebrocortical Nerve Terminals.
Purified synaptosomes (lOOpg) were lysed and then separated using gel electrophoresis, 
before being transferred onto nitrocellulose membrane. The gels used were 10% 
polyacrylamide gels. The nitrocellulose membranes were then immunoblotted using a 
B-Raf-specific primary antibody (1:250, Upstate Biotech) and reported using l- 
labelled protein A. Signal levels were detected using phosphorimager spectroscopy 
(Molecular Dynamics). A. Phosphorimage showing the presence of B-Raf isoforms in 
cerebrocortical nerve terminals. B. Possible pathway through which B-Raf could be 
involved in cAMP-mediated increases in ERK 1,2 activation in synaptosomes.
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active in this system. Of course just identifying the presence of a component does not 
itself necessarily confirm its involvement. The latter objective indeed begs development 
of specific and cell-permeant reagents that can alter the activation of B-Raf.
The final experiments conducted here, examined the involvement of a protein 
phosphorylation substrate found downstream of PKA and ERK 1,2 activation, synapsin I 
(Czemik et al., 1987; Jovanovic et al., 1996). Synapsin I has been shown to be involved 
in the tethering of synaptic vesicles to actin, to form a reserve pool kinetically distinct 
from the docked/primed vesicle pool lodged at the plasma membrane through SNARE 
proteins (Hilfiker et al., 1999). Furthermore, phosphorylation of synapsin I (and other 
members of the family), at various sites, can regulate its interactions with actin, 
resulting in an enhancement of glutamate release through an increase in the number of 
vesicles available for exocytosis (Jovanovic et al., 1996; Chi et al., 2001). Figure 3.13 
shows that treatment of synaptosomes with forskolin/IBMX resulted in an increase in 
PKA-mediated phosphorylation of synapsin I at site 1, as well as an increase in the 
phosphorylation of sites 4 and 5, which are regulated by ERK1,2 (mean ± s.e.m. in % 
compared to 100% 37°C controls: PKA-dependent site 1 = 215 ± 36%; ERK 1,2- 
dependent sites 4/5 = 163 ± 12%). These results confirm that addition of 
forskolin/IBMX is indeed leading to PKA activation, if not PKA-mediated ERK1,2 
activation, and that the observed increase in ERK1,2 phosphorylation can lead to 
synapsin I site 4/5 phosphorylation. These results imply that increased levels of cAMP, 
combined with Ai receptor inhibition, could be leading to the enhancement of glutamate 
release, through a mechanism dependent on increased vesicle availability resulting from 
ERK 1,2 and PKA stimulation of synapsin I phosphorylation.
It is interesting to note that synapsin site 2/3 phosphorylation levels appear to be 
decreasing upon stimulation of the nerve terminals with forskolin/IBMX (individual 
values of site 2/3 phosphorylation levels compared to 100% = 79.0% and 88.9%). Given 
that previous studies indicate that intracellular Ca2+ levels increase upon treatment with
04-forskolin/IBMX, these results were somewhat surprising, as the increased Ca should 
also result in CaMKII activation and, thereby increase phosphorylation of synapsin site
04-2/3 (Jovanovic et al., 2001). A role of the Ca /CAM-dependent phosphatase, 
calcineurin, cannot be posited to explain the dephosphorylation, because the particular
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Figure 3.13 Forskolin/IBMX Regulates Synapsin I Phosphorylation at Multiple
Sites. Synaptosomes were incubated at 37°C with ImM CaCl2 for lOmin either in the 
absence (control) or presence o f  forskolin/IBMX (100mM/50mM) (+forskolin/IBMX), 
or BDNF (lOOng/ml) (+BDNF). Immunoblots were labelled with antibodies specific 
for synapsin I phosphorylated at sitesl, 2/3 or 4/5 (site 2/3 and site 4/5, 1:500; site 1,19S • me
1:200; J.J) and reported using I-labelled protein A. Levels o f  I labelling were 
detected and analysed using phosphorimager spectroscopy (Molecular Dynamics). 
*P<0.05, **P<0.01 compared to 100% 37°C controls (Student’s paired t-test, site 1 n=3; 
site 2/3 n=2; site 4/5 n=9). A. Phosphorimage o f synapsin I phosphorylation levels. B. 
Quantification o f synapsin I phosphorylation levels (N.B. site 2/3 error bar is indicative 
of range).
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Figure 3.14 A Summary of the Possible cAMP/PKA Pathways Involved in 
Regulating ERK1,2 Phosphorylation Following Short Incubation Protocols.
Further studies need to be conducted to confirm cAMP signalling through B-Raf to 
enhance ERK 1,2 phosphorylation. Question marks denote components yet to be fully 
identified and groups of arrows denote tentative signalling pathways. Blue arrows 
indicate an inhibitory pathway, whereas pink arrows indicate a stimulatory effect. 
Abbreviations: AC = adenylate cyclase; ATP = adenosine triphosphate; cyclicAMP = 
cyclic adenosine monophosphate; PKA = protein kinase A; PDE = phosphodiesterase; 
5’AMP = 5’-adenosine monophosphate; Ai = inhibitory adenosine receptor type I; 
ERK 1,2 = extracellular regulated protein kinase 1,2.
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sites in question are not substrates for Ibis phosphatase but rather protein phosphatase 
2A (PP2A, (Jovanovic et al., 2001)). The mechanism leading to this observed 
dephosphorylation of site 2/3 in response to forskolin/IBMX therefore remains cryptic. 
Further experiments confirming the dephosphorylation and elucidating the signalling 
pathways therein need to address whether an increase in the activation of PP2A occurs 
directly as consequence of the application of a combination of forskolin/IBMX. It is 
also interesting to observe that BDNF appears to be decreasing the phosphorylation of 
site 2/3 of synapsin, as well as forskolin/IBMX. Though, again, this needs to be further 
investigated in order to draw any conclusions from it.
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3.4 Summary o f Results
• Increased intracellular levels of cAMP combined with inhibition of Ai receptors 
enhances the levels of glutamate released from cerebrocortical nerve terminals 
by 4-AP.
• This enhancement of release can occur through a mechanism which is 
independent of Ca channel regulation.
• Treatment of synaptosomes with IBMX enhances ERK1,2 phosphorylation 
levels. Combined treatment, with the adenylate cyclase activator forskolin, and 
with IBMX, appears to result in an additive increase in ERK 1,2 phosphorylation 
levels.
• Basal levels of ERK1,2 phosphorylation may be partly dependent of PKA 
activation, whereas forskolin/IBMX stimulation of ERK1,2 phosphorylation 
may occur independently of PKA.
• Regulation of ERK1,2 phosphorylation levels by forskolin/IBMX can be 
bidirectional, depending on the incubation protocol used.
• Forskolin/IBMX increases synapsin I phosphorylation at sites mediated by PKA 
and at the sites regulated by ERK1,2 phosphorylation.
• B-Raf isoforms are present in cerebrocortical nerve terminals.
• Treatment of synaptosomes with the MEK inhibitor, U0126, enhances 4-AP- 
evoked glutamate release, possibly through increasing levels of intracellular 
Ca2+.
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3.5 Discussion
It was interesting to observe that the treatment of synaptosomes with IBMX resulted in 
a significant increase in ERK1,2 phosphorylation levels. As mentioned before, IBMX 
can act at two sites in nerve terminals. This compound can act as an inverse agonist at 
adenosine Ai receptors, reducing activation through a direct inhibitory action on the 
receptor (Klinger et al., 2002). The inverse agonist property of IBMX has also implied 
a role for constitutive activity of the receptor in the regulation of cell function (Schutz 
and Freissmuth, 1992). In addition to this, IBMX can inhibit phosphodiesterase 
activity, resulting in increased levels of cAMP (Corbin and Francis, 2002). This action 
of IBMX could also reduce activation of adenosine receptors, as the phosphodiesterase 
occurs at the first stage of the metabolic pathway which produces adenosine from 
cAMP (Ribeiro et al., 2003).
Adenosine Ai receptors have been shown to couple to Gi and Go G-proteins, resulting 
in the inhibition of adenylate cyclase activity and a decrease in intracellular levels of 
cAMP (Munshi et al., 1991). This means that ERK1,2 activation following treatment 
with IBMX could be mediated by cAMP, levels of which would have been enhanced 
not only by inhibition of phosphodiesterase activity, but also through the relieving of 
the adenylate cyclase inhibition. In contrast to this, studies in CHO cells have found 
that stimulation of all the subtypes of adenosine receptors resulted in the activation of 
the ERK1,2 signalling cascade (Schulte and Fredholm, 2000). This was believed to be 
through the activation of src kinases or PI3Ks, resulting in the downsteam activation of 
Ras (Schulte and Fredholm, 2002; Schulte and Fredholm, 2003). Whether this 
signalling occurs through Py subunits or through direct activation of Gai, is a matter 
which is still under debate (Klinger et al., 2002). However, although Ai receptor 
activation may be following this pathway in contributing to the basal levels of ERK1,2 
phosphorylation observed in nerve terminals, it is unlikely to be mediating the increase 
in ERK1,2 activation following Ai inhibition. Activation of Ai adenosine receptors has 
been shown to decrease Ca influx through presynaptic channels to decrease 
neurotransmitter release from nerve terminals (Park et al., 2001). It is also possible that 
the likely increase in Ca levels following Ai receptor inhibition mediated by IBMX,
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• 2+could be stimulating increases in ERK1,2 phosphorylation levels through Ca - 
dependent GEFs (Farnsworth et al., 1995).
The levels of ERK 1,2 phosphorylation upon the application of both forskolin and IBMX 
are in agreement with a role for IBMX in adenosine receptor inhibition. The substantial 
increase in ERK 1,2 activation is likely due to the combined influence of two pathways, 
rather than just one, seeing as either drug has significantly reduced effects on its own 
(see Figure 3.14). This effect on ERK1,2 activation could be of functional significance 
with regards to presynaptic plasticity and glutamate release. cAMP/PKA-dependent 
increases in glutamate release are transient at the Schaffer collateral-CAl synapse, 
whereas they are long lasting at the mossy fibre-CA3 synapse. Inhibition of the Ai 
receptor in the CA1 region was found to result in an unmasking of the cAMP effect, 
leading to forskolin-induced LTP at this synapse (Lu and Gean, 1999). Further work 
needs to be carried out to identify the exact mechanisms through which IBMX is 
mediating increases in ERK 1,2 activity. This work could start with examining the 
effects of the application of specific phosphodiesterase inhibitors compared to the 
application of specific adenosine Ai receptor antagonists. These experiments would 
help clarify the relative involvements of phosphodiesterase inhibition and Ai inhibition 
on ERK1,2 phosphorylation levels.
The results presented here, suggesting that the forskolin/IBMX-mediated stimulation of 
ERK 1,2 phosphorylation in cerebrocortical synaptosomes, lead to equivocal 
conclusions. On the one hand, parsimoniously it could be suggested that, given the 
known actions of these agents, ERK 1,2 stimulation indicates the mechanistic 
involvement of PKA. On the other hand, in the absence of clear PKA inhibitor profiles 
for the effects seen, one could tentatively invoke that the activation of the MAP kinase 
cascade occurs independently of PKA activation. The latter conclusion would be 
contrary to studies examining forskolin/IBMX-mediated glutamate release in 
cerebrocortical synaptosomes, which found that both H-7, a mixed protein kinase 
inhibitor, and Rp-cAMPS, a PKA inhibitor, were able to inhibit the forskolin/IBMX- 
mediated enhancement of glutamate release (Wang and Sihra, 2003). There are 
potentially several reasons for the discrepancies noted. Firstly, the long incubation 
times (30 minutes before the application of the secretogogue, with forskolin and IBMX 
being added for 5 minutes and 2 minutes, respectively) may suggest that the lack of
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effect of Rp-cAMPS in the current study may solely be due to the shorter incubation 
conditions, allowing insufficient time for the inhibitor to equilibrate into the 
synaptosomes in adequate quantities to significantly inhibit PKA. Arguing against this 
slow-permeability issue is the observation in my studies that both H-89 and KT-5720, 
manifest their effects, albeit somewhat cryptically, in decreasing basal ERK 1,2 
phosphorylation levels following just 10 minutes of incubation. However, while these 
data suggest that these inhibitors are entering the nerve terminal in sufficient quantity to 
elicit effects, the drugs were unable to inhibit forskolin/IBMX-induced enhancement of 
ERK 1,2 activation. Thus, the possibility remains that these effects observed with KT- 
5720 and H-89 could be solely mediated by non-specific events and that inhibition of 
PKA does not occur to sufficient levels to elicit an inhibition in forskolin/IBMX- 
mediated stimulation. The effectiveness of H-89 and KT-5720-mediated inhibition of 
PKA could be tested under these conditions by using a phospho-specific antibody to 
examine the phosphorylation levels of site 1 on synapsin I, which is mediated by PKA 
(Czemik et al., 1987). If the phosphorylation of this site was attenuated by H-89 and 
KT-5720, then this would add evidence to the suggestion that forskolin/IBMX 
stimulation of ERK1,2 phosphorylation is occurring through a signalling pathway which 
is independent of PKA.
A second possible mechanism underlying the lack of correlation between the PKA- 
dependency of enhanced glutamate release and of ERK1,2 phosphorylation could lie 
within the use of indifferent inhibitors. For example, H-7 is able to inhibit PKA, PKC 
and PKG with similar potency, leading to the possibility of the involvement of non­
specific effects in the observed inhibition of glutamate release (Davies et al., 2000). It 
would be interesting to examine the effects of the inhibitors that I have used, on basal 
and forskolin/IBMX-enhanced depolarisation-induced glutamate release. It would be 
interesting to discover whether basal inhibition of ERK1,2 could also lead to a basal 
inhibition of glutamate release. Activation of PKA has been shown to regulate 
glutamate release through a diverse array of different mechanisms (Lonart et al.,
1998b). As a result, it remains possible that the effects of H-7 in inhibiting the 
forskolin/IBMX enhancement of glutamate release, occur through a PKA-dependent 
pathway which does not cross-talk with the ERK 1,2 signalling cascade, or only does so 
under particular conditions.
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The basal effects of the PKA inhibitors, H-89 and KT5720, in decreasing ERK1,2 
activation raises the possibility that a tonically active, PKA-dependent, facilitation of 
ERK1,2 phosphorylation may be present in cerebrocortical nerve terminals. This is in 
contrast to the supposedly PKA-independent facilitatory effects of forskolin/IBMX 
treatment (see Figure 3.14). These results are not without precedent, as a recent study 
conducted by Morozov and collegues in PC 12 cells suggested the existence of different 
pools of ERK1,2 which were subject to differential upstream regulation. Basal levels of 
ERK1,2 phosphorylation were found to be dependent on Rap-1, however, stimulated 
levels of ERK1,2 were found to be only partially dependent on Rap-1 (Morozov et al.,
2003).
It is interesting that longer preincubations result in ERK 1,2 inhibition upon application 
of forskolin/IBMX. The facile explanation, that this inhibition of ERK 1,2 
phosphorylation by forskolin/IBMX is attributed to an extended time in the presence of 
the compounds, is untenable given that the protocol used was such that the only change 
made in the conditions was to increase the preincubation time and not the drug 
application time. A more likely scenario, is that the inhibition could be due to PKA- 
mediated inhibition of Raf-1, or activation of a phosphatase (Dhillon et al., 2002; Usui 
et al., 1998). Further investigations will need to be carried out to substantiate this, 
however, it may also be that the 37°C control values increase following the 
preincubation protocol, leading to an apparent inhibition of ERK1,2 signalling, rather 
than an actual inhibition. This particular mechanism is thought unlikely in the current 
situation, as experiments pertaining to later chapters in this thesis were able to find an 
agonist-mediated stimulation of ERK1,2, albeit using a metabotropic glutamate receptor 
agonist (see Chapter 6). This inhibition of ERK1,2 phosphorylation by forskolin/IBMX 
is also not due to an extended time in the presence of the compounds, as the only 
change made in the conditions was to increase the preincubation time and not the drug 
application time. It is possible this effect is resulting from the cross-talk of signalling 
pathways, as activation of the Group III metabotropic glutamate receptor has been 
shown to attenuate forskolin-enhanced glutamate release from cerebrocortical nerve 
terminals (Millan et al., 2002). It would be interesting to correlate these results 
examining ERK1,2 phosphorylation levels with changes in glutamate release in this 
system. Elucidation of this mechanism could also help explain why treatment with 
forskolin elicits an excitatory response in some systems and an inhibitory response in
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others. Treatment of cells with forksolin has been shown to have different effects, 
depending on the compartmentalisation and the coupling of the effector system (Erhardt 
et al., 1995), and it may be that forskolin/IBMX is acting through several different 
pathways to elicit its effects on ERK1,2 (see Figure 3.14).
The finding that forskolin/IBMX can increase the activation of ERK1,2, resulting in the 
downstream increase in phosphorylation of synapsin I site 4/5, at the very least, 
suggests a mechanism through which these drugs could be enhancing Ca channel- 
independent glutamate release from cerebrocortical nerve terminals. The results in this 
chapter have highlighted the likelihood of the existence of at least two different 
signalling pathways occurring between the level o f forskolin/IBMX stimulation and 
ERK1,2 phosphorylation (see Figure 3.14). This is most probably due to the 
plieotropic nature of the forskolin/IBMX-mediated stimulation, which could also 
complicate the further identification of the upstream signalling components. To address 
this, the next chapter in this thesis goes on to examine the downstream signalling of an 
adenylate cyclase-linked receptor, in order to see whether physiological stimulation of 
AC could be leading to regulation of the ERK1,2 signalling cascade.
I l l
Chapter 4
P-Adrenoceptor-Mediated Modulation of Presynaptic Function: 
Cross-Talk o f PKA and ERK 1,2 Signalling Cascades.
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4.1 Introduction
P-adrenergic receptors are examples of Gs-linked GPCRs which are linked to adenylate 
cyclase, resulting in increased intracellular levels of cAMP and activation of PKA (De 
Blassi, 1990). Reports of an involvement of P-adrenoceptors in synaptic plasticity in 
brain date from as long ago as 1992, when it was found that noradrenaline could 
modulate the generation of long term potentiation (LTP) in the fimbria-CA3 pathway in 
a manner that was attenuated by treatment with a p-adrenoceptor antagonist (Katsuki et 
al., 1992). Since then, P-adrenoceptors have been found to modulate long term 
plasticity in the medial amygdala and the CA1 region of the hippocampus, with 
conflicted reports obtained in the lateral amygdala (Watanabe et al., 1996; Huang et al., 
2000; Winder et al., 1999). As well as postsynaptic effects leading to the activation of 
PKA and the regulation of immediate early gene transcription, roles for P-adrenoceptors 
in the regulation of presynaptic function have also been identified (Roberson et al., 
1999). Several slice preparations have reported an increase in synaptic transmission 
upon the activation of these receptors (Gereau and Conn, 1994; Huang et al., 1996). 
These results have been consolidated in studies using isolated nerve terminal 
preparations, which found an increase in glutamate release following treatment with the 
p-adrenoceptor agonist, isoproterenol (Herrero and Sanchez-Prieto, 1996; Wang et al., 
2002).
Investigations into the mechanisms of isoproterenol-mediated enhancement of 
glutamate release from cerebrocortical nerve terminals have so far identified two 
possible downstream targets. The first study found the isoproterenol-mediated 
enhancement of glutamate release to be dependent on p2-adrenergic receptor activation 
and to be dependent on the activation of PKA, which occurred following increases in 
intraterminal levels of cAMP. The observation that glutamate release was enhanced 
when 4-AP was used as the secretogogue, but not when KC1 was used, led to the 
proposal that the main mechanism for this enhancement of release was mediated by a P- 
adrenoceptor-dependent increase in nerve terminal excitability. A role was also
• • 9+ • •identified for Ca , which was found to shift the dose/response curve for isoproterenol 
stimulation of cAMP production to the left (Herrero and Sanchez-Prieto, 1996). The 
more recent study using cerebrocortical synaptosomes found that treatment with
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isoproterenol significantly increased basal intracellular levels of Ca (Wang et al.,
2002). This has been supported by studies investigating isoproterenol-enhancement of
* * 0  | synaptic transmission in the amygdala, which found a requirement for increased Ca
influx through P-type Ca2+ channels (Huang et al., 1996; Huang et al., 1998). However,
a study in cerebellar neurones has also found that isoproterenol treatment can result in
an increase in the probability of synaptic vesicle release, in a manner independent of the
94-regulation of Ca channels or membrane excitability (Chen and Regehr, 1997).
As well as Gs-coupled activation of AC leading to increased intracellular concentrations 
of cAMP and activation of PKA, P-adrenoceptors have also been shown to signal to the 
ERK1,2 signalling cascade. This cross-talk of signalling cascades has been shown to 
have functional significance in the hippocampus CA1 region, where the induction of 
LTP by combined theta pulse and isoproterenol application was blocked by inhibition of 
ERK1,2 activation (Giovannini et al., 2001). Further studies in the hippocampal CA1 
region have also implicated the ERK 1,2 signalling cascade as the locus of convergence 
of multiple pathways in the regulation of LTP (Watabe et al., 2000). The mechanisms 
regulating ERK1,2 activation downstream of the P-adrenoceptors are still under debate 
and may be dependent on the location of the receptor. It has been suggested that the 
ERK1,2 activation, downstream of p-adrenergic receptor stimulation is dependent upon 
clathrin-mediated endocytosis of the receptor (Daaka et al., 1998; Lefkowitz, 1998). 
However, a study conducted in COS-7 cells using fluorescent-tagged receptors found 
that P2-adrenoceptor endocytosis occurred independently of clathrin-mediated 
endocytosis and ERK activation (Pierce et al., 2000). There have also been suggestions 
that p-adrenoceptor mediated enhancement of ERK1,2 phosphorylation levels can occur 
both PKA-dependently, in HEK293 cells and the CA1 hippocampal region, and PKA- 
independently, in primary afferent nociceptor cells and COS-7 cells (Friedman et al., 
2002; Roberson et al., 1999; Aley et al., 2001; Cao et al., 2000). This begs the question 
whether the forskolin/IBMX-mediated regulation of glutamate release and ERK1,2 
phosphorylation examined in the previous chapter could have a physiological correlate 
representing signalling and cross-talk downstream of presynaptic P-adrenoceptor 
activation.
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The above discussion has shown that isoproterenol can increase glutamate release in the 
cerebellum through a mechanism occurring independently of Ca -channel or 
membrane potential regulation (Chen and Regehr, 1997). This chapter investigates 
whether P-adrenoceptor activation could be enhancing glutamate release from 
cerebrocortical nerve terminals through a similar mechanism, also occurring 
downstream of Ca channel modulation. A possible locus for this enhancement has 
been suggested by studies demonstrating that a neurotrophin-linked ERK 1,2 cascade 
leading to synapsin I phosphorylation could be enhancing glutamate release, by 
increasing the availability of synaptic vesicles (Jovanovic et al., 2000). Recent evidence 
has suggested that stimulation of the ERK 1,2 signalling cascade can also occur 
downstream of P-adrenoceptor activation (Giovannini et al., 2001; Watabe et al., 2000). 
As a result of this, this chapter also examines whether the cAMP/PKA signalling 
cascade, more commonly associated with signalling downstream of P-adrenoceptor 
activation, could be involved in cross-talking with the ERK1,2 signalling cascade to 
elicit increases in synapsin I phosphorylation, as a possible mechanism for this Ca2+- 
channel independent enhancement of release.
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4.2 Method
Synaptosomes were prepared as described in section 2.1. (Sihra, 1997)
4.2.1 Glutamate Release
The standard glutamate release protocol was used, as described in section 2.2 (Nicholls 
and Sihra, 1986; Perkinton and Sihra, 1999). Ionomycin (5pM) was used as the 
secretogogue, with lOpM isoproterenol added 5 minutes prior to the addition of the 
secretogogue (Wang et al., 2002). All incubations were carried out in the presence of 
Tm M CaCb ~ :
4.2.2 Standard Incubation for ERK 1,2 Phosphorylation/Activation
All standard incubations lasted for a total time of 10 minutes at a temperature of 37°C 
and contained ImM CaCE. Pellets of synaptosomes were resuspended at 4°C to give a 
final synaptosomal concentration of 1 mg/ml using HBM, with the HBM itself already 
containing lmg/ml of BSA. Isoproterenol (100pM), propranolol (IOOjjM), H-89 
(lOpM), KT-5720 (lpM ), or Rp-cAMPS (lOOpM) was added immediately prior to the 
transfer of the synaptosomes to the 37°C incubation. The dose response experiments for 
isoproterenol utilised InM, lOnM, lOOnM, lpM, lOpM or lOOpM final concentrations 
of the drug, which were added 5 minutes and 30 seconds prior to the termination of the 
37°C incubation. All incubations were terminated using 5x SDS-PAGE STOP buffer. 
This incubation protocol for measuring ERK 1,2 phosphorylation has previously been 
described by Jovanovic et al., 2000 (Jovanovic et al., 2000).
4.2.3 Preincubation
Synaptosome pellets were resuspended at 4°C to a final synaptosomal concentration of 
lmg/ml using HBM containing lmg/ml of BSA. CaCh (ImM) was added immediately 
prior to the transfer of the synaptosomes to the 37°C incubation. This preincubation 
lasted for 20 minutes, after which the synaptosomes were recentrifuged using a 
microcentrifuge (10,000 x g for 30 seconds). The supernatant was discarded and the 
pellet cooled back to 4°C for 5 minutes. The standard incubation protocol was then 
utilised, with 10pM of isoproterenol being added 6 minutes prior to the termination of 
the incubation.
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Samples were processed for ERK1,2 and synapsin phosphorylation levels as described 
in the main methods in chapter 2 (sections 2.4.3 to 2.5) (Dai et al., 2001; Jovanovic et 
al., 1996)
4.2.4 Reagents
Isoproterenol: p-adrenoceptor agonist (4-[-1-hydroxy-2-[(l-methylethyl)amino] ethyl] - 
1,2-benzenediol hydrochloride).
Dissolved in water immediately prior to experimentation, to give the lOOx 
concentrations of lOOnM, lpM, 10pM, 100pM, ImM, and lOmM.
Propranolol: p-adrenoceptor antagonist ((RS)-l-[(l-methylethyl)amino]-3-(l- 
naphthalenyloxy)-2-propanol hydrochloride) ((Corrodi et al., 1963); (Leszkovszky and 
Tardos, 1965)).
Dissolved in water to a concentration of lOmM, immediately prior to experimentation.
H-89: PKA inhibitor acting at the catalytic site (N-[2-(p-Bromocinnamylamino)ethyl]- 
5-isoquinolinesulfonamide dihydrochloride) (Chijiwa et al., 1990).
This was dissolved with DMSO to give a stock concentration of lOmM, which was 
further diluted with water prior to use to give a concentration of ImM.
KT-5720: PKA inhibitor acting at the catalytic site ((9R,10S,12S)-2,3,9,10,11,12- 
Hexahydro-10-hydroxy-9-methyl-1 -oxo-9,12-epoxy-1 H-diindolo [ 1,2,3 -fg: 3 ’ ,2 ’, I s - 
Kl]pyr°lo[3,4-i][l,6]benxodiazocine-10-carboxylic acid, hexyl ester) (Kase et al., 
1987); (Gadbois et al., 1992).
This was dissolved to a concentration of ImM in DMSO and was further diluted before 
use to 100 pM with water.
Rp -cAMPS: PKA inhibitor acting at the regulatory site (Rp-adenosine 3’,5’-cyclic 
monophosphorothioate triethylammonium salt) (Botelho et al., 1988).
This was dissolved in water to a concentration of lOmM.
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All the above drugs were purchased from the Sigma-Aldrich Company, Gillingham, 
Dorset.
Unless stated, all drugs were added using lOOx stock solutions to minimise volume 
changes and only final concentrations are quoted in the text forthwith.
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4.3 Results
Isoproterenol is a p-adrenoceptor agonist which has been shown to increase glutamate 
release from cerebrocortical nerve terminals (Herrero and Sanchez-Prieto, 1996; Wang 
et al., 2002). Previous experiments examining the mechanisms of isoproterenol- 
mediated enhancement of glutamate release have so far identified two pathways through 
which this could be occurring. The first suggested a role for increasing levels of 
membrane excitability, whereas the second suggested the involvement of presynaptic 
Ca channels (Herrero and Sanchez-Prieto, 1996; Wang et al., 2002). The preliminary 
experiments conducted in this chapter investigated whether isoproterenol couldstill 
mcrease glutamate release from synaptosomes when Ca -channel regulation was 
bypassed. Glutamate release was evoked using ionomycin (5pM), which increases the 
influx of Ca2+ into the nerve terminal independently of Ca2+-channels. Figure 4.1 
illustrates that isoproterenol (lOpM) was still able to significantly enhance ionomycin- 
evoked glutamate release, thus suggesting the additional involvement of a mechanism 
occurring downstream of Ca2+ entry (mean ± s.e.m. cumulative glutamate release 
(nmol/mg) calculated from 4 independent experiments: control = 6.98 ± 1.4; 
isoproterenol = 11.18 ± 1.6).
ERK1,2 phosphorylation has now been shown to occur downstream of p-adrenoceptor 
signalling in several systems (Aley et al., 2001; Friedman et al., 2002; Roberson et al., 
1999). The next series of experiments conducted in this chapter investigated whether 
stimulation with this agonist could also elicit increases in ERK1,2 activation in 
cerebrocortical synaptosomes. Figure 4.2 shows that treatment with isoproterenol can 
indeed stimulate ERK1,2 phosphorylation in a concentration-dependent manner, and 
can be saturated, as illustrated by the sigmoidal log-dose response curve. All the tested 
concentrations of the p-adrenoceptor agonist were able to significantly enhance basal 
ERK1,2 phosphorylation levels following 10 minutes of incubation with 5 mins 30 secs 
in the presence on the drug (mean ± s.e.m. of isoproterenol effect in % compared to 
100% 37°C controls: lnM =  121 ± 10; 10nM= 122 ± 10; 100nM= 131 ± 12; lpM  =
143 ± 11; lOjiM = 149 ± 10; IOOjjM  =152+12). As stated earlier, isoproterenol is a p- 
adrenergic receptor agonist, which implies the observed stimulation of ERK1,2 
phosphorylation is occurring downstream of p-adrenoceptor activation. In order to
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(lOpM)
Control
Time
(60 Seconds Per Division)
Figure 4.1 Isoproterenol Can Enhance Glutamate Release Independently of Ca2+ 
Channel Regulation. Synaptosomes were incubated in the presence of 1 mM CaCb as 
indicated in section 4.2.1. Glutamate release was evoked with the addition of 
ionomycin (5pM, arrow) in the absence (control), or presence (+isoproterenol) of 
isoproterenol (lOfiM). Isoproterenol was added 5mins prior to the addition of the 
secretogogue. The mean traces from four individual experiments, measuring 
cumulative release at 2sec intervals, are shown. Mean ± s.e.m. release was calculated at 
each time point, but the cumulative glutamate release values following 4mins 30secs of 
incubation with the secretogogue were used for statistical analysis **P<0.01; different 
from control (student’s paired t-test; n=4).
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Figure 4.2 Isoproterenol Dose-Dependently Enhances ERK1,2 Phosphorylation.
Synaptosomes were incubated for 10 minutes with ImM CaCE either in the absence 
(control) or presence (+isoproterenol) of varying concentrations of isoproterenol. 
Concentrations used were InM, lOnM, lOOnM, lpM , lOpM and 100pM. 7.5% 
polyacrylamide gels were run. Immunoblots were labelled using phospho-specific 
MAPK primary antibody (NEB, 1:1000) and probed using 125I-labelled protein A. 
Levels of I-labelling from several independent experiments were detected and 
analysed using phosphorimager spectroscopy (Molecular Dynamics). *P<0.05, 
**P<0.01 compared to 100% 37°C control (Student’s paired t-test). A. Phosphorimage 
of effects on ERK 1,2 phosphorylation. B. Quantification of ERK 1,2 phosphorylation 
levels. C. Possible pathway involved (? denotes hypothetical pathway).
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confirm this, the effects of the (3-adrenoceptor antagonist, propranolol, on ERK1,2 
phosphorylation in synaptosomes were examined.
Figure 4.3 demonstrates the levels of ERK1,2 phosphorylation obtained following 10 
mins incubation in the presence of propranolol. As can be seen from the immunoblot 
and the graph, propranolol (100pM) was able to significantly decrease basal levels of 
ERK1,2 activation in this system (mean ± s.e.m. compared to 100% 37°C control: 
propranolol = 81.5 ± 2.8). These results imply that p-adrenoceptors are endogenously 
activated in purified cerebrocortical nerve terminals, and that their activation contributes 
to the basal phosphorylation levels of ERK1,2 found in this system. This observation 
agrees with previous studies which have identified inverse agonist properties for 
propranolol, and also adds evidence to the physiological nature of this pathway in 
synaptosomes (Chidiac et al., 1994; Varma et al., 1999).
In order to investigate whether P-adrenoceptor inhibition could also attenuate 
isoproterenol-mediated increases in ERK1,2 phosphorylation, the next experiments 
looked at the levels of ERK 1,2 activation in synaptosomes treated with isoproterenol 
and propranolol. The results from these experiments are displayed in Figure 4.4. As 
can be seen from the graph and immunoblot, propranolol was still able to inhibit basal 
levels of ERK 1,2 activation, as well as competitively attenuate the isoproterenol- 
induced increases in ERK1,2 phosphorylation (mean ± s.e.m. compared to 100% 37°C 
control: propranolol (100pM) = 80.7 ± 4.8; isoproterenol (lOOpM) = 124 ± 5; 
isoproterenol/propranolol = 87.1 ± 6.0). This confirms the hypothesis that the 
isoproterenol-mediated increase in ERK 1,2 phosphorylation in cerebrocortical 
synaptosomes is occurring downstream of p-adrenoceptor activation.
The results obtained so far in this chapter have been in agreement with the results 
obtained in other systems showing that activation of P-adrenoceptors can lead to 
stimulation of ERK1,2 phosphorylation (Berkeley and Levey, 2003; Storm and 
Khawaja, 1999; Schmitt and Stork, 2000). The pathways involved in mediating this 
stimulation have been further elucidated in several systems. For example, in HEK293 
cells, p2-adrenoceptors have been shown to signal via Src to bring about the activation 
of the Rap-1 /B-Raf/MEK/ERK signalling cascade, occurring following a PKA-
122
ERK 1 
ERK 2
oa
-  2 
pnN O  Cm
A .  £  $  2
'S © *
a  u  s
u  ^  ©© r- o
B. C.
1 0 0 -
icoU
U<Km
o'-Oo
T3<Dc3
CL£oU<uocfi
&
5N=ox
Noradrenaline
 «>
3-Adrenoceptor|
Propranolol
cyclicAMP
? ^
' 4
1
ERK1,2
4°C
Control
37°C
Control
lOO^M
Propranolol
Figure 4.3 Propranolol Significantly Inhibits Basal Levels of ERK 1,2 Activation.
Synaptosomes were incubated with ImM CaCh for 10 minutes either in the absence 
(control), or presence (+propranolol) of lOOpM propranolol. 7.5% polyacrylamide gels 
were used. Immunoblots were labelled with phospho-specific MAPK primary antibody 
(NEB, 1:1000) and reported using l25I-labelled protein A. Levels o f 12 I-labelling were 
detected and analysed from several separate experiments using phosphorimager 
spectroscopy (Molecular Dynamics). **P<0.01 compared to 100% 37°C control 
(Student’s paired t-test, n=10). A. Phosphorimage of the effects of propranolol on 
ERK1,2 phosphorylation. B. Quantification of ERK1,2 phosphorylation levels. C. 
Suggested pathway involved in mediating these effects on ERK 1,2 activation (? 
indicates hypothetical pathways).
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Figure 4.4 Isoproterenol-Mediated Stimulation of ERK 1,2 Phosphorylation is 
Dependent on p-Adrenoceptor Activation. Synaptosomes were incubated at 37°C for 
10 minutes with ImM CaCh either in the absence (control) or presence of lOOpM 
isoproterenol (+isoproterenol) and/or lOOpM propranolol (+propranolol). 7.5% 
polyacrylamide gels were run. A Phospho-specific MAPK primary antibody (NEB,
1:1000) was used to label immunoblots which were probed with 125I-labelled protein A. 
Levels of I were detected and analysed using phosphorimager spectroscopy 
(Molecular Dynamics). **P<0.01, *P<0.05 compared to 100% 37°C control (ANOVA 
followed by Duncan’s post hoc analysis, isop n=16, prop and isop/prop n=5). A. 
Immunoblot showing ERK1,2 phosphorylation levels. B. Quantification of effects. C. 
Proposed pathway involved in these effects (? denotes hypothetical pathways).
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mediated phosphorylation of Src (Schmitt and Stork, 2002; Friedman et al., 2002). A 
PKA-dependency has also been observed in the p-adrenoceptor-mediated enhancement 
of ERK1,2 phosphorylation in the CA1 region of the hippocampus (Roberson et al., 
1999). However, several studies have also found signalling to ERK1,2 downstream of 
P-adrenoceptor activation to occur in a manner independent of PKA, albeit in COS-7 
cells and primary nociceptor afferents (Cao et al., 2000; Aley et al., 2001). In order to 
elucidate the pathway involved in this system, the next experiments conducted in this 
chapter investigated the PKA-dependency of the P-adrenoceptor-mediated enhancement 
of ERK1,2 activation in cerebrocortical synaptosomes.
Figure 4.5 illustrates the effects of the PKA inhibitor, H-89, on isoproterenol stimulated 
levels of ERK1,2 phosphorylation. As can been seen from the immunoblot in Figure 
4.5A and from Figure 4.5B, H-89 was able to attenuate the enhancement of ERK1,2 
phosphorylation by isoproterenol. The ERK1,2 phosphorylation levels in the presence 
of H-89 alone and those in the presence of H-89 and isoproterenol were found to be no 
different from each other, however, they were both found to be significantly lower than 
control levels (mean ± s.e.m. in % compared to 100% 37°C control: isoproterenol =124 
± 5; H-89 = 60 ± 1; isoproterenol/H-89 = 62 ± 9). These results suggest that the 
signalling to ERK1,2 downstream of p-adrenoceptor activation in cerebrocortical nerve 
terminals is dependent upon the activation of PKA (Figure 4.5C). However, as 
discussed in the previous chapter, H-89 is not highly specific for PKA, so it remains 
possible that the observed attenuation of ERK1,2 activation could be occurring through 
a mechanism which is PKA-independent. In order to confirm a role for PKA in this 
signalling pathway in synaptosomes, the effects of a second PKA inhibitor were 
examined.
The effects of the second PKA inhibitor, KT-5720, on isoproterenol-enhanced levels of 
ERK1,2 phosphorylation are shown in figure 4.6. KT-5720 was also found to attenuate 
p-adrenoceptor-mediated increases in ERK1,2 activation and, as with H-89, both the 
ERK1,2 phosphorylation levels with KT-5720, whether in the absence and presence of 
isoproterenol, were found to be significantly lower than control levels (mean ± s.e.m. in 
% compared to 100% 37°C control: KT-5720 = 78 ± 6; KT-5720/isoproterenol = 79 ± 9; 
isoproterenol = 124 ± 5). These results are in complete agreement with those obtained
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Figure 4.5 P-Adrenoceptor-Mediated Stimulation of ERK 1,2 May Be Dependent 
on PKA. Synaptosomes were incubated with ImM CaCb for 10 mins at 37°C either in 
the absence (control) or presence of lOOpM isoproterenol (+isoproterenol) and/or lOpM 
H-89. 7.5% polyacrylamide gels were run. Immunoblots were labelled with phospho- 
specific MAPK primary antibody (NEB, 1:1000) followed by secondary labelling with 
1 5I-bound protein A. Signal levels of 12:>I from several separate experiments were 
detected and analysed using phosphorimager spectroscopy (Molecular Dynamics). 
**P<0.01 (ANOVA followed by Duncan’s post hoc analysis, isop n=16, H-89 and 
isop/H-89 n=6). A. Phosphorimage of ERK 1,2 phosphorylation. B. Quantification of 
ERK 1,2 effects. C. A suggested pathway mediating isoproterenol stimulation of 
ERK 1,2 activation (? = hypothetical pathway).
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Figure 4.6 KT-5720 Also Inhibits Isoproterenol-Mediated Stimulation of ERK 1,2.
Synaptosomes were incubated at 37°C for 10 mins with ImM CaCl2 either in the 
absence (control) or presence of lOOpM isoproterenol (+isoproterenol) and/or lpM  KT- 
5720 (+KT-5720). 7.5% Polyacrylamide gels were used. Immunoblots were labelled 
using a phospho-specific MAPK primary antibody (NEB, 1:1000) and reported using 
l25I-labelled protein A. Signal levels from several separate experiments were detected 
and analysed using phosphorimager spectroscopy (Molecular Dynamics). **P<0.01, 
*P<0.05 compared to 100% 37°C control (ANOVA followed by Duncan’s post hoc 
analysis, isop n=16, KT-5720 and isop/KT n=5). A. Example of an immunoblot. B. 
Quantification of ERK1,2 phosphorylation levels. C. Possible pathway mediating these 
effects (? = hypothetical pathway).
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with H-89, and imply a role for PKA in regulating the signalling between p- 
adrenoceptors and ERK1,2 in cerebrocortical nerve terminals.
The final experiments conducted in this chapter to examine the role of PKA, used an 
inhibitor of the regulatory subunit of PKA, Rp-cAMPS. In the previous chapter, this 
inhibitor was found not to be active against the forskolin/IBMX-mediated enhancement 
of ERK1,2 phosphorylation following the 10 minute incubation protocol. This was 
thought likely to be due to low levels of the inhibitor crossing the plasma membrane, 
however, it could also have been due to displacement of the drug by the high levels of 
cAMP produced, or to PKA-independency of the pathway. Activation of p-
"adrenoceptorsby isoproterenolshouldalsoresultinenhanced xAMP produetionrbut the--------
levels of the second messenger would be expected to be lower, and thus less likely to 
displace Rp-cAMPS. The previous experiments have also suggested that the p- 
adrenoceptor-mediated enhancement in ERK1,2 activation is likely to be PKA- 
dependent. Notwithstanding, Figure 4.7 shows that Rp-cAMPS was also unable to 
inhibit isoproterenol-mediated enhancement of ERK 1,2 activation. This experiment 
confirms the original hypothesis, that this incubation protocol is not allowing Rp- 
cAMPS to accumulate in synaptosomes in sufficient quantity to inhibit PKA activation 
(mean ± s.e.m. in % compared to 100% 37°C control: isoproterenol = 124 ± 5; Rp- 
cAMPS = 100 ±13; Rp-cAMPS/isoproterenol = 124 ± 6).
The results obtained so far suggest that the p-adrenoceptor-mediated enhancement of 
ERK1,2 phosphorylation is PKA-dependent. This is in contrast to the results obtained 
in the previous chapter, which found the majority of the forkolin/IBMX-mediated 
enhancement of ERK1,2 phosphorylation might be occurring independently of PKA. 
Combined, these results suggest the presence of more than one cAMP-mediated 
pathway able to regulate ERK1,2 activity in cerebrocortical nerve terminals. The next 
experiments conducted in this chapter investigated whether the p- 
adrenoceptor/PKA/ERKl,2 pathway was able to undergo a time-dependent switch from 
facilitation of ERK1,2, to inhibition, as observed with the forskolin/IBMX mediated 
pathway.
Synaptosomes were preincubated for 20 minutes at 37°C then re-pelleted and cooled
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Figure 4.7 Rp-cAMPS Does Not Inhibit Isoproterenol-Mediated Stimulation of 
ERK 1,2 Phosphorylation. 37°C incubation o f synaptosomes with ImM CaCE lasted 
for 10 mins either in the absence (control) or presence o f  lOOpM Rp-cAMPS (+Rp- 
cAMPS) and/or lOOpM isoproterenol (+isoproterenol). 7.5% polyacrylamide gels were 
run. Immunoblots were labelled with a phospho-specific MAPK antibody (NEB,
1:1000) and probed using protein A labelled with 25I. Levels o f 125I-labelling from 
several separate experiments were detected and analysed using phosphorimager 
spectroscopy (Molecular Dynamics). **P<0.01, *P<0.05 compared to 100% 37°C 
control (ANOVA with Duncan’s post hoc analysis, isop n=16, Rp-cAMPS and isop/Rp 
n=5). A. Phosphorimage o f  effects. B. Quantification o f  ERK 1,2 phosphorylation 
levels.
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back to 4°C before undergoing the standard 10 minute incubation protocol.
Isoproterenol (10pM) was added for a total of 6 minutes. The results from these 
experiments are shown in figure 4.8 and, as can be seen from the immunoblot (Figure 
4.8A) and the graph (Figure 4.8B), isoproterenol was still able to significantly enhance 
ERK1,2 phosphorylation levels following this preincubation protocol (mean ± s.e.m. in 
% compared to 100% 37°C control: isoproterenol = 125 ± 6). This suggests that the p- 
adrenoceptor signalling pathway is differentially regulated compared to the 
forskolin/IBMX signalling pathway, and that positive signalling through the P- 
adrenoceptor does not undergo endogenous desensitisation following this incubation 
protocol.
So far, this chapter has identified a signalling pathway through which P-adrenoceptor 
activation leads to a PKA-dependent increase in ERK 1,2 phosphorylation. The next set 
of experiments proceed to investigate the signalling occurring downstream of ERK 1,2 
activation. Previous studies have identified synapsin I as a synaptic vesicle tethering 
protein which can be phosphorylated by multiple protein kinases. The phosphorylation 
of this protein by PKA or ERK1,2 has been shown to decrease the tethering of synaptic 
vesicles and to increase their availability for release, thus presenting a possible 
mechanism for increasing glutamate release from nerve terminals (Chi et al., 2001; Chi 
et al., 2003). Figure 4.9 shows examples of immunoblots labelled with phospho- 
specific antibodies for the sites of synapsin I phosphorylated by PKA or by ERK1,2. As 
can be seen from the blots, treatment of synaptosomes with isoproterenol led to 
increases in synapsin I phosphorylation by both PKA and ERK1,2. Further experiments 
will need to be conducted to absolutely confirm these results, but the data as they are, 
suggest that the component of P-adrenoceptor-mediated glutamate release occurring
0 -4-downstream of Ca channel regulation, could be occurring through a mechanism 
involving enhanced synapsin I phosphorylation and increased synaptic vesicle 
availability. If this is so, then it shares a mechanism with the neurotrophin-mediated 
enhancement of glutamate release that has been described in cerebrocortical nerve 
terminals (Jovanovic et al., 2000). This immediately begs the question as to whether the 
p-adrenoceptor-mediated and neurotrophin-mediated enhancements are occurring 
within the same or different populations of ERK1,2.
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Figure 4.8 Isoproterenol is Still Able to Enhance ERK1,2 Phosphorylation Levels 
in Preincubated Synaptosomes. Synaptosomes were preincubated with 1 mM CaC^, 
as described in section 4.2.3. A lOmin 37°C incubation followed, with either water 
(control) or lOpM isoproterenol (+isoproterenol) added 6mins prior to the termination 
o f the reaction. Gels containing 7.5% polyacylamide were run. Immunoblots were 
labelled with phospho-specific MAPK antibody (NEB, 1:1000) and probed using 125I- 
labelled protein A. Levels o f  labelling from several separate experiments were detected 
and analysed using phosphorimager spectroscopy (Molecular Dynamics). **P<0.01 
compared to 100% 37°C control (ANOVA followed by Duncan’s post hoc analysis, 
n=5). A. Phosphorimage o f  effects. B. Quantification o f  ERK 1,2 phosphorylation 
levels.
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Figure 4.9 Stimulation of Synaptosomes with Isoproterenol May Be Leading to 
Increased Phosphorylation of Synapsin I at Two Different Sites. Synaptosomes 
were incubated at 37°C for 10 minutes with ImM CaCE either in the absence (control) 
or presence (+isoproterenol) of lOOpM isoproterenol. 7.5% polyacrylamide gels were 
run. Immunoblots were labelled with phospho-specific primary antibodies either for 
phosphorylation site 1 (1:200, J.J) or site 4/5 (1:500, J.J.) of synapsin I. Blots were 
probed using ,25I-labelled protein A, with levels of labelling being detected using 
phosphorimager spectroscopy (Molecular Dynamics). A. A suggested pathway for the 
Ca channel-independent regulation of glutamate release by p-adrenoceptors (? = 
hypothetical pathways). B. Examples of immunoblots showing increased levels of 
synapsin I site 1 and site 4/5 phosphorylation with isoproterenol.
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The final experiments conducted in this chapter investigated whether the (3-adrenoceptor 
and neurotrophin receptor signalling to ERK1,2 could be occurring within the same 
nerve terminals. Synaptosomes were incubated for 10 minutes with BDNF added for 6 
minutes, to stimulate TrkB receptors, and isoproterenol added for 5 minutes and 30 
seconds, to stimulate p-adrenoceptors. Figure 4.10 A and B illustrate the effects of 
coapplication of BDNF (50ng/ml) and isoproterenol (10pM) on ERK1,2 
phosphorylation levels. Both BDNF and isoproterenol were found to significantly 
enhance ERK1,2 activation when applied alone, but not when applied together (mean ± 
s.e.m. in % compared to 100% 37°C control: BDNF (50ng/ml) = 175 ± 29; 
isoproterenol (10pM) = 174 ±11; BDNF/isoproterenol = 142 ± 9). This could imply 
that these two signalling pathways are interacting to limit ERK1,2 activation, however, 
no significant differences were found between the effects of isoproterenol and BDNF 
alone, compared to their combined effects. Therefore, further experiments would need 
to be conducted to elucidate on any interacting properties of these signalling cascades, 
as only a small number of repeats were obtained on this occasion.
Figure 4.10 also describes the results obtained with this protocol when a higher 
concentration of BDNF (lOOng/ml) was used (see Figures 4.10 C and D). These results 
show a similar pattern of ERK1,2 phosphorylation to that described with the lower, 
50ng/ml, BDNF concentration. Both BDNF and isoproterenol were found to 
significantly enhance ERK 1,2 activation when applied alone, but not when added in 
combination (mean ± s.e.m. in % compared to 100% 37°C control: BDNF (lOOng/ml) = 
185 ± 30; isoproterenol (10pM) = 162 ± 14; BDNF/isoproterenol = 127 ± 10). On this 
occasion the level of ERK 1,2 response in the presence of BDNF alone was also found 
to be significantly different from the level obtained in the presence of BDNF and 
isoproterenol. This suggests that the activation of P-adrenoceptors in cerebrocortical 
nerve terminals may be having an attenuating effect on neurotrophin-mediated ERK1,2 
activation when these concentrations of agonists are used. However, further 
experiments would also need to be carried in order to absolutely confirm the results 
obtained here.
The final combination of BDNF and isoproterenol concentrations used were lOOng/ml 
and lOOpM, respectively. Figure 4.11 illustrates the results obtained with these
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Figure 4.10 Isoproterenol and BDNF-Mediated Increases in ERK 1,2 
Phosphorylation are not Additive. Synaptosomes were incubated for 10 minutes with 
ImM CaCb either in the absence (control) or presence o f  BDNF (+BDNF) and/or 
isoproterenol (+isop.). BDNF (50 or 1 OOng/ml) was added 6mins prior, and 
isoproterenol (lOpM) 5mins 30s prior to the termination o f the reactions. 7.5% 
polyacrylamide gels were run. Immunoblots were labelled with phospho-ERK primary 
antibody (1:1000, NEB) and probed using I-labelled protein A, levels o f  which were 
detected and analysed with phosphorimager spectroscopy (Molecular Dynamics). 
*P<0.05 compared to 100% 37°C control (ANOVA followed by Duncan’s post hoc 
analysis, B (50ng/ml BDNF) n=3; D (1 OOng/ml BDNF) n=4). A&B. Phosphorimages o f  
isoproterenol and BDNF effects. C&D. Quantification o f  ERK 1,2 phosphorylation 
levels.
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concentrations of agonists. On this occasion both BDNF and isoproterenol in isolation, 
as well as the two agonists in combination, were able to significantly enhance ERK1,2 
phosphorylation levels (mean ± s.e.m. in % compared to 100% 37°C control: BDNF 
(1 OOng/ml) = 203 ± 34; isoproterenol (IOOjiM) = 167 ±19; BDNF/isoproterenol =181 
± 7). No significant differences were found between the levels of ERK1,2 activation 
with the individual agonists or when they were coapplied. The lack of additivity of 
BDNF and isoproterenol treatment, as well as the possible attenuating effect of (3- 
adrenoceptor activation on neurotrophin-mediated signalling, implies the involvement 
of the same pool of ERK1 and ERK2 in the regulation of these effects. This suggests 
that these receptor-linked signalling pathways are present within the same nerve 
terminals (as illustrated in Figure 4.12), adding evidence to the hypothesis that 
isoproterenol may be utilising parts of the same downstream pathway as BDNF to 
enhance glutamate release from cerebrocortical nerve terminals. Further investigation is 
required to confirm this hypothesis and the level of interaction of the two pathways also 
remains to be determined.
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Figure 4.11 Combined Effects of Isoproterenol and BDNF on ERK 1,2 Activation.
Synaptosomes were incubated with ImM CaC^ for 10 mins in the presence o f  
1 OOng/ml BDNF (+BDNF) added 6 mins prior to the termination o f the incubation, 
and/or lOOpM isoproterenol (+isop.) added 5 mins 30 sec prior to the end o f  the 
incubation. Gels containing 7.5% polyacylamide were run. Immunoblots were labelled
•  19 Swith phospho-specific MAPK primary antibody (1:1000, NEB) and reported using I-
nc ..
labelled protein A. I-labelling was quantified using phosphorimager spectroscopy 
(Molecular Dynamics). P>0.05, P>0.01 (ANOVA with Duncan’spost hoc analysis, 
n=3). A. Phosphorimage o f  isoproterenol and BDNF effects. B. Quantification of  
isoproterenol and BDNF effects.
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Figure 4.12 A Summary Diagram Illustrating a Possible Role for ERK 1,2 in the 
Cross-Talk of Neurotrophin and Adrenergic Receptor Signalling Pathways in the 
Regulation of Glutamate Release. BDNF stimulates the TrkB receptor resulting in 
phosphorylation of the receptor and binding of the adaptor protein GRB2. This, in turn, 
binds the Ras guanine nucleotide exchange factor (Sos), resulting in the exchange of 
Ras-GDP for Ras-GTP and activation of the Ras/Raf/MEK/ERK signalling cascade. 
Isoproterenol stimulates the p-adrenoceptor GPCR leading to activation of PKA and 
ERK 1,2. The exact mechanism for the PKA-dependency of ERK 1,2 activation remains 
to be determined, as well as the level of interaction of the two signalling pathways. 
Abbreviations: AC = adenylate cyclase, cyclic AMP = cyclic adenosine monophosphate, 
ATP = adenosine triphosphate, PKA = protein kinase A, ERK 1,2 = extracellular- 
regulated protein kinase 1 and 2, MEK = mitogen activated protein kinase kinase.
(? Indicate hypothetical pathways).
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4.4 Summary o f  Results
• p-adrenoceptor-mediated enhancement of depolarisation-induced glutamate
* •  24"release can be manifested in a mechanism occurring downstream of Ca entry 
in cerebrocortical nerve terminals.
• Activation of p-adrenoceptors leads to a dose-dependent enhancement of 
ERK1,2 phosphorylation in cerebrocortical nerve terminals.
• Stimulation of ERK1,2 phosphorylation downstream of p-adrenoceptor 
activation occurs through a signalling cascade which is dependent on PKA.
• Endogenous stimulation of P-adrenoceptors appears to partially account for the 
basal levels of ERK1,2 activation observed in cerebrocortical nerve terminals.
•  Evidence suggests that p-adrenoceptor activation may be leading to the 
enhancement of PKA- and ERK 1,2-dependent phosphorylation of synapsin I,
 ^i t
thus providing a mechanism for Ca channel independent increases m glutamate 
release from synaptosomes treated with isoproterenol.
• p-adrenoceptor and TrkB mediated signalling to ERK1,2 appears to occur within 
the same nerve terminals.
• These results, combined with those obtained in the previous chapter, indicate the 
existence of a pathway for ERK1,2 activation following forskolin/IBMX 
treatment that displays differential characteristics to the p- 
adrenoceptor/PKA/ERKl,2 pathway described here.
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4.5 Discussion
The p-adrenoceptor has been shown to be a Gs-coupled GPCR, whose activation leads 
to the stimulation of adenylate cyclase and increased intracellular levels of cAMP 
which, in turn, leads to enhanced PKA activation (De Blassi, 1990). The PKA 
inhibitors, H-89 and KT-5720, were both shown to attenuate P-adrenoceptor-mediated 
increases in ERK1,2 phosphorylation, which naturally leads to the conclusion that the 
signalling pathway occurring between the P-adrenoceptor and ERK1,2, in 
cerebrocortical synaptosomes, is dependent on PKA. These results are in contrast to 
those obtained following the enhancement of intracellular cAMP levels and inhibition 
of adenosine Ai receptors with forskolin/IBMX, which indicated that the stimulation of 
ERK1,2 phosphorylation might occur independently of PKA based on inhibitor profile. 
It is possible, considering the non-specific effects of these inhibitors described in the 
previous chapter, that the attenuation of P-adrenoceptor signalling to ERK1,2 is 
mediated through the inhibition of another kinase, and not PKA. However, several 
studies have identified a role for PKA in regulating the signalling occurring between P- 
adrenoceptors and ERK1,2, such as in the CA1 region of the hippocampus, and in 
HEK293 cells (Roberson et al., 1999; Schmitt and Stork, 2002). A number of factors 
also point towards separate pathways mediating the effects of p-adrenoceptor signalling 
and the signalling occurring following treatment with forskolin/IBMX in cerebrocortical 
nerve terminals. These include the PKA-dependency of p-adrenoceptor signalling 
versus the PKA-independency of forskolin/IBMX signalling to ERK, as well as the 
persistent stimulatory effect on ERK1,2 phosphorylation of isoproterenol versus the 
switch from facilitation to inhibition by forskolin/IBMX.
The regulation of ERK1,2 phosphorylation by different cAMP-mediated pathways is 
not without precedent, as a number of reports have identified a role for direct cAMP 
activation of the ERK1,2 signalling cascade through stimulation of a Rapl-GEF, such 
as Epac (de Rooij et al., 1998; Lin et al., 2003). This means that the forskolin/IBMX- 
mediated increases in ERK1,2 phosphorylation could be occurring through cAMP- 
dependent but PKA-independent signalling pathway. If this was found to be so, then it 
would suggest the existence of two different cAMP-mediated ERK 1,2 activation 
pathways in nerve terminals. However, it is also possible that the differences found
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between ERK1,2 activation following p-adrenoceptor stimulation and treatment with 
forskolin/IBMX are mediated by adenosine A l receptor inhibition, rather than 
enhancement of cAMP levels. It would be interesting to further investigate these 
differences in regulation of ERK1,2 phosphorylation by isoproterenol and 
forskolin/IBMX in nerve terminals, and in particular, to clarify the cAMP-dependency 
of the forskolin/IBMX effect.
The results showing a propranolol-mediated inhibition of basal ERK1,2 activation 
levels, combined with those obtained with the PKA inhibitors, H-89 and KT5720, adds 
weight to the proposal from the previous chapter, that a PKA-dependent basal 
phosphorylation of ERK 1,2 occurs in nerve terminals. These results also suggest that 
the p-adrenergic receptor is providing a locus for at least part of the basal level of 
ERK 1,2 phosphorylation observed in synaptosomes. Studies conducted in other 
systems have found that propranolol, as well as being a P-adrenoceptor inverse agonist, 
can also have partial agonist responses in stimulating the ERK1,2 signalling cascade, 
which could suggest a role for this compound as a dual efficacy ligand (Azzi et al.,
2003; Baker et al., 2003). However, propranolol was found to significantly decrease 
ERK1,2 phosphorylation in cerebrocortical synatosomes, rather than to elicit any 
increase, suggesting this is not occurring here.
As mentioned before, p-adrenoceptor-mediated increases in ERK1,2 phosphorylation 
have been shown to be dependent on PKA in several different systems, nevertheless, the 
exact mechanisms involved are still under debate. In PC 12 cells, for example, PKA has 
been shown to directly phosphorylate Rapl, leading to increased GTP-binding and 
activation of the Rapl/B-Raf/MEK/ERK1,2 signalling cascade (Vossler et al., 1997). 
This is in contrast to more recent studies in cortical neurones which have identified an 
increase in Ras-GTP levels following PKA stimulation, leading to activation of the 
Ras/Raf-1/MEK/ERK1,2 cascade (Ambrosini et al., 2000). There is also evidence to 
suggest that PKA can directly phosphorylate and activate Src, leading to recruitment 
and activation of Rap-1 in HEK293 cells (Schmitt and Stork, 2002). However, also of 
note is that PKA has been shown to phosphorylate the P-adrenoceptor resulting in the 
switching of the coupling from Gs to Gi/o and consequent activation of the ERK1,2 
signalling cascade through py subunits (Zamah et al., 2002; Laroche-Joubert et al.,
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2003). Though this mechanism may be dependent on the cell type studied, as the 
dominant mechanism for p-adrenoceptor activation of ERK1,2 in HEK293 cells did not 
require PKA phosphorylation of the receptor but did require the activation of a Src 
family member (Friedman et al., 2002). Further experiments would need to be 
conducted to clarify the mechanism for PKA-dependent ERK1,2 activation in 
cerebrocortical synaptosomes. It would be possible to determine the Src-dependency of 
PKA signalling to ERK1,2, downstream of p-adrenoceptor activation in cerebrocortical 
synaptosomes by using the selective Src family kinase inhibitor, SU6656 (Blake et al., 
2000). Several studies have demonstrated that the same GPCR has the ability to 
activate ERK1,2 via multiple signalling pathways and the cellular context within which 
a receptor is expressed can determine the mechanism of GPCR-mediated ERK 
activation (Della Rocca et al., 1999; Pierce et al., 2000). This means that until further 
experiments are conducted, the mechanism determining the PKA-dependency of p- 
adrenoceptor-mediated ERK1,2 activation can at best, only be speculation.
The combined activation of TrkB receptors (with BDNF) and p-adrenoceptors (with 
isoproterenol) did not result in an addition of the ERK 1,2 phosphorylation levels in 
cerebrocortical nerve terminals. This suggests that these two receptors are involved in 
regulating the same pool of ERK1 and 2. Studies conducted in COS-7 cells have 
identified a mechanism through which p-adrenoceptors are able to ‘transactivate’ 
neurotrophin receptors, albeit epidermal growth factor receptors (EGFR) (Pierce et al., 
2000; Maudsley et al., 2000). It was found that activation of P-adrenoceptors could lead 
to endocytosis of the EGFR and stimulation of the ERK1,2 signalling cascade. It is 
possible that the stimulation of synaptosomes with isoproterenol is leading to p- 
adrenoceptor-mediated ‘transactivation’ of the TrkB receptor, which would explain how 
both receptors could be stimulating the same pool of ERK1 and 2. However, a role for 
PKA in this signalling pathway has yet to be defined, although Src activation has been 
shown to be required, so it is possible that PKA is involved in phosphorylating and 
activating Src (Maudsley et al., 2000). It should be noted that ‘transactivation’ of TrkB 
receptors by p-adrenoceptors and PKA-mediated phosphorylation of Src is yet to be 
shown in cerebrocortical synaptosomes, and so this mechanism for activation of 
ERK 1,2 remains speculative until further experiments can be conducted.
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In a study conducted in the striatum, P-adrenoceptor-mediated enhancement of 
glutamate release was found to occur through a cAMP/PKA upregulation of kainate 
receptors (Dohovics et al., 2003a; Dohovics et al., 2003b). Although this mechanism 
cannot be ruled out for the enhancement, by P-adrenoceptors, of glutamate release from 
cerebrocortical nerve terminals, the stimulation of ERK1,2, combined with the observed 
phosphorylation of the downstream protein, synapsin I, at least implies the presence of 
an alternative mechanism for the regulation of glutamate release in this system. The 
phosphorylation of synapsin I on sites mediated by both PKA and ERK1,2 opens the 
way for an involvement of p-adrenoceptor signalling in the regulation synaptic vesicle 
availability. Increased phosphorylation of synapsin I at these sites has been shown to 
decrease the tethering of synaptic vesicles, resulting in an increase in the number of 
vesicles available for release (Chi et al., 2001; Chi et al., 2003). This hypothesis could 
be used to explain the ability of isoproterenol to enhance glutamate release 
independently of Ca channel modulation in cerebrocortical nerve terminals, as well as 
independently of the regulation of membrane excitability and Ca2+ influx in cerebellar 
cells (Chen and Regehr, 1997) (see Figure 4.12). However, only examples of 
isoproterenol-mediated signalling to synapsin I are shown in Figure 4.9, and so further 
experiments will need to be conducted to prove the role of synapsin I downstream of p- 
adrenoceptor signalling in presynaptic nerve terminals.
The results obtained in this chapter have described an ability of two major presynaptic 
signalling cascades, PKA and ERK1,2, to cross-talk with each other downstream of 
GPCR activation, resulting in a possible functional involvement in the regulation of 
glutamate release. The next chapter in this thesis goes on to investigate whether another 
major presynaptic signalling cascade, the PKC cascade, could also be able to cross-talk 
with ERK1,2 in presynaptic cerebrocortical nerve terminals.
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Chapter 5
Phorbol Ester-Mediated Modulation o f Presynaptic Function: 
Cross-Talk o f PKC and ERK 1,2 Signalling Cascades.
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5.1 Introduction
Protein kinase C (PKC) has long been known to enhance the release of various 
neurotransmitters from neurones, including noradrenaline (Allgaier et al., 1986), 
acetylcholine (Allgaier et al., 1988), glutamate (Barrie et al., 1991), GABA (Bartmann 
et al., 1989), dopamine (Nichols et al., 1987), and serotonin (Feuerstein et al., 1987). It 
is commonly agreed that depolarisation of nerve terminals followed by the inevitable 
influx of Ca2+ ions leads to the activation of PKC (Wang et al., 1988). However, the 
mechanisms through which PKC is able to modulate release are still under debate.
There are currently believed to be four possible ways through which PKC could mediate
* 2+its effects on increasing neurotransmitter release. These are through: regulation of Ca 
channels, regulation of K+ channels, interactions with the exocytotic machinery, or by 
regulating the size of the readily releasable pool of synaptic vesicles.
Exocytosis of synaptic vesicles can be triggered by calcium influx through N-, P/Q-, 
and R-type calcium channels (Heidelberger et al., 1994; Dunlap et al., 1995; Wu et al.,
*7-4-1998). Increases m exocytosis can be mediated by increasing the Ca influx through 
these channels. PKC has been shown to enhance synaptic transmission mediated by Q- 
type channels in hippocampal neurones (Wheeler et al., 1994). N- and P/Q-type 
channels are also reputed to be necessary for the enhancement of glutamate release 
resulting from PKC activation in cerebrocortical nerve terminals (Vazquez and 
Sanchez-Prieto, 1997). It has since been shown that these channels can undergo a shift 
to an easily activated state following direct PKC phosphorylation, representing an 
established PKC-dependent mechanism for increasing neurotransmitter release (Hamid 
et al., 1999; Herlitze et al., 2001).
I
As well as phosphorylating Ca channels to increase neurotransmitter release, PKC 
could also be modulating K+ channel function. K+ channels, in nerve terminals, are 
responsible for the hyperpolarisation phase of the action potential and are involved in 
regulating the general excitability of the membrane. Inhibitory effects on these 
channels by PKC would result in an increased propensity towards depolarisation of the 
plasma membrane. This could increase the probability of Ca2+ channel opening and of 
vesicular release. A study using guinea pig cerebrocortical synaptosomes suggested
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phorbol ester stimulation of glutamate release was due to PKC mediated inhibition of 4- 
AP resistant K+ channels (Barrie et al., 1991). There has also been a study using 
cultured rat cerebellar granule cells where it was suggested that PKC was stimulating 
[3H]-D-Aspartate release through inhibition of a dendrotoxin-1-sensitive K+ channel 
(Cousin et al., 1999). It should be noted however, that neither of these studies looked 
for direct phosphorylation of the K+ channels by PKC, making it impossible to rule out 
other factors in their regulation. Further studies are needed to identify a specific 
location for PKC-dependent K+ channel modulation in nerve terminals.
The third mechanism for PKC-mediated enhancement of neurotransmitter release is 
through interactions with the exocytotic machinery. PKC has recently been shown to 
phosphorylate Munc-18 in adrenal chromaffin cells. This phosphorylation results in the 
decreased affinity of Munc-18 for syntaxin 1A, allowing progression from the primary 
SNARE conformation to the binary conformation. However, this phosphorylation 
served only to modulate single vesicle release kinetics and did not affect the number of 
exocytotic events that phorbol esters are also able to regulate (Barclay et al., 2003). This 
suggests the involvement of additional pathways in phorbol ester mediated increases in 
release.
The fourth and, currently, final mechanism through which PKC could increase 
neurotransmitter release is by regulating the interactions of small synaptic vesicles with 
the actin cytoskeleton. The vesicles are tethered away from the plasma membrane, to 
the actin cytoskeleton, to form the reserve pool of synaptic vesicles. Their interactions 
to the cytoskeleton can be regulated through phosphorylation, resulting in an increase in 
the number of vesicles available for release. Recent evidence has suggested that PKC 
could be involved in regulating the tethering of synaptic vesicles to the actin 
cytoskeleton. Work on glutamate release from retinal bipolar cells has highlighted a 
possible role for PKC modulation of vesicle recruitment. Phorbol ester treatment 
increased glutamate release from the second, slow component of vesicles, suggesting 
that PKC was working to increase the pool size of the slow component in these nerve 
terminals (Minami et al., 1998; Berglund et al., 2002). PKC regulation of vesicle 
availability has also been shown to have a role in enhancing noradrenalin release from 
isolated nerve terminals (Walaas, 1999) and, work on hippocampal slices suggested a
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modulatory involvement of PKC in the disassembly dynamics of synaptic vesicles from 
the actin cytoskeleton (Pasantes-Morales et al., 2002).
Synapsin I is a vesicular protein that binds synaptic vesicles to the actin cytoskeleton in 
glutamatergic cerebrocortical nerve terminals. Phosphorylation of synapsin I by kinases 
such as ERK 1,2 has been shown to reduce tethering by synapsin I, resulting in an 
increase in glutamate release from these nerve terminals (Jovanovic et al., 2000). PKC 
has not been shown to directly regulate synapsin I phosphorylation but it is possible that 
it interacts with, and activates, kinases upstream of ERK 1,2 and synapsin I 
phosphorylation.
PKC activation has been shown to upregulate ERK 1,2 phosphorylation in many 
different systems including PC 12 cells (Brodie et al., 1999), SH-SY5Y neuroblastoma 
cells (Olsson et al., 2000), HEK 293 cells (Kawasaki et al., 1998), cultured astrocytes 
(Neary et al., 1999; Zhao and Brinton, 2003), and CA1 hippocampal neurones 
(Roberson et al., 1999). The exact location for PKC crosstalk with the ERK 1,2 
pathway is still yet to be ascertained, but recent studies have identified a Raf kinase 
inhibitory protein (RKIP) that is phosphorylated directly by PKC. This releases RKIP 
from Raf-1, enabling signalling to continue down the ERK 1,2 pathway (Corbit et al., 
2003). There are also reports of PKC pathway interactions at the level of Ras 
signalling. More recent evidence, however, suggests that signalling through Ras could 
be mediated by a PKC-independent DAG stimulation of RasGEFs (Lorenzo et al., 
2000).
The evidence considered here suggests that, as well as modulating neurotransmitter 
release through the phosphorylation of Ca2+ channels and regulation of K+ channels, 
PKC could also be acting through an alternative mechanism to increase vesicular 
availability. This chapter aims to investigate whether PKC could be stimulating ERK
1,2 phosphorylation in cerebrocortical nerve terminals, and whether this could lead to 
downstream synapsin I phosphorylation. If so, this could provide a basis for PKC 
modulation of glutamate release through increasing the availability of synaptic vesicles 
in cerebrocortical nerve terminals. This would not only suggest an alternative 
mechanism for PKC modulation of glutamate release downstream of Ca2+ entry, but 
would also imply that distinct receptor-mediated signalling pathways coupled to protein
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phosphorylation, could crosstalk with each other to produce a common mechanism for 
the modulation of glutamate release.
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5.2 Methods
Synaptosomes were prepared as described in section 2.1 (Sihra, 1997).
5.2.1. Glutamate Release
The standard release protocol was followed as described in section 2.2 (Nicholls and 
Sihra, 1986; Perkinton and Sihra, 1999). PDBu (lpM ) was added 1 minute prior to the 
addition of ionomycin 5pM.
5.2.2. Time Course of ERK 1,2 Phosphorylation/Activation
The synaptosomes were resuspended at 4°C to a final synaptosomal concentration of 
1 mg/ml using HBM containing BSA. CaCh was added, to give a final concentration of 
ImM, immediately prior to splitting the synaptosomes into two test tubes primed with 
solutions of either 0.1% DMSO or lpM  PDBu (final concentrations given). lOOpg 
samples of the synaptosomes were then simultaneously taken from each test tube and 
added to small Eppendorf tubes containing 25pi of 5X SDS-PAGE STOP buffer to 
terminate any reactions. These 4°C samples were taken to check for similar low levels 
of basal ERK 1,2 phosphorylation. The two test tubes were then immediately put to 
incubate at 37°C with stirring. Further lOOpg samples were simultaneously taken from 
each tube following 1, 3, 6,10, and 15 minutes of incubation. These were also added to 
small Eppendorf tubes containing 25 pi of 5X SDS-PAGE STOP buffer in order to 
terminate any reactions.
5.2.3. Preincubation
HBM containing BSA was used to resuspend synaptosomes to a final synaptosomal 
concentration of 1 mg/ml whilst being kept at 4°C. CaClj (ImM final concentration) 
was added before immediately splitting the synaptosomes into two tubes and putting 
them to incubate at 37°C with stirring. Following 10 minutes of incubation, 500nM 
calphostin C was added to one tube, with 0.05% DMSO being added to a control tube. 
These additions were carried out in the dark to reduce degradation of calphostin C 
before it could enter the nerve terminals. The light was reinstated after a further 5 
minutes of incubation to allow activation of the calphostin C that had entered the 
synaptosomes (Bruns et al., 1991). The incubations were continued for a further 20
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minutes before the contents of the two tubes were pelleted using a 30 second pulse at 
10,000 x g using a microcentrifuge. The supernatants were removed from the pellets, to 
aid with cooling, and transferred to separate tubes. Both the pellets and the supernatants 
were cooled for 10 minutes at 4°C to return ERK 1,2 phosphorylation back to basal 
levels. Once cooled the pellets were carefully resuspended with the kept supernatants 
before being split into three tubes per pellet, which had also been cooled to 4°C. Two 
tubes from each condition, control and + calphostin C, were then incubated at 37°C for a 
further 10 minutes. PDBu (lpM ) was added to one of these tubes from each condition,
1 minute prior to the termination of the incubation, with a final concentration of 0.1% 
DMSO being added to the other tube as the vehicle control. The remaining tubes were 
kept at 4°C until the end of the experiment (see Scheme 5.2). Reactions were 
terminated through addition of 5X SDS-PAGE STOP buffer.
Scheme 5.2: Sample division, preincubation and incubation protocol. 
1st Resuspension Preincubation Final Incubation
HBM 
+ ImM 
CaCl2
4°C Control
+ 0.05% 
DMSO 37°C Control
lpM  PDBu
4°C Control
+ 500nM 
Calphostin 37°C Control
lpM  PDBu
5.2.4. Standard Incubation
Synaptosomes were resuspended at 4°C using HBM with BSA to a final synaptosomal 
concentration of 1 mg/ml. A final concentration of ImM CaCl2 was added immediately
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prior to splitting the resuspension into individual sample tubes. The sample tubes 
contained solutions which would give final concentrations of either 500nM calphostin 
C, lpM  Ro-32-0432, 0.1% DMSO, or 0.05% DMSO upon addition of the 
synaptosomes. The sample tubes were then incubated at 37°C for 10 minutes with 
either 0.1% DMSO or 1 pM PDBu being added 1 minute prior to the termination of the 
incubation. One sample tube was always kept at 4°C for the duration of the experiment 
to act as a 4°C control. Reactions were terminated by addition of 5X SDS-PAGE STOP 
buffer to each of the sample tubes. This incubation protocol for measuring ERK 1,2 
phosphorylation has previously been described by Jovanovic et al., 2000 (Jovanovic et 
al., 2000).
Samples were processed for MAPK and synapsin phosphorylation levels as described in 
the main methods in chapter 2.4 (Dai et al., 2001; Jovanovic et al., 1996).
5.2.5. Reagents
PDBu: Analogue of diacylglycerol that is a potent stimulator of conventional and novel 
forms of PKC (phorbol 12,13-dibutyrate) (Arcoleo and Weinstein, 1985; Majewski and 
Iannazzo, 1998).
Dissolved in DMSO to give a stock concentration of lOmM. The stock solutions were 
diluted to ImM with DMSO and then on to 100pM with water just before use. This 
ensured the DMSO concentration in the presence of synaptosomes was not more than 
0.1%.
Calphostin C: PKC inhibitor acting at the regulatory site, from Cladosporium 
cladosporioides (UCN-1028c) (Kobayashi et al., 1989).
Maintained in a ImM 100% DMSO stock solution in the dark. It was diluted, with 
water, to a concentration of 50pM immediately before use.
Ro-32-0432 hydrochloride: PKC inhibitor which binds to the catalytic site in the C3 
domain (Bisindoylmaleimide XI; 2-(8-[(Dimethylamino)methyl]-6,7,8,9- 
tetrehydropyrido[l,2-a]indol-3-yl)-3-(l-methylindol-3-yl)maleimide) (Wilkinson et al., 
1993).
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Dissolved to a stock solution of ImM in 100% DMSO. Immediately prior to use, the 
stock concentration was diluted to lOOpM using water.
All the above reagents were purchased from the Sigma-Aldrich Company, Gillingham, 
Dorset.
Unless stated, all drugs were added using lOOx stock solutions to minimise volume 
changes and only final concentrations are listed.
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5.3 Results
The first experiment described in this chapter investigated the ability of the phorbol 
ester, PDBu, to enhance ionomycin-elicited glutamate release from cerebrocortical 
nerve terminals. PDBu was used as it is a potent stimulator of all the currently 
identified nerve terminal PKC isoforms. It also has a more rapid rate of activation than 
other phorbol esters, which should limit the problems encountered with 
dephosphorylation when using the slower forms of phorbol ester (Majewski and 
Iannazzo, 1998). As can be seen from Figure 5.1, PDBu significantly increased 
glutamate release from nerve terminals when ionomycin is used as the secretogogue 
(mean ± s.e.m. accumulated release in nmol/mg: control =7.21 ± 0.6, PDBu = 14.48 ±
1.8). This suggests that, as well as regulating Ca channels to increase glutamate 
release; PKC can act via an alternative pathway, which is downstream of Ca entry.
The next step in this chapter was to investigate whether ERK 1,2 may be involved in 
this pathway. One way of addressing this would be to see if MEK inhibitors could 
attenuate the PDBu-enhancement of glutamate release. However, as discussed 
previously in Chapter 3, it was not possible to use MEK inhibitors with release 
protocols based on fluorescent readouts. Instead, I looked at ERK 1,2 phosphorylation 
levels following the activation of PKC with phorbol ester treatment. To do this I used 
an antibody which detects only the dually phosphorylated, activated, forms of ERK 1 
and ERK 2, obtained from New England Biolabs (as described in Section 2.4.4).
Synaptosomes were incubated in the presence and absence of PDBu and immunoblotted 
for phosphorylated ERK 1,2. Figure 5.2 suggests that PDBu can enhance ERK 1,2 
phosphorylation levels and that this possibly occurs in a time-dependent manner.
Figure 5.3 confirms that PDBu can significantly enhance ERK 1,2 phosphorylation 
levels in cerebrocortical nerve terminals (mean ± s.e.m. %: 1 min = 117 ±6, 10 min = 
126 ± 8 compared to 100% control levels). The total incubation time for the 
experiments in Figure 5.3 was 10 minutes, with the times stated on the graph being the 
length of incubation in the presence of PDBu.
I have shown that treatment of nerve terminals with PDBu can increase ERK 1,2 
phosphorylation levels, which is indicative of ERK 1,2 activation. Phorbol esters can
152
PDBu (lpM )
oo
Control
Time
(60 seconds per division)
Figure 5.1 Effect of Phorbol Ester on Ionomycin-Elicited Glutamate Release.
Synaptosomes were incubated in the presence o f  1 mM CaCb as indicated in section
5.2.1. Glutamate release was elicited with the addition o f  ionomycin (5pM, arrow) in 
the absence (control), or presence (+PDBu) o f  1 pM PDBu, added 1 min prior to the 
secretogogue. The mean traces from four independent experiments, measuring 
accumulative release at 2 sec intervals, are shown. Mean ± s.e.m. release was 
calculated at each time point, but the cumulative glutamate release values following 4 
mins o f  incubation with the secretogogue were used for statistical analysis *P<0.05; 
different from control (Student’s paired t-test; n=4).
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Figure 5.2 PDBu Stimulation of ERK 1 and ERK 2 Phosphorylation/Activation.
Synaptosomes were incubated in the presence o f  1 mM CaCl2 as indicated in section
5.2.2. Immunoblot analysis o f synaptosomes incubated in the absence (control) or 
presence (+PDBu) o f  lpM  PDBu for 1, 3, 6, 10, or 12 mins. 7.5% polyacrylamide gels 
were used. Immunoblots were probed with a 1:1000 dilution o f  primary antibody
195 • 195(NEB) and ' I-Protein A used as the reporter. I-labelling was assessed by 
Phosphorimager spectroscopy (Molecular Dynamics). A. Representative 
phosphorimage o f time-course. B. Representative quantification o f  ERK 1,2 
phosphorylation (n=l).
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Figure 5.3 Significant Enhancement of ERK 1,2 Phosphorylation by PDBu.
Synaptosomes were incubated with 1 mM CaCE for 10 mins, either in the absence 
(control) or presence (+PDBu) o f  1 pM PDBu. 1 min and 1 Omin denote the time in the 
presence o f PDBu, as described in section 5.2.4. Gels containing 7.5% polyacrylamide 
were used. Immunoblots probed with phospho-MAPK antibody (1:1000, NEB) and 
l25I-Protein A and analysed using phosphorimager spectroscopy (Molecular Dynamics) 
to assess the 125I-labelling. Mean ± s.e.m. ERK 1,2 phosphorylation levels obtained 
from separate experiments individually normalised to 100% 37°C control levels. 
*P<0.05, **P<0.01 (Student’s paired t-test, lmin n=4; 10 min n=l 1). A. 
Phosphorimage o f PDBu effect. B. Quantification o f  ERK 1,2 phosphorylation levels. 
C. Proposed pathways leading to ERK 1,2 phosphorylation.
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strongly activate PKC but may not necessarily function exclusively to enhance the 
activity of only this kinase (Lorenzo et al., 2000). In order to confirm whether PDBu 
could enhance ERK 1,2 phosphorylation in a PKC-dependent manner, the following 
experiments investigated whether a PKC inhibitor could attenuate PDBu-enhanced ERK
1,2 phosphorylation. Calphostin C, like phorbol esters, binds to the DAG binding site 
on novel and conventional PKC isoforms (Kobayashi et al., 1989). As nerve terminals 
are currently believed to only contain novel and conventional forms of PKC, calphostin 
C should inhibit all of them. The synaptosomes were preincubated at 37°C for 20 
minutes with calphostin C before being pelleted, cooled back to 4°C, and resuspended 
ready for a standard 10 minute incubation. This protocol was used as it has been 
suggested that longer incubation times with calphostin C would be required in order to 
obtain complete inhibition of PKC. Figure 5.4 shows the effects of this “long” 
incubation with calphostin C on basal ERK 1,2 phosphorylation levels in 
cerebrocortical nerve terminals. The graph shows a significant increase in 4°C ERK 1,2 
phosphorylation levels in the presence of the inhibitor when compared to control (mean 
± s.e.m. compared to 100% 37°C control: 4°C control = 33 ± 4%, 4°C calphostin C = 77 
±13%). Given that the protocol involves a preincubation step in the presence of the 
inhibitor followed by a cooling step, these data suggest that calphostin C is causing 
either a stimulation of a phosphorylating component of the ERK 1,2 cascade or an 
inhibition of a dephosphorylating component.
Figure 5.5 examines the effect of calphostin C on PDBu-enhanced ERK 1,2 
phosphorylation levels. Data was analysed by comparing the sample containing PDBu 
to the DMSO control (100%), and the sample containing PDBu and calphostin C to the 
calphostin C control (100%). Given the effects of calphostin C on its own, this 
normalization was done to identify any effects of PDBu in isolation from the effect of 
calphostin C. While calphostin C appeared to suppress the effects of PDBu in some 
experiments, overall analysis found no significant differences between the control 
samples and those containing PDBu using an ANOVA (mean ± s.e.m. in %: PDBu =
139 ± 12, PDBu with calphostin C = 115 ± 30). The evident variability could, in part, 
be introduced by calphostin C altering the basal levels of ERK 1,2 phosphorylation, by 
either upregulating an activity stimulating the ERK 1,2 cascade, or by down-regulating 
the dephosphorylation of ERK 1,2 itself under these conditions. Notably, PDBu is able
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Figure 5.4 Stimulation of Basal ERK 1,2 Phosphorylation with Prolonged 
Exposure to Calphostin C. Synaptosomes were preincubated with ImM CaCl? for 30 
mins, with 20 mins in the absence (control) or presence (+Calphostin) o f  calphostin C, 
as described in section 5.2.3. 7.5% polyacrylamide gels were run. Immunoblots
•  125labelled with 1:1000 phospho-MAPK primary antibody (NEB) were reported using I- 
Protein A and quantified with phosphorimager spectroscopy (Molecular Dynamics). 
Mean ± s.e.m is from 10 independent experiments, each o f which had previously been 
normalised to its own 100% 37°C control. **P<0.01 different from 4°C control 
(Student’s paired t-test, n=10). A. Phosphorimage o f  calphostin C effect. B. 
Quantification o f ERK 1,2 phosphorylation levels. C. Proposed pathways leading to 
ERK 1,2 phosphorylation.
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Figure 5.5 Effect of Prolonged Calphostin C Exposure on PDBu-Stimulated ERK
1,2 Phosphorylation. Synaptosomes were preincubated as described in section 5.2.3 
followed by a 10 min incubation with 1 min in the presence (+PDBu) or absence 
(control) o f  PDBu. ERK 1,2 phosphorylation levels were detected using phospho-
•  •  •  195 •MAPK primary antibody (1:1000, NEB), reported with I-Protein A, and measured 
using phosphorimager spectroscopy (Molecular Dynamics). Mean ± s.e.m. from 6 
independent experiments, individually normalised to their own relevant 37°C control. 
A. Phosphorimage o f  combined effects o f calphostin C and PDBu. B. Quantification o f  
combined effects (no significant differences, ANOVA). C. Quantification o f PDBu 
effect following long preincubation protocol, **P<0.01 (Student’s paired t-test, n=9).
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to significantly increase ERK 1,2 phosphorylation levels on its own under these 
conditions (mean ± s.e.m. in % compared to 100% 37°C control: PDBu = 126 ± 4). The 
increase in ERK 1,2 phosphorylation levels with calphostin C alone may be as a result 
of effects introduced or enhanced by the long incubation protocol. The next 
experiments conducted in this chapter used the inhibitor with the shorter, standard 10 
minute protocol, in order to try and minimise the potentially non-specific effects of the 
drug produced by the long incubation.
Calphostin C (500nM) was added to the synaptosomes at 4°C and then incubated for 10 
minutes at 37°C. As can be seen from Figure 5.6, the inhibitor significantly reduces 
ERK 1,2 phosphorylation levels (mean ± s.e.m. compared to 100% 37°C control = 73 ± 
7%). Figure 5.7 shows the effect of calphostin C on PDBu-enhanced ERK 1,2 
phosphorylation. The effect of PDBu on its own was found to be significantly reduced 
compared to the effect of PDBu with calphostin C (mean ± s.e.m. compared to 37°C 
control: PDBu = 117 ± 6%, PDBu with calphostin C = 85 ± 6%, calphostin C = 81 ± 
9%). This suggests that calphostin C is inhibiting PDBu-stimulated ERK 1,2 
phosphorylation, which also suggests PDBu is acting through PKC to mediate the 
observed increases in ERK 1,2 phosphorylation levels. However, phorbol esters 
activate novel and conventional forms of PKCs by interacting with the Cl domain at the 
site of DAG binding (Hurley et al., 1997). This means their actions may not simply be 
limited to PKC isoforms as they are able to bind other, unrelated proteins with a typical 
Cl domain (Hurley et al., 1997). These include proteins such as Ras-GRP, a guanine 
nucleotide exchange factor, which is able to activate the ERK signalling cascade 
(Lorenzo et al., 2001). As calphostin C works through the same binding site to inhibit 
PKC, it could be possible it is inhibiting “non-specific” binding to Cl domains in these 
other proteins, rather than just inhibiting PKC isoforms. This could also mean that 
effects of calphostin C on ERK 1,2 phosphorylation are mediated through such effects. 
In order to try and address this possibility, a second PKC inhibitor was used, which 
utilises an alternative binding site.
Ro-32-0432 was chosen as the alternative PKC inhibitor as it is known to block all the 
isoforms found in nerve terminals and does not bind to the C l domain. Ro-32-0432 
acts through binding to the ATP site in the C3 catalytic domain, thus preventing
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Figure 5.6 Short Incubation with Calphostin C Decreases ERK 1,2 
Phosphorylation. Synaptosomes were incubated for 10 min with ImM CaCC either in 
the absence (control) or presence (+Calphostin) o f  calphostin C. 7.5% polyacrylamide 
gels were used. Immunoblots were probed with 1:1000 dilution o f  the phospho-MAPK
12^  • 125 •primary antibody (NEB) and I-Protein A used as a reporter. I-labelling was 
assessed by phosphorimager spectroscopy (Molecular Dynamics). Mean ± s.e.m. was 
obtained from 8 independent experiments with each experiment being normalised to its 
own 100% 37°C value, **P<0.01 (Student’s paired t-test, n=8). A. Phosphorimage o f  
calphostin C effect. B. Quantification o f calphostin C effect. C. Proposed pathways 
involved.
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Figure 5.7 Calphostin C Attenuates PDBu-Enhanced ERK 1,2 Phosphorylation.
Synaptosomes were incubated for 10 min with 1 mM CaCh in the presence 
(+calphostin) or absence (Control) o f  calphostin C. PDBu was added 1 min prior to the 
termination o f  the experiment, as described in section 5.2.4. Gels containing 7.5% 
polyacrylamide were used. Immunoblots were labelled with phospho-MAPK primary
195 195antibody (1:1000, NEB) and reported using I-Protein A. I-levels were detected 
using phosphorimager spectroscopy and normalised to 100% individual 37°C controls, 
*P<0.05 (ANOVA with Duncan’s post hoc analysis, n=4). A. Phosphorimage o f  
calphostin C effect. B. Quantification o f calphostin C and PDBu effects. C. Proposed 
pathway mediating the calphostin C and PDBu effects.
161
ERK
B. C.
zo
p<>
pu<(N
140-
or. 120 -
coU
£  100- m
oxO
2  80-
o
~o<u
0 U
g 40-
§
Urn
iS1  20-
4°C 37°C I|iM
Ro-32-0432
ER K  1,2
Control Control Ro-32-0432
Figure 5.8 Ro-32-0432 Stimulates ERK 1 and 2 Phosphorylation/Activation.
Synaptosomes were incubated for 10 mins with ImM CaCE either in the absence 
(control) or presence (+Ro-32-0432) o f Ro32-0432. ERK 1,2 phosphorylation levels 
were detected through immunoblotting with phospho-M APK primary antibody and ~ I-
• 195Protein A as the reporter. I-signal levels were ascertained using phosphorimager 
spectroscopy. Data was taken from 6 independent experiments and normalised to 
individual 100% 37°C control levels, *P<0.05 (Student’s paired t-test, n=6). A. 
Phosphorimage o f  Ro-32-0432 effect. B. Quantification o f  Ro-32-0432 effect. C. 
Possible pathways involved in mediating Ro-32-0432 effect.
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Figure 5.9 ERK 1,2 Phosphorylation Levels with Ro-32-0432 and PDBu.
Synaptosomes were incubated for 10 mins with ImM CaCh either in the presence 
(+R.O-32-0432) or absence (control) o f  Ro-32-0432. PDBu was added to those samples 
labelled +PDBu, 1 min prior to the termination o f  the experiment. 7.5% polyacrylamide 
gels were used. Immunoblots were labelled with phospho-MAPK primary antibody
1 *75 17S(1:1000, NEB) and reported using I-Protein A. I-labelling was quantified using 
phosphorimager spectroscopy (Molecular Dynamics) with individual values normalised 
to 100% 37°C control samples. No significance was found between conditions 
(ANOVA, n=4). A. Phosphorimage o f  PDBu and Ro-32-0432 effects. B. Quantification 
o f PDBu and Ro-32-0432 effects.
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activation of PKC (Birchall et al., 1994). Figure 5.8 shows the results obtained from 
incubating synaptosomes in the presence of 1 jjM  Ro-32-0432 for 10 minutes. As can 
be seen from the graph, Ro-32-0432 was found to significantly increase basal ERK 1,2 
phosphorylation levels on its own (mean ± s.e.m. in % compared to 100% control: 129 
± 13). It is not known whether this is a PKC-dependent or non-specific effect. Figure 
5.9 shows the combined effects of 1 pM PDBu and 1 pM Ro-32-0432 on ERK 1,2 
phosphorylation in cerebrocortical nerve terminals. No significant differences were 
found between the samples, although there is a suggestion that Ro-32-0432 may be 
inhibiting PDBu increases in ERK 1,2 phosphorylation levels (mean ± s.e.m. in % 
compared to 100% control: PDBu = 108 ± 1, Ro-32-0432 = 113 ± 10, PDBu/Ro-32- 
0432 = 100 ± 5). Looking for Ro-32-0432-mediated attenuation of the stimulatory 
effect of PDBu on ERK 1,2 phosphorylation is complicated by the comparable effects 
of PDBu and Ro-32-0432 when presented alone. However, the intrinsic stimulatory 
effect of Ro-32-0432 is peculiar to the ERK 1,2 pathway, because direct assay of PKC 
activity using an intrasynaptosomal PKC substrate has demonstrated a clear inhibitory 
effect o f the compound on PKC-dependent phosphorylation (Coffey et al., 1993).
The final experiments in this chapter examined the effects of PDBu on synapsin site 4/5 
phosphorylation. Synapsin is a presynaptic nerve terminal protein which is regulated by 
phosphorylation and is involved in tethering synaptic vesicles to the presynaptic actin 
cytoskeleton. ERK 1,2 is known to be able to phosphorylate synapsin on site 4 and 5, 
representing a possible mechanism for the regulation of glutamate release through 
greater availability of glutamate containing vesicles. Synapsin site 4/5 phosphorylation 
was examined to see if this could be a possible alternative mechanism for PDBu- 
enhanced release at cerebrocortical nerve terminals. The experiment in Figure 5.10 
shows that PDBu significantly enhanced synapsin site 4/5 phosphorylation levels (mean 
± s.e.m. compared to 100% 37°C control values: 161 ± 6%), supporting the possibility 
that synapsin phosphorylation may, in part, contribute to the PDBu-mediated 
enhancement of glutamate release.
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Figure 5.10 PDBu Stimulates Synapsin Site 4/5 Phosphorylation.
Synaptosomes were incubated for 10 mins with 1 mM CaCE with the final minute being 
either in the presence (+PDBu) or absence (control) o f  PDBu. 7.5% polyacrylamide 
gels were used. Immunoblots were labelled with site 4/5 phospho-synapsin primary
• 1 2 5  • 125antibody (1:500, J.J.), with I-Protein A used as the reporter. I-levels were detected 
with phosphorimager spectroscopy. Data was obtained from 5 independent experiments 
and normalised to their individual 100% 37°C control values, **P<0.05 (Student’s 
paired t-test, n=5). A. Phosphorimage o f  PDBu effect. B. Quantification o f PDBu 
effect. C. Proposed pathway for PDBu effect.
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5.4. Summary o f  Results
• 1 jiM PDBu can significantly enhance glutamate release from cerebrocortical 
nerve terminals independently of calcium channel regulation.
• A 30 minute total incubation with 20 minutes of calphostin C results in a 
paradoxical increase in levels of ERK 1,2 phosphorylation in cerebrocortical 
nerve terminals.
• A 10 minute incubation with the PKC inhibitor, calphostin C, significantly 
reduces basal ERK 1,2 phosphorylation and prevents PDBu-induced increases in 
ERK 1,2 phosphorylation.
• A 10 minute incubation with the PKC inhibitor, Ro-32-0432, significantly 
increases basal levels of ERK 1,2 phosphorylation but the effects on PDBu 
enhanced ERK 1,2 phosphorylation levels remain unclear.
• Different PKC inhibitors, Ro-32-0432 and calphostin C, have opposing effects 
on ERK 1,2 phosphorylation levels following 10 minutes of incubation.
• A 10 minute total incubation time with 1 minute of PDBu produces an 
enhancement of ERK 1,2 phosphorylation, as well as increased site 4/5 synapsin 
phosphorylation; this representing a mechanism for a PDBu-mediated increase 
in glutamate release which is independent of calcium channel regulation. This 
mechanism seems likely to be PKC-dependent, but remains to be conclusively 
established through the further use of PKC inhibitors which lack the 
complicating features of calphostin C and Ro-32-0432, possibly contingent to 
their targeting of conserved Cl and ATP binding domains.
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5.5 Discussion
The results have clearly shown that the phorbol ester, PDBu, is able to increase ERK
1,2 and synapsin site 4/5 phosphorylation levels in cerebrocortical nerve terminals. 
Confirmation that the increase in ERK 1,2 and synapsin I phosphorylation is mediating 
the increase in glutamate release has not been obtained on this occasion due to 
difficulties with MEK inhibitors. A precedence for this kind of regulation, however, 
has been observed in cerebrocortical synaptosomes following exposure to BDNF 
(Jovanovic et al., 2000). This makes it a likely candidate for involvement on this
vesicle fusion are unlikely to prove a major mechanism under these conditions (Cousin 
and Robinson, 2000; Coffey et al., 1993). Final confirmation that PDBu is utilising the 
ERK/synapsin I pathway to modulate glutamate release could be obtained by using an 
HPLC instrument. This would allow measurements of the PDBu-enhanced glutamate 
release in the presence and absence of the MEK inhibitor, PD098059, to be made.
This chapter has, unfortunately, not been able to prove conclusively whether the PDBu 
enhancement of ERK 1,2 phosphorylation is PKC dependent or not. This is mainly due 
to the PKC inhibitors being able to regulate basal levels of ERK 1,2 phosphorylation on 
their own. The longer, 20 minute, incubation with calphostin C resulted in a decrease in 
ERK 1,2 dephosphorylation. Previous studies have shown that this particular inhibitor 
can also modulate certain protein phosphatases in other systems. Calphostin C has been 
shown to inhibit the induction of MAPK phosphatase 1 (MKP1) in a ERK 1,2- 
independent manner (Stawowy et al., 2003), but this particular phosphatase has only 
been located in the nucleus of cells. The prominent cytosolic dual specificity 
phosphatase is believed to be MKP3 but this is only thought to be transcribed upon 
ERK 1,2 activation (Camps et al., 2000), and no link with calphostin C has yet been 
identified. The more likely explanation for calphostin C mediated decreases in ERK 1,2 
dephosphorylation is through inhibition of a PKC-dependent pathway. Protein 
phosphatase 2A (PP2A) is a family of protein phosphatases, some of which can undergo 
rapid activation and dephosphorylate ERK 1,2 without the need for transcription (Alessi 
et al., 1995). PP2A has also been found in nerve cytosol (Sontag, 2001) and has been 
implicated in regulating neurotransmitter release (Sistiaga and Sanchez-Prieto, 2000b).
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However, further experiments using phosphatase inhibitors, such as okadaic acid, would 
be needed to confirm any involvement of PP2A in the dephosphorylation of MAPK 
under these conditions.
The short, 10 minute incubation, with calphostin C elicited a decrease in basal ERK 1,2 
phosphorylation levels. Calphostin C has been found to block PDBu binding of a 
RasGEF known as RasGRP through its Cl binding domain (Lorenzo et al., 2000). It is 
possible that the observed inhibition of MAPK phosphorylation levels is due to a non­
specific binding of Cl domains. However, immunostaining for RasGRP in the striatum 
and hippocampus has found it solely localised to the soma and dendritic tree (Pierret et 
al., 2001; Pierret et al., 2002). There has not yet been a study conducted looking at 
distribution in the cortex but it seems likely that RasGRP is not a synaptosomal protein. 
This does not rule out the possibility that calphostin C could be acting through this 
pathway, but it does make it more unlikely.
Previous studies have shown that inhibition of PKC by Ro-32-0432 can be overcome by 
strong activation, such as with PDBu, which could explain why variable levels of ERK
1,2 phosphorylation are obtained when using this inhibitor. Also of note, is that recent 
studies have been using this compound as an inhibitor of GRK5 (G-protein receptor 
kinase), rather than of PKC (Aiyar et al., 2000). This raises the possibility that the 
observed basal effects of Ro-32-0432 on ERK 1,2 phosphorylation levels could be 
mediated through the inhibition of GRK5. Further experiments would be needed to 
elucidate on any role of GRK5 in the regulation of ERK 1,2 signalling, but this 
nevertheless highlights the lack of PKC specificity encountered with this particular 
inhibitor.
One way of trying to confirm the role of PKC in the PDBu-enhancement of ERK 1,2 
phosphorylation would be to use other inhibitors of PKC. This is not without its own 
complications as specific inhibitors of PKC that can easily transverse plasma 
membranes are not readily available. For example, chelerythrine is known to inhibit 
some PKC isoforms found in nerve terminals but it has also been to shown stimulate 
some PKC isoforms and to have non-specific effects on the MAPK family of proteins 
(Lee et al., 1998; Yu et al., 2000). The PKC inhibitor peptide is a very specific inhibitor 
of PKC but it does not readily transverse plasma membranes and so even in the
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myristolated form would require long preincubation times (Eichholtz et al., 1993). This 
can be effective in cell cultures but, as can be seen ffom the previous chapters in this 
thesis, long incubation times with synaptosomes can result in added complications and 
the running down o f signalling pathways.
In conclusion, stimulation o f cerebrocortical synaptosomes with PDBu results in 
increased ionomycin-elicited glutamate release, increased ERK 1,2 phosphorylation, 
and increased synapsin I phosphorylation at the ERK 1,2 sites. The data suggests that 
this could be occurring through a PKC-dependent mechanism but further experiments 
need to be conducted in order to prove this. The diagram below shows a schematic o f  
the possible mechanisms involved if  PKC mediates regulation o f  ERK 1,2 
phosphorylation in cerebrocortical nerve terminals.
PKC
m i k
PP2A
ERK 1,2
Synapsin
Increase in availability 
of synaptic vesicles for 
release
Figure 5.11 A schematic diagram illustrating a possible mechanism for PKC-mediated 
ERK 1,2 phosphorylation in cerebrocortical nerve terminals.
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The non-specific effects of PDBu combined with the non-specific effects of the PKC 
inhibitors have made it very difficult to prove PKC-dependency of increased ERK 1,2 
phosphorylation levels. Another way to address this issue would be to use activators of 
cell surface receptors that are known to link to PKC-dependent signalling cascades. Not 
only would these be more specific activators of downstream PKC pathways, but they 
would also be more likely to highlight endogenous cross-talking between signalling 
pathways. The following chapter investigates whether stimulation of cell surface 
receptors can lead to PKC-dependent increases in ERK 1,2 phosphorylation levels in 
cerebrocortical nerve terminals.
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Chapter 6
Signalling Downstream of Group I Metabotropic Glutamate 
Receptors: Cross-Talk with ERK 1,2.
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6.1 Introduction
Group I metabotropic glutamate receptors (mGluRs) have long been established as 
regulators of neurotransmission at post-synaptic terminals (Review, Alagarsamy et al., 
2001). The presence of these receptors at presynaptic terminals, however, has been 
more controversial. Most localisation studies using antibodies raised against the C- 
terminal region of mGluRl and 5 have only found these receptors in post-synaptic 
locations (Baude et al., 1993; Shigemoto et al., 1993; Petralia et al., 1997; Shigemoto et 
al., 1997), with a particular emphasis on perisynaptic and extrasynaptic areas. There are 
only a limited number of studies that have found these receptors in a presynaptic 
location. For example, Hubert et al., (Hubert et al., 2001) have seen light labelling of 
striatal axons terminals with an antibody to mGluRla in the substantia nigra pars 
reticulata. Despite the limited immunohistochemical evidence for presynaptic Group I 
mGluRs, there is growing pharmacological evidence suggesting a role for these 
receptors in regulating neurotransmitter release from nerve terminals.
The first evidence suggesting that mGluRs may play a role in facilitating 
neurotransmitter release came from a study by Herrero et al in 1992. They used 
(1S,3R)-ACPD, a non-specific mGluR agonist, to enhance 4-AP elicited glutamate 
release from rat cerebrocortical synaptosomes. Arachidonic acid (AA) was required for 
the enhancement of release by (1S,3R)-ACPD, suggesting the presence of more than 
one pathway acting in concert to facilitate release (Herrero et al., 1992). A number of 
other groups have also found a requirement for polyunsaturated fatty acids (PUFAs) in 
the enhancement of release by (1S,3R)-ACPD from rat hippocampal synaptosomes and 
cortical slices (McGahon and Lynch, 1994; Lombardi et al., 1996). Upon subsequent 
investigation of the mGluR pathway involved in enhancing release from cerebrocortical
94-nerve terminals, it was found that the regulation of release occurred upstream of Ca 
channels or Ca -secretion coupling. (1 S,3R)-ACPD stimulated increases in DAG 
production were observed and the AA pathway was found to act downstream of DAG 
production in the synergistic activation of PKC (Coffey et al., 1994a: Herrero et al., 
1994; Vazquez et al., 1994). This data in itself suggests the activation of PLC-coupled 
Group I mGluRs but the subsequent availability of more specific Group I mGluR
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agonists, such as (3,5)-dihydroxyphenylglycine (DHPG), allowed confirmation of this 
(Herrero et al., 1998).
More recent studies have also found a role for Group I mGluRs in the regulation of 
neurotransmitter release that has not been limited to the cerebrocortex, nor to 
glutamatergic neurones. mGluRl and 5 have been found to work in conjunction with 
each other to enhance KCl-elicited acetylcholine release from striatal synaptosomes 
(Marti et al., 2001). In the periaqueductal grey stimulation of mGluR5 is believed to be 
responsible for the increase in glutamate and GABA in the dialysates of freely moving 
rats (de Novellis et al., 2003). Electrically stimulated efflux of [3H]-D-aspartate from 
rat forebrain slices was also found to be enhanced by stimulation of mGluR5 (Thomas 
et al., 2000). Regulatory Group I mGluRs have subsequently been found in the rat 
spinal cord where DHPG increased glutamate release and spontaneous nociceptive 
behaviour, both of which were blocked by MPEP, a mGluR5 antagonist (Lorrain et al., 
2002).
Most of the work looking at pathways downstream of receptor activation have linked 
Group I mGluRs to PLC via Gq or Gi/o proteins. This leads to PIP2 hydrolysis and 
production of IP3 and DAG. DAG, in concert with an increase in intracellular calcium 
concentration, following voltage-dependent Ca2+ influx or IP3-stimulated release from 
intracellular stores, activates conventional isoforms of PKC (Kishimoto et al., 
1980;Sugiyama et al., 1987;Murphy and Miller, 1988; Manzoni et al., 1990; Pin et al.,
1992). PKC can in turn phosphorylate mGluRl and 5 in a negative feedback loop 
(Gereau and Heinemann, 1998; Francesconi and Duvoisin, 2000). Studies on 
nociception have also linked Group I mGluRs to ERK 1,2 signalling pathways (Karim 
etal., 2001).
Recent research into nociception in mice has identified an ERK 1,2-dependent pathway 
in dorsal horn neurones that can lead to enhanced pain sensitivity. Stimulation of 
mGluRl and 5 by DHPG resulted in an increased phosphorylation of ERK 1,2, which 
could be partially inhibited by the application of CPCCOEt or MPEP. Notably, 
application of both antagonists together failed to have an additive effect on the 
reduction of ERK 1,2 phosphorylation, suggesting an overlap of roles for these two 
receptors when functioning postsynaptically (Karim et al., 2001). More postsynaptic
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effects of DHPG-regulated ERK 1,2 phosphorylation have been found in the striatum.
Acute administration of amphetamine is known to lead to increases in glutamate release 
in the striatum (McGinty, 1999). The glutamate goes on to activate Group I mGluRs 
which, in turn, lead to stimulation of ERK 1,2 phosphorylation and activation of the 
transcription factors Elk-1 and CREB (Choe and Wang, 2001a; Choe et al., 2002).
Signalling downstream of Group I mGluR activation and upstream of ERK 1,2 
phosphorylation was later found to be dependent on PKC stimulation. Interestingly, the 
pathway between PKC and increased ERK 1,2 phosphorylation was also shown to be 
sensitive to NMD A receptor inhibition and CaMKII phosphorylation (Choe and Wang,
2001b, Choe and Wang, 2002). This evidence suggests a role for group I mGluR
signalling through ERK 1,2 in neuronal plasticity. A recent study examining-long-term----------
potentiation in the dentate gyrus of adult rats has linked the requirement of AA in the 
(1S,3R)-ACPD enhancement of glutamate release to the ERK 1,2 pathway. It was 
found that AA and (1S,3R)-ACPD stimulated ERK 1,2 phosphorylation and that the 
MEK inhibitor, PD98059, inhibited the interaction between AA and (1S,3R)-ACPD on 
glutamate release (McGahon et al., 1999). Cultured rat cortical glia have also been 
found to possess a pathway whereby activation of mGluR5 by DHPG leads to the 
phosphorylation of ERK 1,2 through a PKC-independent mechanism (Peavy and Conn,
1998).
In the last chapter it was demonstrated that PDBu could act via PKC to stimulate ERK
1,2 and synapsin phosphorylation and increase glutamate release from cerebrocortical 
nerve terminals. Given the recent evidence suggesting that Group I mGluRs can 
regulate ERK 1,2 signalling cascades, this chapter investigates whether Group I 
mGluRs are the start of a receptor-linked signalling cascade which can utilise PKC to 
regulate downstream ERK 1,2 and synapsin phosphorylation. It also examines the 
relevance of this pathway as a possible common mechanism for regulation of glutamate 
release from cerebrocortical nerve terminals, linking neurotrophin and GPCR-mediated 
signalling pathways.
174
6.2 Methods
Synaptosomes were prepared as stated in section 2.1 (Sihra, 1997).
6.2.1 Standard Incubation for ERK 1,2 Phosphorylation/Activation
Synaptosomes were kept at 4°C and resuspended using HBM with BSA, to a final 
synaptosomal concentration of 1 mg/ml. A final concentration of ImM CaCh was 
added immediately prior to splitting the resuspension into individual sample tubes. All 
incubations were at 37°C for 10 minutes, with drugs requiring 10 minute time points 
being added at 4°C, immediately before transferring the sample to the 37°C water bath. 
All other time points refer to the length of time, prior to the termination of the reaction, 
for which the drug was added to the sample. For the concentration-response 
experiments final concentrations of lOOnM, lpM, lOpM, IOOjliM and ImM DHPG 
were used, added either 1 minute, 10 minutes, or 5 minutes 30 seconds prior to the 
termination of the reactions. The Ro-32-0432, MPEP and synergism experiments also 
used this protocol where lpM  Ro-32-0432 was added for 10 minutes, lOpM MPEP 
added for 2 minutes and 50, 100 or 200ng/ml BDNF added for 6 minutes. One sample 
tube was always kept at 4°C for the duration of the experiment to act as a 4°C control. 
Reactions were terminated using 5x SDS-PAGE STOP buffer. This incubation protocol 
for measuring ERK 1,2 phosphorylation has previously been described by Jovanovic et 
al., 2000 (Jovanovic et al., 2000).
6.2.2 Preincubation
The same preincubation protocol was used for calphostin C as described in section 
5.2.3, with DHPG (lOpM) being added 1 minute prior to the final termination of the 
reactions with 5x SDS-PAGE STOP buffer.
Experiments using BAPTA-AM utilised the same preincubation protocol as for 
calphostin C except that a final concentration of lOOpM BAPTA-AM was added instead 
of calphostin C. Following preincubation, the synaptosomes were spun using a 30 
second pulse of centrifugation at 5,000g and the supernatants removed and discarded. 
The pellets were then resuspended using ice-cold HBM/BSA and recentrifuged as 
before. This process was repeated once more to remove any remaining external
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BAPTA-AM from the medium. Following washing, the synaptosome pellets were left 
to cool at 4°C for a further 5 minutes before being resuspended in HBM/BSA to a 
concentration of 1 mg/ml for a final time. The synaptosomes were then divided up as 
shown in Scheme 6.2.
Scheme 6.2: Sample division, preincubation and incubation protocol.
1st Resuspension Preincubation Following Final Incubation
Resuspension
Synaptosomes 
at 1 mg/ml in 
HBM/BSA 
and ImM CaCl2
+ 1% 
DMSO
+ lOOpM 
BAPTA-AM
+ O.lmM 
EGTA
+ ImM 
CaCl2
+ O.lmM 
EGTA
+ ImM 
CaCl2
4°C Control 
37°C Control 
lOpMDHPG
4°C Control 
37°C Control 
lOpMDHPG
4°C Control 
37°C Control 
lOpMDHPG
4°C Control 
37°C Control 
lOpMDHPG
The concentrations listed are all final concentrations.
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Following addition of calcium or EGTA, the synaptosomes were split into their 
incubation tubes and the 37°C control and DHPG put to incubate at 37°C for 10 
minutes. DHPG was added 1 minute prior to the termination of the reaction by 5x SDS- 
PAGE STOP buffer. Control samples (4°C) were terminated without any incubation. 
Samples were processed for MAPK and synapsin phosphorylation levels as described in 
the main methods in Chapter 2.4.4 (Dai et al., 2001; Jovanovic et al., 1996).
6.2.3 Glutamate Release
The standard glutamate release protocol was followed, as described in section 2.2 
(Nicholls and Sihra, 1986); (Perkinton and Sihra, 1999). DHPG (lpM ) was added 1 
minute prior to the addition of the secretogogue, 4-AP (ImM), and PDBu (lpM ) was 
added 30 seconds prior to the secretogogue (Coffey et al., 1993; Herrero et al., 1998).
6.2.4 Reagents
DHPG: Group I metabotropic glutamate receptor agonist ((R,S)-3,5- 
Dihydroxyphenylglycine) (Ito et al., 1992)
Dissolved using water immediately prior to experimentation, to give lOOx solutions of 
lOmM, ImM, 100pM, lOpM, lpM, lOOnM or lOmM.
Calphostin C: PKC inhibitor acting at the regulatory site, from Cladosporium 
cladosporioides (UCN-1028c) (Kobayashi et al., 1989).
Maintained in a ImM 100% DMSO stock solution in the dark. It was diluted, with 
water, to a concentration of 50pM immediately before use.
Ro-32-0432 hydrochloride: PKC inhibitor which binds to the catalytic site in the C3 
domain (Bisindoylmaleimide XI; 2-(8-[(Dimethylamino)methyl]-6,7,8,9- 
tetrehydropyrido[l,2-a]indol-3-yl)-3-(l-methylindol-3-yl)maleimide) (Wilkinson et al.,
1993).
Dissolved to a stock solution of ImM in 100% DMSO. Immediately prior to use, the 
stock concentration was diluted to IOOjiM using water.
MPEP: mGluR5 non-competitive antagonist (6-Methyl-2-(phenylethynyl)pyridine) 
(Gasparini et al., 1999)
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Dissolved in water to a concentration of 5mM. When final concentrations of 10pM 
were used, the stock was further diluted with water to give a concentration of ImM 
MPEP.
 ^i
BAPTA-AM: Cell permeable rapid Ca chelator (l,2-Bis(2-aminophenoxy)ethane- 
N,N,N’ ,N’-tetraacetic acid tetrakis(acetoxymethyl ester)) (Tsien, 1980; Lew et al., 
1982))
Maintained in a 32.69mM 100% DMSO stock solution and was diluted to lOmM with 
DMSO, immediately prior to use.
All the above reagents were purchased from the Sigma-Aldrich Company, Gillingham, 
Dorset, with the exception of BAPTA-AM, which was obtained from Calbiochem, 
Beeston, Nottingham.
Unless stated, all drugs were added using lOOx stock solutions to minimise volume 
changes and final concentrations are quoted in the text forthwith.
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6.3 Results
The first experiment conducted in this chapter investigated whether stimulation of 
Group I mGluRs could result in an increase in levels of ERK 1 and ERK 2 
phosphorylation in cerebrocortical nerve terminals. An agonist selective for Group I 
mGluRs, DHPG, was added to the synaptosomes for 1 minute at varying concentrations 
(Ito et al., 1992). Group I mGluRs are known to be desensitised through 
phosphorylation by PKC in a negative feedback loop (Gereau and Heinemann, 1998; 
Francesconi and Duvoisin, 2000). For this reason, a 1 minute time point was used in an 
attempt to observe any effects on ERK 1,2 phosphorylation before any desensitisation 
of the receptors (Herrero et al., 1998). Varying concentrations of DHPG were used to 
investigate the dose dependency of the effect. Figure 6.1 shows that stimulation of 
Group I mGluRs can result in increases in phosphorylation of ERK 1 and ERK 2 in 
cerebrocortical nerve terminals (mean ± s.e.m. % change from 37°C Control: lOOnM = 
190 ± 20%, 1 pM = 142 ± 11%, lOpM = 129 ± 11%). The graph also shows that DHPG 
does not have a differential effect on the two ERKs (mean ± s.e.m. values for 1 pM 
DHPG: p42 = 141 ± 16% and p44 =154 ± 19%). As a result of this, all subsequent data 
has been represented as combined (1 + 2 ) ERK values unless differences were 
identified.
The next experiment investigated the concentration response effects of DHPG on ERK
1,2 phosphorylation over longer incubation times. The longer incubation times were 
used to examine the possible desensitisation properties of the receptor/s and to elucidate 
on the appropriateness of different incubation protocols for subsequent studies. Figure 
6.2A and B shows that DHPG can increase ERK 1,2 phosphorylation levels when added 
5 minutes and 30 seconds prior to the termination of the incubation with a total length 
of 10 minutes. These data also show that the magnitude of ERK 1,2 phosphorylation 
does not decrease with increasing DHPG concentration as might be expected with 
receptor desensitisation. Instead, the ERK 1,2 response increases from 123 ± 11% to 
180 + 33% upon addition of 0.1 and InM DHPG respectively. With InM DHPG, the 
response appears to have reached a maximum and continues at this level to the highest 
concentration tried of 100pM (mean ± s.e.m. in %: lOnM = 158 ± 11, lOOnM = 149 ± 
12, lpM  = 157 ± 13 ,lOpM = 159 ± 17, lOOpM = 166 ± 25).
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Figure 6.1 DHPG Stimulation of ERK 1 AND ERK 2 Activation.
Synaptosomes were incubated for 10 mins in the presence o f  ImM CaCE as indicated in 
section 6.2.1, with the final minute being in the absence (control) or presence (+DHPG) 
of lOOnM, lpM , or lOpM DHPG. 7.5% polyacrylamide gels were used. Immunoblots 
were probed using a 1:1000 dilution o f  phospho-MAPK antibody (NEB) with 125I- 
Protein A used as the reporter. 125I-labelling was assessed by Phosphorimager 
spectroscopy (Molecular Dynamics). Mean ± s.e.m. ERK 1,2 phosphorylation levels 
obtained from separate experiments were individually normalised to 100% 37°C control 
levels. ** P<0.01, *P<0.05 (Students paired t-test). A. Phosphorimage o f  dose 
response. B. Quantification o f ERK 1,2 phosphorylation. C. Proposed pathway leading 
to ERK 1,2 phosphorylation/activation.
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Figure 6.2 Concentration-Responses of DHPG Stimulation of ERK 1,2 Activation.
Synaptosomes were incubated for 10 min with ImM CaCh in the presence (+DHPG) or 
absence (control) o f  varying concentrations o f  DHPG. DHPG was added for either 
5min 30sec (A and B) or 10 min (C and D) prior to the end o f  the incubation, as 
described in section 6.2.1. 7.5% polyacrylamide gels were run. Samples were 
immunoblotted using phospho-MAPK primary antibody (NEB) and 1 5I-Protein A as 
the reporter. Phosphoimages were analysed using spectroscopy (Molecular Dynamics) 
with mean ± s.e.m. obtained from several separate experiments each normalised to their 
own 100% 37°C control values. ** P<0.01, *P<0.05 (Students paired t-test). A. and C. 
Phosphorimages o f  concentration-responses. B. and D. Quantification o f ERK 1,2 
phosphorylation.
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Figure 6.2C and D examines the effects of DHPG when added to synaptosomes still in 
their un-incubated state. The cerebrocortical nerve terminals were kept at 4°C until 
required, when DHPG was added immediately before commencing the 37°C incubation. 
The reactions were terminated following 10 minutes of incubation. Under these 
conditions, maximal increases in ERK 1,2 phosphorylation were observed when using 
IOjjM DHPG (mean ± s.e.m.: lOOnM -  103 ± 5%, lpM  = 112 ± 8%, lOpM = 129 ±
6%, IOOjiM = 125 ± 9%). The response also appeared to decrease at higher 
concentrations of DHPG, suggesting a possible desensitisation of the pathway (mean ± 
s.e.m.: ImM DHPG = 114 ± 6% compared to control levels of 100%).
The dose response data obtained for lOOnM, lpM  and lOpM DHPG has also been 
represented as time courses, as shown in Figure 6.3A. The results show that the 
increases in ERK 1,2 phosphorylation levels following 10 minutes incubation with 
DHPG were significantly smaller than those obtained following 5 mins 30 sec 
incubation with DHPG. This suggests that the levels of ERK 1,2 phosphorylation 
obtained when synaptosomes are treated with DHPG are sensitive to lengthening 
incubation times in the presence of the drug. It is also possible that the timing of 
addition of DHPG (before or after commencing 37°C incubation) may be a factor in 
determining the levels of ERK 1,2 phosphorylation obtained. Having carried out all 
these concentration-response and time course experiments, it was now possible to 
identify the appropriate concentrations of DHPG required to elicit a reliable increase in 
ERK 1,2 phosphorylation under different conditions.
The results so far show that DHPG is able to increase ERK 1,2 phosphorylation in 
cerebrocortical nerve terminals. The next stage of this investigation looks to examine 
the pathway upstream of ERK 1,2 phosphorylation. Group I mGluRs are known to 
activate PKC and PKC is known, under some circumstances, to stimulate the ERK 1,2 
signalling cascade (Roberson et al., 1999). PKC is also known to desensitise Group I 
mGluRs in a negative feedback loop (Gereau and Heinemann, 1998; Francesconi and 
Duvoisin, 2000), and so inhibition of PKC could result in increased activity downstream 
of the receptor. However, if the increase in ERK 1,2 phosphorylation is downstream of 
PKC activation then the increase should be blocked by a PKC inhibitor, whether the 
receptor is desensitised or not. The next series of experiments examines whether
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Figure 6.3 DHPG Stimulation of ERK 1,2 Activation Using Different Protocols.
Synaptosomes were incubated at 37°C with ImM CaCl2. Immunoblots were labelled1using phospho-MAPK antibody (NEB) and reported with I-labelled protein A.
Signals were quantified using phosphorimager spectroscopy and mean ± s.e.m. values 
were taken from several independent experiments and normalised to individual 100% 
37°C controls. *P<0.05 (Students t-test) A. Quantification of ERK 1,2 phosphorylation 
levels where the total incubation time was 10 mins and the time stated is the time in the 
presence of DHPG (see section 6.2.1). Statistical analysis was of ERK 1,2 
phosphorylation levels after 5 min 30 secs, compared to ERK 1,2 phosphorylation levels 
after 10 minutes, all in the presence of DHPG.
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Group I mGluRs are acting through PKC to stimulate ERK 1,2 phosphorylation in 
cerebrocortical nerve terminals.
Figure 6.4 shows the effects of calphostin C, a PKC inhibitor, on the DHPG 
enhancement of ERK 1,2 phosphorylation levels (Kobayashi et al., 1989). A 
preincubation protocol was used (described in section 6.2.3), whereby synaptosomes 
were incubated with calphostin C for 20 minutes before being cooled back to 4°C. The 
synaptosomes were then reincubated at 37°C for 10 minutes, with DHPG being added 1 
minute prior to termination of the reaction. This protocol was used because other 
studies using synaptosomes have utilised longer protocols to allow calphostin C to cross 
plasma membranes and enter the cell in sufficient quantity to inhibit PKC (Matveeva et 
al., 2001). The earlier data in this chapter also shows that the observed effect of DHPG 
on ERK 1,2 phosphorylation levels may desensitise in incubations lasting longer than 
10 minutes, hence the cooling of synaptosomes back to 4°C between the preincubation 
and incubation steps was designed to limit this effect. The results obtained for the 
effects of calphostin C on ERK 1,2 phosphorylation levels using this protocol have 
already been shown in the previous chapter (Figure 5.4), where it was found that 
calphostin C increased ERK 1,2 phosphorylation even at 4°C levels. In order to account 
for the effects of calphostin C on basal phosphorylation levels, the samples containing 
DHPG were each normalised to their individual 37°C controls. Thus, the samples 
containing DHPG were normalised to 100% 37°C control values and the samples 
containing DHPG and calphostin C were normalised to 100% 37°C calphostin C values. 
DHPG was found to significantly increase ERK 1,2 phosphorylation levels in both the 
control sample and the sample containing calphostin C (mean ± s.e.m: control DHPG = 
185 ± 24%, calphostin C DHPG = 172 ± 15%, P<0.05, ANOVA with Duncan’s post 
hoc analysis). No significant difference was, however, found between the DHPG 
enhancement of ERK 1,2 phosphorylation levels in calphostin C and control samples.
These results suggest that, under the conditions used, the pathway between Group I 
mGluRs and ERK 1,2 is not dependent on the activation of PKC in as much as there is 
an apparent lack of sensitivity to calphostin C. However, the effect of calphostin C on 
basal ERK 1,2 phosphorylation levels could be confounding the observations in the 
presence of DHPG. It is also possible that the properties of the Group I mGluRs could
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Figure 6.4 No Effect of Prolonged Calphostin C Exposure on DHPG-Stimulated 
ERK 1,2 Activation. Synaptosomes were preincubated as described in section 6.2.2 
followed by a 10 min incubation with 1 min in the absence (control) or presence 
(+DHPG) of lOpM DHPG. 7.5% polyacrylamide gels were run. ERK 1,2 
phosphorylation levels were detected using phospho-MAPK primary antibody (1:1000, 
NEB), reported with 125I-Protein A, and measured using phosphorimager spectroscopy 
(Molecular Dynamics). Mean ± s.e.m. from 4 independent experiments, individually 
normalised to their own relevant 37°C control. *P<0.05 (ANOVA with Duncan’s post 
hoc analysis, n=4). A. Phosphorimage of combined effects of calphostin C and DHPG.
B. Quantification of combined effects. C. Proposed pathways involved in mediating 
these effects.
185
be changing with the long preincubation protocol necessary to administer the calphostin
C. Considering these factors, the next experiment conducted looked at the effects of the 
PKC inhibitor, Ro-32-0432, on DHPG-enhancement of ERK 1,2 phosphorylation levels 
following a short incubation protocol (Kobayashi et al., 1989).
In the next series of experiments, the usual short incubation protocol was followed, 
whereby synaptosomes were incubated for 10 minutes in the presence of lpM  Ro-32- 
0432. DHPG (lOpM) was used as this was the concentration shown to work best under 
the 10 minute incubation protocol. Results are shown in Figure 6.5 and, as expected, 
DHPG was found to significantly increase ERK 1,2 phosphorylation levels (mean ± 
s.e.m.: 146 ± 5% compared to 100% control, P<0.05, ANOVA followed by Duncan’s 
post hoc analysis). In agreement with the results obtained in Chapter 5 (Figure 5.8), 
Ro-32-0432 was also found to significantly increase ERK 1,2 phosphorylation levels 
(mean ± s.e.m.: 154 ± 16% compared to 100% control, P<0.05, ANOVA followed by 
Duncan’s post hoc analysis). When Ro-32-0432 and DHPG were added together, 
however, significant increases in ERK 1,2 phosphorylation levels were no longer 
observed (mean ± s.e.m.: 116 ± 18% compared to 100% control, P>0.05, ANOVA 
followed by Duncan’s post hoc analysis). Although this in itself could suggest an 
inhibition of DHPG enhanced ERK 1,2 phosphorylation by Ro-32-0432, there was no 
statistically significant difference between the DHPG stimulated samples and the 
DHPG/Ro-32-0432 samples, possibly due to the low number of replicates (n=3). 
Notwithstanding, in every experiment performed (3/3), the levels of ERK 1,2 
phosphorylation were found to be lower with DHPG/Ro-32-0432 compared to DHPG 
on its own.
The stimulatory effect of Ro-32-0432 on basal levels of ERK 1,2 phosphorylation 
appears to be peculiar to the ERK 1,2 pathway, as previous studies have demonstrated a 
clear inhibitory effect of the compound on PKC-dependent phosphorylation (Wilkinson 
et al., 1993). It remains to be seen, however, whether the stimulatory effect could be 
attributed to inhibition of phosphatase activation through inhibition of PKC or, to some 
other, non-specific effect due to interactions of Ro-32-0432 with enzymatic ATP 
binding sites, towards which the drug was originally targeted (Aiyar et al., 2000). 
Notwithstanding, this does invoke the possibility that the apparent inhibition of DHPG
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Figure 6.5 Ro-32-0432 Attenuates DHPG-Enhanced ERK 1,2 Activation.
Synaptosomes were incubated for 10 mins with ImM CaCl2 either in the presence 
(+Ro-32-0432) or absence (control) of Ro-32-0432. DHPG was added to those samples 
labelled +DHPG, 1 min prior to the termination of the experiment. 7.5% 
polyacrylamide gels were used. Immunoblots were labelled with phospho-MAPK 
primary antibody (1:1000, NEB) and reported using l25I-Protein A. 12:>I-labelling was 
quantified using phosphorimager spectroscopy (Molecular Dynamics) with individual 
values normalised to 100% 37°C control samples. *P<0.05 compared to 37°C control 
(ANOVA with Duncan’s post hoc analysis, n=3). A. Phosphorimage of DHPG and Ro- 
32-0432 effects. B. Quantification of DHPG and Ro-32-0432 effects. C. Possible 
pathways involved in mediating these effects.
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activation of ERK 1,2 by Ro-32-0432 could also be due to a non-specific interaction of 
the drug rather than inhibition of PKC. The role of PKC in controlling MAPK 
phosphorylation levels seems to be complicated and remains unresolved with the PKC 
inhibitors used here. Given, however, that DHPG clearly affects ERK 1,2 
phosphorylation, the next set of experiments looks at signalling upstream of PKC, at the 
level of the Group I mGluRs.
There are two receptors that constitute the Group I mGluRs, mGluRl and mGluR5.
The following experiments aimed to investigate which of the Group I mGluRs could be 
mediating the effect of DHPG on MAPK phosphorylation. In order to do this an 
mGluR5 specific non-competitive antagonist, MPEP, was added to the synaptosomal 
preparation one minute prior to the addition of DHPG (Gasparini et al., 1999). The 
results obtained from these experiments are illustrated in Figure 6 .6 . MPEP (lOpM) 
was found to significantly increase basal levels of ERK 1,2 phosphorylation on its own 
(mean ± s.e.m. compared to 100% 37°C control samples: 181 ± 36%, P<0.05 ANOVA 
with Duncan’s post hoc analysis). Addition of MPEP with DHPG (lpM ) was found to 
have no significant effect on basal levels of ERK 1,2 phosphorylation and to 
significantly decrease the phosphorylation levels observed with MPEP alone (mean ± 
s.e.m.: 99 ± 5% compared to 100% basal levels). Despite DHPG values always being 
larger than control values (5/5 experiments) (mean ± s.e.m. for DHPG: 145 ± 15% 
compared to 100% basal levels), in this particular series of experiments, DHPG was not 
found to increase basal level of ERK 1,2 phosphorylation to statistical significance. 
Considering this protocol has yielded significant DHPG-induced increases in ERK 1,2 
phosphorylation in previous experiments (see Figure 6.1), additional repetitions would 
be predicted to resolve the large variability of the current dataset with DHPG.
These results suggest that DHPG-induced enhanced ERK 1,2 phosphorylation is 
mediated through mGluRl rather mGluR5. MPEP does appear to block DHPG- 
enhanced ERK 1,2 phosphorylation, but also has substantial positive effects on its own. 
This may suggest that the observed inhibition by MPEP is the result of it interacting 
with downstream pathways rather than as a direct effect of mGluR5 blockade. These 
results do imply that mGluR 1 and mGluR5 occur in the same nerve terminals and that 
their downstream pathways can both regulate ERK 1,2 phosphorylation levels. Which
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Figure 6.6 The Combined Effects of MPEP and DHPG on ERK 1,2 Activation
Synaptosomes were incubated at 37°C, for 10 mins, in the presence of ImM CaCh.
1 OpM MPEP was added 2 mins prior, and 1 pM DHPG 1 min prior to the termination of 
the reactions (labelled +MPEP, and +DHPG respectively). 7.5% polyacylamide gels 
were used. Western blots were performed, labelled with phosphospecific MAPK 
antibody (1:1000, NEB) and detected with (125I)-labelled protein A. Signals from 
several independent experiments were quantified with phosphorimager spectroscopy 
and normalised to individual 100% 37°C controls. *P<0.05 compared to 37°C control, 
ANOVA with Duncan’s post hoc analysis (n=5). A. Phosphorimage of MPEP and 
DHPG effects. B. Quantification of MPEP and DHPG effects. C. Possible pathways 
involved in mediating these effects. ECD = extracellular domain.
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downstream pathways are involved still remains unclear.
It was interesting to observe that both Ro-32-0432, the PKC inhibitor, and MPEP, the 
mGluR5 inhibitor, gave the same pattern of results with regard to levels of ERK 1,2 
phosphorylation in the presence and absence of DHPG. Recent evidence has suggested 
that the transmembrane domain of Group I mGluRs may be constitutively active 
(Pagano et al., 2000;Carroll et al., 2001). This could result in tonic inhibition of 
mGluRl by mGluR5 through a PKC-dependent mechanism (Poisik et al., 2003). It may 
be that MPEP is removing a tonic inhibition of mGluRl by mGluR5, leading to 
mGluRl-mediated stimulation of the ERK 1,2 signalling cascade. It is also possible 
that Ro-32-0432 is removing this tonic inhibition of mGluRl by mGluR5 as well, by 
inhibiting the signalling pathway acting between mGluR5 and mGluRl. The Group I 
mGluRs have also been shown to be able to couple to different G proteins depending on 
their phosphorylation state, resulting in the activation of different signalling cascades 
(Francesconi and Duvoisin, 2000).
The next set of experiments conducted aimed to elucidate the pathways involved in 
regulating the crosstalk between mGluR 1 and mGluR5 and the ERK 1,2 pathway in 
nerve terminals. The experiments have used the PKC inhibitor, calphostin C, along 
with MPEP and DHPG, to determine whether PKC was also involved in this case. The 
long preincubation protocol was used, as described before for Figure 6.4, with MPEP 
and DHPG being added 2 mins and 1 min prior to the termination of the reactions, 
respectively.
The blot shown in Figure 6.7 indicates that the treatment of synaptosomes with DHPG 
or MPEP still results in an increase in ERK 1,2 phosphorylation levels when the 
preincubation protocol is used. It is interesting to note that the results also suggest that 
the MPEP-mediated inhibition of DHPG-induced enhancement of ERK 1,2 
phosphorylation is no longer present under these control conditions. This in itself 
implies that the inhibition seen with the short protocol is time-dependent and that when 
synaptosomes are preincubated, the signalling between the level of DHPG-simulation of 
Group I mGluRs and ERK 1,2 phosphorylation changes. It is possible that this change 
is mediated by a cross-talk between mGluR 1 and mGluR5, and that it may no longer be
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Figure 6.7 Combined Effects of Calphostin C, MPEP and DHPG on ERK 1,2 
Activation. Synaptosomes were preincubated with ImM CaCE either in the presence 
(+ calphostin) or absence (control) o f calphostin C as described in section 6.2.2. 
Samples were then incubated for a further 10 mins, with 1 min in the presence 
(+DHPG) or absence (-DHPG) o f DHPG and/or 2 mins in the presence (+MPEP) or 
absence (-MPEP) o f  MPEP. Immunoblots were labelled with phospho-MAPK primary 
antibody and reported using 1251-labelled protein A. Phosphorimage o f calphostin C, 
MPEP and DHPG effects. B. Table demonstrating the changes in ERK 1,2 
phosphorylation/activation levels seen with different drug treatments and incubation 
protocols. (^  = increase; — = no change).
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present in preincubated synaptosomes. However, it is also possible that the lack of 
effect of MPEP on DHPG-induced ERK 1,2 phosphorylation is due to the higher 
concentration of DHPG used in this instance. Previous studies have found that 
inhibition of mGluR5 by MPEP can be overcome by treatment with higher 
concentrations of DHPG (Lorrain et al., 2002).
Figure 6.7 also indicates that the MPEP-induced increase in ERK 1,2 phosphorylation 
levels may not be PKC-dependent when the preincubation protocol is used. This is 
because ERK 1,2 phosphorylation levels still appear to be enhanced by MPEP despite 
treatment with calphostin C. The final point of note is that the ERK 1,2 
phosphorylation levels induced by the combined treatment of DHPG and MPEP appear 
to be additive in the presence of calphostin C, compared to treatment with DHPG or 
MPEP alone. As this is only one blot, more experiments need to be conducted in order 
to confirm the results obtained here, but the indications are that the signalling between 
Group I mGluRs and ERK 1,2 is complex and that the specific aspects of the regulation 
revealed depends on the incubation protocol utilised.
Group I mGluRs can signal through PLC to evoke the hydrolysis of PI-4,5-P2 into DAG 
and IP3 (Sugiyama et al., 1987). IP3 is known to stimulate the release of calcium from 
intracellular stores which, along with DAG, activates conventional forms of PKC 
(Kishimoto et al., 1980). The previous experiments in this chapter imply that PKC may 
be regulating ERK 1,2 phosphorylation following DHPG stimulation with the short 
incubation protocol, but not necessarily with the preincubation protocol. These 
experiments also suggest that if PKC is involved, its signalling may not necessarily be 
direct, though it has not been possible to clearly define this role using PKC inhibitors. 
Notwithstanding, Group I mGluRs could be signalling to ERK 1,2 in a PKC- 
independent manner, through direct DAG activation of a Ras-GEF (Ebinu et al., 1998; 
Kawasaki et al., 1998), or by a Ca2+-dependent activation (Walker et al., 2003). To 
further examine the pathways involved downstream of mGluR stimulation leading up to 
ERK 1,2 phosphorylation, I examined the Ca -dependency of the ERK 1,2 activation. 
If the enhancement in phosphorylation of ERK 1,2 with DHPG was found to be
^ 1
completely Ca -dependent, then this would rule out a direct involvement of DAG 
signalling through a Ras-GEF, but include a Ca2+-dependent activation of ERK 1,2 
involving PKC and/or intracellular Ca2+ stores released by IP3.
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Figure 6.8 Ca2+-Dependent Component to Basal ERK 1,2 Activation levels.
Synaptosomes were preincubated with ImM CaCh either in the absence (-BAPTA) or 
presence (+BAPTA) of BAPTA-AM. The following incubation was then carried out in 
the presence (+EGTA) or absence (-EGTA) of EGTA, as described in section 6.2.2. 
7.5% polyacrylamide gels were run. Immunoblots were labelled with phospho-MAPK 
primary antibody (1:1000, NEB) and reported using ,25I-Protein A. 125I-labelling was 
quantified using phosphorimager spectroscopy (Molecular Dynamics) with individual 
values normalised to 100% 37°C control samples. 37°C samples were compared to 
37°C control and 4°C samples were compared to 4°C control *P<0.05, ANOVA with 
Duncan’s post hoc analysis (n=6). A. Phosphorimage of EGTA and BAPTA effects. B. 
Quantification of EGTA and BAPTA effects.C. Proposed pathways for these effects
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Figure 6.9 BAPTA Attenuates DHPG Stimulation of ERK 1,2 Activation.
Synaptosomes were preincubated with ImM CaCh and either BAPTA-AM or DMSO. 
The following incubation was then carried out either in the presence of 1 mM CaCb (- 
EGTA) or EGTA (+EGTA). DHPG was added 1 min prior to the termination of the 
reactions. 7.5% polyacrylamide gels were used. Immunoblots were labelled with 
phospho-MAPK primary antibody (1:1000, NEB) and reported using 125I-Protein A. 
25I-labelling was quantified using phosphorimager spectroscopy (Molecular Dynamics) 
with samples normalised to 100% individual 37°C controls. *P<0.05, ANOVA with 
Duncan’s post hoc analysis (n=4). A. Phosphorimage of EGTA and BAPTA effects on 
DHPG-enhanced ERK 1,2 phosphorylation. B. Quantification of these effects. C. 
Proposed pathways involved.
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BAPTA is a rapid chelator of Ca2+ which, with the addition of an acetoxymethyl ester 
group, is able to traverse cell membranes (Tsien, 1980; Lew et al., 1982). Upon entry to 
the cell, the acetoxymethyl ester group is removed, trapping the BAPTA within the cell,
I
making it a valuable tool for studying the role of intracellular Ca . EGTA is a slower 
chelator of Ca which remains outside the cell (Tsien, 1980). The combined use of
internal BAPTA (introduced as BAPTA-AM) and external EGTA makes it possible to
2 1
examine the respective contributions of both intracellular and extracellular Ca . 
Synaptosomes were first preincubated in the presence of ImM CaCl2 for 10 minutes to 
allow the filling of intracellular stores before the addition of either BAPTA-AM or 
DMSO for a further 20 minutes. EGTA was not added until the start of the incubation 
stage as described in section 6.2.2., with ImM CaCl2 being added to control samples. 
DHPG (IOjiM) was added 1 minute prior to the termination of the final incubation. It 
should be noted that buffered solutions were used to minimise the changes in pH that 
can occur following Ca2+ chelation by EGTA. No significant differences were found 
between the basal 4°C ERK 1,2 phosphorylation levels for each of the conditions 
(Figure 6 .8) (mean ± s.e.m. for 6 independent experiments compared to 100% 37°C 
control: Control = 35 ± 4%, EGTA = 50 ± 10%, BAPTA = 45 ± 6%, EGTA/BAPTA = 
45 ± 4%). However, the increase in ERK 1,2 phosphorylation levels observed when the 
synaptosomes are incubated at 37°C does appear to be partially dependent on
04-extracellular Ca , as phosphorylation levels were significantly decreased in the 
presence of EGTA (mean ± s.e.m. compared to 100% 37°C control: EGTA = 64 ± 4%, 
EGTA/BAPTA = 68 ±4%). BAPTA on its own did not significantly decrease the levels 
of ERK 1,2 phosphorylation found when synaptosomes were heated to 37°C (mean ± 
s.e.m. compared to 100% 37°C control: BAPTA = 89 ± 8%), suggesting that Ca2+ from 
intracellular stores is not responsible for the basal level of ERK 1,2 phosphorylation.
In contrast to the extracellular Ca -dependency of basal ERK 1,2 phosphorylation 
levels, DHPG appears to require intracellular Ca2+ in order to increase the 
phosphorylation levels of ERK 1,2 (Figure 6.9). DHPG was found to significantly 
increase ERK 1,2 activation in control samples and in the presence of EGTA alone 
(mean ± s.e.m. of DHPG effect in % compared to individual 100% 37°C controls:
DHPG =123 ±6, EGTA = 127 ± 11). However, treatment with DHPG no longer caused
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an enhancement of ERK 1,2 phosphorylation levels when BAPTA was also present 
(mean ± s.e.m. of DHPG effect in % compared to individual 100% 37°C controls: 
BAPTA = 96 ± 1, EGTA/BAPTA = 107 ± 8). This means that, when a preincubation 
protocol is followed, Group I mGluRs are likely to be signalling either through a 
conventional form of PKC, though a Ca2+-dependent Ras-GEF, or another Ca2+- 
dependent intermediary, to elicit the ERK 1,2 response observed in cerebrocortical 
nerve terminals.
This chapter, thus far, has only looked at signalling pathways between the Group I 
mGluRs and ERK 1,2, the next section looks at signalling downstream of ERK 1,2 and 
how it correlates with glutamate release. The first experiments looked at the 
phosphorylation of a protein, synapsin I, known to be a direct downstream substrate of 
ERK 1,2 in presynaptic nerve terminals (Jovanovic et al., 1996). Interestingly, neither 
lpM  or lOpM DHPG increased synapsin site 4/5 phosphorylation following the short 
incubation protocol (Figure 6.10) (mean ± sem in % compared to 100% 37°C control: 
lpM  DHPG = 106 ± 4, lOpM DHPG = 99 ± 2 (n=3)). This would appear to suggest 
that, if DHPG is able to increase glutamate release under these conditions, Group I 
mGluRs are not using the ERK/synapsin signalling cascade as part of this release 
regulation. Consistent with this, Figure 6.11 demonstrates, DHPG (lpM ) was unable to 
enhance 4-AP elicited glutamate release from cerebrocortical synaptosomes (cumulative 
glutamate release (nmol/mg) following 5 min incubation with secretogogue: 4-AP = 
10.1, 4-AP/DHPG = 10.5). In the same experimental instances, in contrast to the lack 
of effect of DHPG, I was able to demonstrate a strong facilitation of glutamate release 
with PDBu (Figure 6.11), both agents being able to increase levels of ERK 1,2 
phosphorylation in positive control phosphorylation experiments carried out in parallel. 
The recalcitrance of glutamate modulation to DHPG is in agreement with previous 
studies conducted on cerebrocortical synaptosomes, where it was found that singular 
stimulation of Group I mGluRs alone was not able to enhance glutamate release, but 
rather required endogenous or exogenous arachidonic acid (AA) with DHPG, or the 
presence of a phosphatase 2B inhibitor (Coffey et al., 1994a; Sistiaga and Sanchez- 
Prieto, 2000a). In the experimental conditions used in this chapter, because 
synaptosomes are incubated in HBM containing BSA, the free fatty acid binding
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Figure 6.10 DHPG Does Not Enhance Total Levels of Synapsin Site 4/5 
Phosphorylation. Synaptosomes were incubated for 10 mins with ImM C a C h  either in 
the presence (+DHPG) or absence (control) of lpM  or lOpM DHPG for the final 
minute (detailed in section 6.2.1.). 7.5% polyacrylamide gels were run. Immunoblots 
were labelled with site 4/5 phospho-synapsin primary antibody (1:500, J.J.), with !251- 
Protein A used as the reporter. 25I-levels were detected with phosphorimager 
spectroscopy. Data was obtained from 3 independent experiments and normalised to 
their individual 100% 37°C control values, no significant differences were found 
(Student’s paired t-test, n=3). A. Phosphorimage of DHPG effect. B. Quantification of 
DHPG effect. C. Proposed pathway for DHPG effect.
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Figure 6.11 DHPG Does Not Appear to Enhance Glutamate Release on Its Own.
Synaptosomes were incubated in the presence of 1 mM CaCb as indicated in section 
5.2.1. A. Glutamate release was elicited with the addition of 4-AP (ImM, arrow) in the 
absence (control), or presence (+DHPG) of 1 pM DHPG, or 1 pM PDBu (+PDBu). 
DHPG was added 1 min prior, and PDBu added 30 secs prior to the secretogogue. 
Accumulative release was measured at 2 sec intervals. A representative experiment is 
shown.
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capacity of the latter (including AA) ((Lombardi et al., 1996)), obviates any potential 
influence of endogenous AA. In the one specific instance where regulation by DHPG 
was reported to occur in the absence of AA, the regulation of [3H]-glutamate release 
was addressed, rather than endogenous neurotransmitter (Reid et al., 1999).
The results obtained so far have correlated a lack of increase in synapsin I site 4/5 
phosphorylation with a lack in enhancement of glutamate release. The lack of increase 
in site 4/5 synapsin phosphorylation with DHPG, however, appears to be contrary to 
clear increases in phosphorylation observed in ERK 1,2, believed to be directly 
upstream of synapsin. The most facile explanation for this would be that ERK 1,2 is not 
the active kinase phosphorylating synapsin on site 4/5, despite a large body of data 
indicating to the contrary (Jovanovic et al., 1996; Yamagata et al., 2002). Alternatively, 
pathways acting in parallel to ERK 1,2 activation that are increasing the 
dephosphorylation of these sites on synapsin (Jovanovic et al., 2001), may play a role to 
reverse the effects of DHPG stimulated ERK 1,2 on the molecule. Group I mGluRs 
stimulate increases in intracellular Ca levels through production of IP3, as well as 
through PKC-dependent pathways. This increase, also alluded to in the foregoing
 ^I
mentioned series of experiments, could lead to the activation of Ca -dependent 
phosphatases, such as calcineurin (PP2B) (Tonks and Cohen, 1983), known to 
dephosphorylate synapsin I on site 4/5 (Jovanovic et al., 2001). The earlier experiments
 ^I
described in this chapter looked at the roles of intracellular and extracellular Ca on 
ERK 1,2 phosphorylation. It was, therefore, decided to return to use the same 
conditions to study the levels of synapsin site 4/5 phosphorylation, in conditions 
showing a Ca2+-dependent activation of ERK 1,2.
Synaptosomes were preincubated with ImM CaCL for 10 mins before addition of 
BAPTA-AM. Preincubation continued for a further 20 mins before synaptosomes were 
harvested and washed. A standard 10 min incubation protocol was then followed in the 
presence of either ImM CaCL or EGTA, as described previously. The results obtained 
are shown in Figure 6.12 and agree with previous reports ((Jovanovic et al., 2001)), in 
that the levels of synapsin site 4/5 phosphorylation significantly increase with the 
removal of Ca2+ (mean ± s.e.m. of 37°C samples compared to 100% 37°C control:
EGTA = 158 ± 13; BAPTA = 122 ± 7; EGTA/BAPTA = 163 ± 8). It is interesting to
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Figure 6.12 EGTA and BAPTA Stimulate Basal Levels of Synapsin Site 4/5 
Phosphorylation. Synaptosomes were preincubated with ImM CaCE and either 
BAPTA-AM or DMSO. The following incubation was then carried out either in the
presence of ImM CaCE (-EGTA) or EGTA (+EGTA) as described in 6.2.2. 7.5% 
polyacrylamide gels were used. Immunoblots were labelled with phospho-synapsin site
• •  • O S  • •4/5 primary antibody (J.J, 1:500) and reported using I-labelled Protein A. Signal 
levels were detected and analysed using phosphorimage spectroscopy (Molecular 
Dynamics). Samples were normalised to the 100% 37°C control value. **P<0.01, 
*P<0.05, ANOVA with Duncan’s post hoc analysis (n=3) A. Phosphorimage of 
combined effects of BAPTA and EGTA. B. Quantification of these effects on synapsin 
site 4/5 phosphorylation. C. Possible pathways involved.
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note that these increases occur despite the fact that, under the same conditions, ERK 1,2 
phosphorylation levels were decreased compared to controls (Figure 6.9 and compared 
in Table 6.2). This suggests the presence of an alternative pathway involving a
 ^I
phosphatase, the activity of which is substantially suppressed with the removal of Ca .
Table 6.2: Changing ERK 1,2 and Synapsin Site 4/5 Phosphorylation Levels.
Control Control + DHPG
DHPG EGTA BAPTA BAPTA/
EGTA
EGTA BAPTA BAPTA/
EGTA
ERK 1,2 t * * ■ t
Synapsin
4/5 ft t ft t t
The Ca2+-dependency of the basal levels of ERK 1,2 and synapsin site 4/5 
phosphorylation, combined with the opposing Ca2+-dependency of DHPG-enhanced 
ERK 1,2 phosphorylation, has made it difficult to assess and interpret the levels of 
synapsin site 4/5 phosphorylation regulated by Ca2+. For example, the blot shown in 
Figure 6.13, shows a slight DHPG-mediated increase in synapsin I site 4/5 
phosphorylation in controls and EGTA/BAPTA containing samples. Apparently 
paradoxically, however, the BAPTA containing sample shows a slight DHPG-mediated 
decrease, with the synapsin I site 4/5 phosphorylation levels in the EGTA-containing 
case showing no response to the agonist. It should be noted that this was a 
representative blot and further experiments need to be conducted to confirm the validity 
of this study. However, these results do point towards the possibility for a Ca2+- 
dependency of Group I mGluR-mediation of synapsin I site 4/5 phosphorylation levels. 
The effects of the different Ca2+ conditions in the presence and absence of DHPG on 
ERK 1,2 and synapsin site 4/5 phosphorylation are illustrated in Table 2, where it can 
be clearly seen that changes in ERK 1,2 activation are not necessarily conducive to the 
same changes in synapsin site 4/5 phosphorylation.
The final experiments described in this chapter elucidated on the proximity of the 
neurotrophin-mediated trkB/Ras/RafTMEK/ERK 1,2/synapsin, and glutamate-mediated 
Group I mGluR/PKC or Ca2+/ERK 1,2/synapsin signalling cascades. As both cascades
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Figure 6.13 Combined Effects of Ca2+ and DHPG on Synapsin Site 4/5 
Phosphorylation. Synaptosomes were preincubated with ImM CaCl2 and either 
BAPTA-AM or DMSO. The following incubation was then carried out either in the 
presence of ImM CaCE (-EGTA) or EGTA (+EGTA). DHPG was added 1 min prior to 
the termination of the reactions. 7.5% polyacrylamide gels were used. Immunoblots 
were labelled with synapsin site 4/5 primary antibody (1:500, J.J.) and reported using 
12sI-Protein A. A. Phosphorimage of combined effects of EGTA, BAPTA and DHPG 
on synapsin site 4/5 phosphorylation. B. Schematic diagram showing the possible 
pathways involved in signalling to synapsin site 4/5 following this protocol.
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are acting through increasing ERK 1,2 phosphorylation, it should be possible to 
examine their colocalisation by measuring levels of ERK 1,2 activation. Additive levels 
of ERK 1,2 phosphorylation could suggest the involvement of different populations of 
neurones, whereas lack of additivity or in fact, synergism, could be taken to indicate 
immediate intrasynaptosomal proximity or cross-talk of the pathways within neurones.
Cerebrocortical synaptosomes were incubated for a total time of 10 mins with 6mins in 
the presence of varying concentrations of BDNF, a trkB receptor agonist, and/or 5 mins 
30 sec in the presence of varying concentrations of DHPG, a Group I mGluR agonist. 
The results obtained are shown in Figure 6.14 and Figure 6.15. Although lOOnM 
DHPG appears to increase ERK 1,2 phosphorylation (Figure 6.14), the enhancement 
was not found to be statistically significant (mean ± s.e.m.: DHPG (lOOnM) = 148 ±
15). In contrast, both 50ng/ml and lOOng/ml BDNF were able to significantly increase 
ERK 1,2 activation (mean ± s.e.m.: BDNF (50ng/ml) = 174 ± 29; BDNF (lOOng/ml) = 
202 ± 34). It is interesting that the combined effects of these submaximal 
concentrations of DHPG and BDNF were neither synergistic nor additive, with 
increases in ERK 1,2 phosphorylation comparable with levels obtained with either drug 
alone (mean ± s.e.m.: DHPG/BDNF (100nM/50ng/ml) = 157 ± 18; DHPG/BDNF 
(1 OOnM/1 OOng/ml) = 153 ± 15).
The results in Figure 6.15 led to similar conclusions as those in Figure 6.14. Both 
1 OOng/ml and 200ng/ml BDNF significantly increased ERK 1,2 activation (mean ± 
s.e.m.: BDNF (lOOng/ml) = 185 ± 29; BDNF (200ng/ml) = 233 ± 28), as did lpM. 
DHPG (mean ± s.e.m.: DHPG A/C (lfxM) = 171 ± 17; DHPG B/D (lpM ) = 156 ± 13). 
The enhancement in ERK 1,2 activation levels upon combining 1 OOng/ml or 200ng/ml 
BDNF with 1 pM DHPG was, however, comparable to that obtained with either 
neurotrophin or mGluR 1/5 agonist alone (mean = s.e.m.: DHPG/BDNF 
(ImM /l OOng/ml) = 169 ± 9; DHPG/BDNF (lmM/200ng/ml) = 209 ± 32), indicating no 
additivity. The foregoing data suggest that the neurotrophin-mediated signalling 
through ERK 1,2 and the GPCR-mediated signalling through ERK 1,2 are likely 
occurring within the same population of nerve terminals
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Figure 6.14 Combined Effects of DHPG and BDNF on ERK 1,2 Phosphorylation 
Levels. Synaptosomes were incubated at 37°C for 10 mins with ImM CaCh. 50ng/ml 
or 1 OOng/ml BDNF (+BDNF) was added 6 mins prior to the end o f  the incubation. 
lOOnM DHPG (+DHPG) was added 5 mins 30 sec prior to the termination o f the 
incubation. 7.5% polyacrylamide gels were run. Immunoblots from several separate 
experiments were labelled with phospho-specific MAPK primary antibody (NEB,
1:1000) which was probed using 125I-labelled protein A. Signal levels were quantified 
using phosphorimager spectroscopy. P>0.05 (ANOVA with Duncan’s post hoc 
analysis, n=3) A and C: Phosphorimages o f  BDNF and DHPG effects. B and D: 
Quantification o f BDNF and DHPG effects.
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Figure 6.15 DHPG and BDNF-Mediated Increases in ERK 1,2 Activation are Not 
Additive. Synaptosomes were incubated with ImM CaCk for 10 mins in the presence 
of 1 OOng/ml or 200ng/ml BDNF (+BDNF) added 6 mins prior to the termination of the 
incubation, and/or lpM  DHPG (+DHPG) added 5 mins 30 sec prior to the end of the 
incubation. 7.5% polyacrylamide gels were run. Immunoblots were labelled with
1 'yc
phospho-specific MAPK primary antibody and reported using I-labelled protein A. 
25I-labelling was quantified using phosphorimager spectroscopy (Molecular 
Dynamics). P>0.05 (ANOVA with Duncan’s post hoc analysis, B: n=4; D: n=3). A 
and C: Phosphorimages of DHPG and BDNF effects. B and D: Quantification of 
DHPG and BDNF effects.
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6.4 Summary o f  Results
• Group I mGluR agonist, DHPG, enhances p42 and p44 MAPK phosphorylation 
levels in presynaptic cerebrocortical nerve terminals.
• Group I mGluR-mediated enhancement of MAPK phosphorylation levels, 
although not desensitising as such, were dependent on agonist concentration and 
incubation protocol.
• mGluRl is tonically inhibited under control, short incubation conditions.
• Removal of mGluRl tonic inhibition leads to enhanced p42 and p44 MAPK 
phosphorylation levels in synaptosomes.
• Basal MAPK phosphorylation levels are dependent on extracellular Ca2+ in 
presynaptic cerebrocortical nerve terminals.
• Group I mGluR-mediated increase in MAPK phosphorylation is dependent on 
intracellular Ca2+, but not PKC, when the preincubation protocol was followed.
• Synapsin I site 4/5 phosphorylation is highly dependent on intracellular and 
extracellular Ca2+ concentration, in a manner which does not bear relation to 
MAPK activation alone but additionally to the tone of Ca2+-dependent 
dephosphorylation activity.
• Neurotrophin and GPCR signalling to MAPK occur in the same nerve terminals.
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6.5 Discussion
The original basis for this work was to identify whether receptor linked pathways could 
be signalling through ERK 1,2 and synapsin as a common mechanism for regulating 
glutamate release from cerebrocortical nerve terminals. In support of this idea, this 
chapter has found that DHPG, a Group I mGluR agonist is able to increase levels of 
ERK 1 and ERK 2 phosphorylation in synaptosomes. Moreover, the evidence points to 
a Ca2+-dependence of this activation appearing to be contingent on the release of 
intrasynaptosomal Ca2+.
Characteristics of mGluRl/5 Activation: Desensitisation.
Previous studies have shown that the DHPG-mediated facilitation of glutamate release 
rapidly desensitises and is no longer present upon subsequent addition of the agonist 
(Herrero et al., 1998). The increase in levels of DAG produced by Group I mGluR 
stimulation was found to peak 5 seconds after treatment and be reduced back to basal 
following 5 minutes of incubation with DHPG. This effect was suggested to be due to 
phosphorylation of the C-terminal domain of the receptors by PKC, which is acting in a 
negative feedback loop (Herrero et al., 1998). During a desensitisation of a receptor- 
mediated response, it has traditionally been observed that increasing levels of agonist 
will increase the rate of desensitisation (Rodriguez-Moreno et al., 1998; Gereau and 
Heinemann, 1998). My investigations, looking at levels of ERK 1,2 phosphorylation 
following 10 min incubation with 1 min in the presence of varying concentrations of 
DHPG, indicate that the mean response does decrease with increasing concentrations of 
agonist, although at present, further experiments are warranted using the lowest 
concentrations of DHPG to obtain statistical support in this regard. Notwithstanding, it 
was interesting to note that although 100pM DHPG significantly increased ERK 1,2 
phosphorylation levels following a 10 min incubation with the drug, the higher 
concentration (ImM DHPG) did not. While these data would in principle support a 
desensitisation argument, the validity of this result could be called into question on the 
basis of the extremely high concentration of agonist required. Especially considering 
the EC50 for DHPG stimulation of mGluR 1 and mGluR5 demonstrated in oocytes was 
6-10pM and 2pM respectively, notably some 100 fold lower than the concentration 
found here to ‘desensitise’ the receptor(s) (Ito et al., 1992).
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In general, my investigations looking at the time course and dose response 
characteristics of the increase in ERK 1,2 phosphorylation levels with DHPG, found a 
pattern of response different to that observed with the desensitisation of the DAG 
response reported previously (Herrero et al., 1994). When synaptosomes were 
incubated for 10 minutes with 5mins 30sec in the presence of DHPG, the first signs of 
significant increase in the level of ERK 1,2 phosphorylation was obtained with InM 
DHPG. A similar level of increase in ERK 1,2 phosphorylation was still present with 
IOOjjM DHPG, despite having increased the drug concentration by 105 fold, suggesting 
that the ERK 1,2 response was certainly not diminishing with increasing concentration 
of agonist. When the incubation length with DHPG was increased to 10 mins, lOOnM 
and lpM  DHPG were no longer able to significantly increase ERK 1,2 phosphorylation 
levels. This could be construed as a desensitisation effect (Rodriguez-Moreno et al., 
1998; Gereau and Heinemann, 1998), but a higher concentration of IOjjM DHPG was 
still able to significantly enhance levels of ERK 1,2 phosphorylation. These 
observations, suggesting that higher concentrations of DHPG are required to elicit 
increases in ERK 1,2 phosphorylation with increasing incubation times, are features 
contrary to conventional notions of desensitisation.
Underlying this unorthodox behaviour may be the presence of multiple convergent 
pathways with different characteristics. This lack of correlation between the time 
course of activation of DAG production by DHPG and of ERK 1,2 phosphorylation has, 
for example, also been reported in a study conducted in astrocytes (Peavy et al., 2002). 
In this study, mGluR5 activation was found to lead to increases in ERK 1,2 
phosphorylation through a pathway dependent on Gaq, but completely independent of 
Gpy regulation and PLCpi activation of PKC. Interestingly, this implied presence of 
two separate signalling pathways downstream of mGluR5 activation was also coupled 
with observations of unusual receptor desensitisation behaviour, in that the increase in 
ERK 1,2 activation in the continued presence of the Group I mGluR agonist, only 
diminished over periods extending to an hour. These types of observations suggest that 
experiments with lengthened incubation periods are warranted, to fully investigate any 
potential desensitisation of DHPG-induced increases in ERK 1,2 phosphorylation in 
synaptosomes.
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Although the matter of desensitisation of the ERK 1,2 pathway downstream of Group I 
mGluR activation remains to be fully resolved, it is notable from the foregoing results 
and discussion that the levels of ERK 1,2 phosphorylation obtained in the presence of 
DHPG are evidently dependent on the incubation protocol and concentration of the drug 
used. Accordingly, my subsequent discussion of signalling pathways will be divided to 
assess separately effects found with a short 10 minute incubation, and those found 
following a preincubation protocol.
Group I mGluR Signalling to ERK 1,2: Role of PKC and Intrasynaptosomal Ca2+.
Following on from the basic observations discussed above, my subsequent experiments 
related to investigating the nature of the pathway involved in signalling between the 
Group I mGluRs and ERK. Given that the facilitatory effects of Group I mGluRs in 
nerve terminals (Sistiaga and Sanchez-Prieto, 2000b), as well as the signalling to ERK
1.2 in other systems (Peavy and Conn, 1998), have been attributed to mGluR5 
activation, I examined the involvement of this receptor subtype in the activation of ERK
1.2 in nerve terminals, using the non-competitive antagonist MPEP. Downstream of 
Group I mGluR activation, the stimulation of PKC has also been well documented (Pin
• • 94-and Duvoism, 1995, review), as has the release of intracellular stores of Ca . The 
relative contributions of these limbs of signalling, found downstream of 
PLCp activation, to the Group I mGluR-mediated regulation of ERK 1,2 activation in 
nerve terminals was also assessed.
Group I metabotropic glutamate receptors contain a large N-terminal extracellular 
domain (ECD) consisting of two lobes which are able to exist in an open or closed 
conformation. The glutamate binding pocket is located in the hinge region in between 
the two lobes, and glutamate binding is believed to stabilise the ECD in the closed 
conformation and bring about activation of the receptor (Kunishima et al., 2000). 
Competitive antagonists are thought to bind at the same site as glutamate but not bring 
about the conformational changes and stabilisation of the receptor, resulting in the 
inhibition of activation. Non-competitive antagonists such as MPEP, however, are 
believed to act at the seven transmembrane domain (7TMD) of Group I mGluRs, to 
stabilise the conformation of this domain in an inactive state (Pagano et al., 2000; 
Malherbe et al., 2003). In the current study, MPEP effectively eliminated the agonist-
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induced stimulation of ERK 1,2 activity, by presumably blocking transduction of 
signalling at the level of the 7TMD. However, additionally, the antagonist displayed 
agonist properties in causing ERK 1,2 activation by itself. Recent evidence has come to 
light which suggests that the 7TMD of mGluRl and mGluR5 can be activated 
independently of agonist stimulation of the ECD (Ango et al., 2001; Goudet et al.,
2004). Group I mGluRs have been found to be able to display a constitutive activity in 
heterologous cells which can only be attenuated by non-competitive antagonists, such as 
MPEP and BAY36-760, acting at the 7TMD, and not by competitive antagonists acting 
at the ECD. This has also led to the classification of MPEP as an inverse agonist (see 
(Gasparini et al., 2002, for review). However, with MPEP acting in this mode, if 
anything, the activity of ERK 1,2 might have been expected to have been diminished 
rather than enhanced in the manner observed here. Rationalization of this unexpected 
behaviour of MPEP may nonetheless be forthcoming with consideration of activation of 
multiple mGluRs in the system.
mGluRl and mGluR5 have been found to coexist in many neuronal preparations, 
including striatal cholinergic intemeurones (Pisani et al., 2001), type II globus pallidus 
neurones (Poisik et al., 2003), dorsal horn neurones (Karim et al., 2001), and CA1 
pyramidal cells (Mannaioni et al., 2001; Ireland and Abraham, 2002). A recent study in 
type II globus pallidus neurones has proposed the existence of a modulating pathway 
between these two receptors, whereby, the constitutive activity of mGluR5 was 
suggested to be resulting in the tonic inhibition of mGluRl through a PKC-mediated 
mechanism (Poisik et al., 2003). These findings could help explain the results I 
obtained showing a significant increase in ERK 1,2 phosphorylation levels in the 
presence of MPEP following the 10 minute incubation protocol. Thus, if MPEP, as an 
inverse agonist, attenuates the constitutive activity of the mGluR5 receptor, it would 
relieve inhibition of mGluRl receptor activity and result in increased downstream ERK
1,2 activation. Such a mechanism is also consistent with the finding that treatment with 
MPEP alone is able to increase glutamate release in the medial vestibular nuclei of rat 
brainstem slices (Grassi et al., 2002).
The above discussion regarding the tonic inhibition of mGluRl by mGluR5 mediated 
through a PKC-dependent pathway may also be relevant in synaptosomes, when 
considering the effects of PKC inhibitors. Of note in this regard was my observation of
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the ability of the PKC inhibitor, Ro-32-0432, to increase ERK 1,2 phosphorylation 
levels on its own. Ro-32-0432 has, in fact, been shown to inhibit G-protein receptor 
kinase (GRK) activity of GRK5 (Moore and et al., 1998). In transfected HEK-293 
cells, GRK5 has been shown to be able to mediate mGluRl a desensitisation and 
internalisation (Dale et al., 2000). The observations with Ro-32-0432 appear therefore 
to parallel those obtained with MPEP, in that it is a relief of the tonic inhibition of 
mGluRl that is resulting in increased stimulation of ERK 1,2 phosphorylation through 
this receptor type in cerebrocortical synaptosomes.
Notwithstanding the aforementioned discussion, it is possible that the increases in 
MAPK phosphorylation found with treatment of synaptosomes with MPEP are due to 
non-specific actions of the drugs, rather than inhibition of the constitutive activation of 
mGluR5. Although, MPEP has been shown to inhibit the noradrenaline transporter in 
transfected cells, and to increase noradrenaline-mediated effects in vivo (Heidbreder et 
al., 2003), it does not, however, appear to have any effect on excitatory amino acid 
uptake (Fazal et al., 2003). At the receptor level, there are also suggestions that MPEP 
may be a positive allosteric modulator of mGluR4 in transfected cell lines (Mathiesen et 
al., 2003). This begs the use of newer non-competitive mGluR5 antagonists to 
authenticate or refute the finding here with MPEP. The effects of MPEP would also 
bear comparison with the effects of a selective competitive mGluR5 antagonist, 
LY34454, which should not regulate the constitutive activity of the receptor (Gasparini 
et al., 2002). Finally, it would be essential to try and elucidate on the relative 
contributions of mGluR 1 and mGluR5 in DHPG-induced ERK 1,2 phosphorylation. 
CPCCOEt is a non-competitive mGluRl antagonist which inhibits agonist-induced 
activation, but not constitutive activation, through inhibition of the interaction between 
the ECD and 7TMD (Pagano et al., 2000). This antagonist, together with another, 
BAY36-7620, which acts as a selective mGluRl inverse agonist (Carroll et al., 2001), 
may be useful in investigating the role of the constitutive activity of mGluRl in 
signalling to ERK 1,2.
Signalling Pathways Linking mGluR Stimulation with ERK 1,2 Activation.
Group I mGluRs have been shown to dynamically couple to different G-protein 
subunits and in doing so, regulate different downstream signalling pathways (De Blasi 
et al., 2001). It is possible that relief of inhibition of the 7TMD of the receptors,
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combined with stimulation of the ECD by DHPG, switches the downstream coupling of 
the receptors to pathways not involving ERK 1,2. There is precedent for a switch in the 
control of glutamate release from nerve terminals following repeated exposure of Group 
I mGluRs to their agonist (Herrero et al., 1998). There is also evidence that Group I 
mGluR downstream signalling through PLC can be selectively desensitised by 
phosphorylation, whilst leaving signalling through cAMP intact (Francesconi and 
Duvoisin, 2000). Considering that coupling to Gq, Gi/o and Gs have all been shown to 
signal to ERK 1,2 in hippocampal neurones (Berkeley and Levey, 2003), the key 
question here is which particular signalling pathway(s) mediate the enhancement of 
ERK 1,2 phosphorylation in nerve terminal in response to DHPG. Given the known 
facilitatory effects of Group I mGluRs through a Gq mediated stimulation of PLCP to 
produce the DAG and IP3, the respective roles of the targets of these second
1
messengers, i.e. PKC and Ca stores, were examined.
Involvement of PKC.
Using the PKC inhibitors, calphostin C and Ro-32-0432, it has not been possible to 
absolutely confirm or refute PKC-mediated regulation of increases in ERK 1,2 
phosphorylation downstream of Group I mGluR activation. Both calphostin and Ro-32- 
0432 per se actually produced ERK 1,2 activation themselves, although the latter did 
also inhibit the DHPG stimulation. As discussed in chapter 5, a major contributory 
factor to the complicated picture produced with inhibitor studies is likely the lack of 
complete specificity of the agents. Additionally, however, given the multiple roles of 
the enzyme in nerve, effects of inhibitors on the basal activity of the kinase would tend 
to confound interpretation.
In lieu of further studies to address the role of PKC in ERK 1,2 signalling, of note are 
several studies reporting a PKC-independence to the ERK 1,2 signalling downstream of 
Group I mGluRs, in a variety of systems, including, cortical astrocytes (Peavy et al., 
2002), neostriatal slices (Tanaka and Nishizaki, 2003), and Chinese hamster ovary 
(CHO) cell lines (Thandi et al., 2002). Considering the diversity of messages involved 
within Group I mGluR signalling, other than DAG/PKC, a number of regulators 
including cAMP/PKA, PI3K and Ca2+, could be involved (Gutkind, 2000, review). I
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examined the last of these as a potential product of mGluR activation following PLC 
activation and the IP3 generation.
Involvement of Intrasynaptosomal Ca2+
Results presented here suggest that the while about 50% of the basal ERK 1,2 activity
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seen in nerve terminals seems to be supported by extracellular Ca (external EGTA 
sensitive), the DHPG-mediated increase in ERK 1,2 phosphorylation, following a 
preincubation protocol, appears to be entirely dependent on intracellular Ca (internal 
BAPTA sensitive). This suggests that, at least under these particular conditions, 
signalling between Group I mGluRs and ERK 1,2 is not occurring through DAG 
stimulation of a Ras-guanine nucleotide exchange factor (Ebinu et al., 1998). While it 
is possible that the observed enhancement of MAPK activation is occurring through a 
conventional PKC isoform, which requires Ca2+ for activation (Hug and Sarre, 1993), 
the lack of attenuation of the DHPG-mediated increase in ERK 1,2 phosphorylation by 
the PKC inhibitor, calphostin C, suggests that this may not be the case (although see 
caveats discussed above). The question remains then as to the mechanism by which 
Ca2+ mediates the stimulation of ERK 1,2. Potential crosstalk to the cAMP/PKA 
pathway is possible through the stimulation of Ca /calmodulin sensitive isoforms of 
adenylate cyclase (Hurley, 1999). Linking into the Ras-cascade for ERK 1,2 activation 
is also possible through the activation of Ca2+ -sensitive non-receptor tyrosine kinases 
(nRTK) such as src. Given the recent co-localization of PI3K with synapsin I in nerve
0-4-terminal (Cousin et al., 2003), PI3K may form another segway between Ca and ERK
1,2 activation. Further experiments are clearly warranted to assess this potential 
involvement and contribution of cAMP, nRTKs or PI3K to the Ca -mediated activation 
of MAPK in cerebrocortical nerve terminals reported herein.
Synapsin I: a Target for an mGluR/ERK 1,2 Signalling Cascade.
Having identified the presence of a MAPK signalling cascade downstream of Group I 
mGluR activation in cerebrocortical synaptosomes, in the subsequent experiments 
conducted I went on to investigate whether this cascade could be signalling through 
synapsin I in order to regulate glutamate release, as described with a neurotrophin- 
mediated pathway (Jovanovic et al., 2000).
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Despite the clear effect of DHPG on ERK 1,2 activation, the agonist was unable to 
either enhance levels of 4-AP-elicited glutamate release under these conditions, or to 
increase synapsin site 4/5 phosphorylation. The lack of net increase in site 4/5 synapsin 
I phosphorylation levels is not necessarily a surprise as Group I mGluRs are known to 
increase production of IP3, which in turn can increase internal Ca concentrations 
through release from internal stores (Murphy and Miller, 1988; Dale et al., 2001). The 
increase in Ca2+ concentration can lead to the activation of the phosphatase calcineurin, 
which is known to dephosphorylate synapsin I at site 4/5, counteracting the increase in 
phosphorylation by ERK 1,2 (Jovanovic et al., 2001). This role of Ca2+ in determining 
the level of synapsin I phosphorylation at ERK 1,2 sites was evident from dramatic 
increases in synapsin I site 4/5 phosphorylation levels I obtained following the removal 
of Ca2+ from the experimental media using EGTA. It could therefore be postulated that, 
although Group I mGluRs are signalling through ERK 1,2, opposing or contradicting 
signals at the level of synapsin I prevent significant increases in phosphorylation of this 
protein, thus preventing increases in vesicle availability to support the facilitation of 
glutamate release.
Notwithstanding the postulated requirement for AA and for mGluR-mediated regulation 
of glutamate release, some studies have indeed found that DHPG is able to increase 
glutamate release without the need for exogenous AA (Reid et al., 1999). These 
differences in opinion could be consolidated in two ways: either that endogenous AA 
contributes in studies where no exogenous AA has been added (Thomas et al., 2000), or 
that modulation of release is not simply contingent on the presence of AA, but also 
determined by other factors including the Ca2+ concentrations of the preparation. With 
regard to the latter, as already discussed above, synapsin site 4/5 phosphorylation levels 
are highly regulated by Ca2+, due to the activation of the Ca2+-dependent phosphatase, 
calcineurin (Jovanovic et al., 2001). Thus, it could be that in preparations where no
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exogenous AA is required, basal Ca levels are lower, and as such, affect lower levels 
of calcineurin-mediated synapsin I site 4/5 dephosphorylation and thereby promote 
facilitation of release. This hypothesis is in agreement with studies conducted in 
cerebrocortical synaptosomes which found that protein phosphatase 2B inhibitors 
(inhibitors of calcineurin) were able to mimic the action of AA on Group I mGluR- 
mediated increases in glutamate release (Sistiaga and Sanchez-Prieto, 2000b). Clearly, 
further experimentation is necessary to support this hypothesis. This would include
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looking at ERK 1,2 and synapsin I phosphorylation levels in the presence of AA, as it is 
possible that AA is acting via several alternative mechanism to increase glutamate 
release, including increasing the activation of neuromodulin, a protein involved in the 
exocytotic machinery (Schaechter and Benowitz, 1993). With respect to the novel 
finding here that a Ca2+ dependent activation of ERK 1,2 can be affected by DHPG
• o iinduced increases in intracellular Ca , it is essential to establish that the lack of 
significant increase in synapsin I phosphorylation is indeed due to an opposing Ca2+ 
dependent dephosphorylation tone. This could be done by testing in detail the effects of 
FK506, a calcineurin inhibitor, on Group I mGluR-mediated phosphorylation of 
downstream signalling molecules and modulation of neurotransmitter release.
The identification of neurotrophin (BDNF)-mediated and GPCR-mediated (Group I 
mGluR) signalling operating on the same pool of ERK 1,2 in co-stimulation 
experiments, suggests these pathways coexist in the same presynaptic, glutamatergic 
nerve terminals It would be interesting to investigate the relative contributions of 
these pathways and whether signalling through one can influcence the nature of the 
signalling through the other.
This chapter has found that ERK 1,2 can be activated downstream of presynaptic Group 
I mGluR stimulation, but the pathways involved are complex and subject to regulation 
from multiple sources. It has not been possible, thus far, to confirm ERK 1,2 and 
synapsin I involvement in Group I mGluR-mediated increases in glutamate release from 
presynaptic nerve terminals although the indications are promising. The current work 
has invoked a number of further experiments which will be key to fully elucidating and 
detailing the mechanisms involved in regulating glutamate release downstream of 
presynaptic Group I mGluR activation.
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7. Discussion
The protein kinases, ERK 1 and ERK 2, have been shown to be involved in many 
aspects of cell signalling, depending on cell type and situation (Gutkind, 2000). They 
were originally identified in mammalian cells as molecules involved in mediating the 
mitogenic effects of growth factors (Cooper and Hunter, 1983; Cooper and Hunter, 
1981), and later in the decade as activities stimulated by insulin or various growth 
factors, that were able to phosphorylate the model substrates microtubule-associated 
protein 2 (MAP2) and myelin basic protein (MBP) (Ray and Sturgill, 1987; Hoshi et al., 
1988; Hoshi et al., 1989). Numerous subsequent studies have suggested a central 
involvement of ERK1 and 2 in the regulation of cell proliferation through the transfer of 
signals from the cytosol to the nucleus, with constitutive activation of the pathway 
resulting in tumerogenesis (Pages et al., 1993; Mansour et al., 1994). Since then, work 
in mature neurones has also shown ERK1 and 2 to have major roles in conducting 
signals between the cytoplasm and nucleus in the regulation of synaptic plasticity, 
particularly at the level of the postsynaptic compartment (Sweatt, 2004; Thomas and 
Huganir, 2004). The majority of this latter work has focused on the hippocampus, an 
area of the brain where synaptic plasticity has been hypothesised to underlie the 
formation of memories (Sweatt, 2004; Malenka and Nicoll, 1999), but further roles for 
ERK 1,2 signalling are beginning to be uncovered in areas such as the dorsal root 
ganglia (Obata et al., 2003) and the striatum (Sanna et al., 2002). As research 
progresses into this postsynaptic ERK activation/phosphorylation, more and more 
upstream regulators are being identified, including PKA, PKC and Ca , amongst others 
(Roberson et al., 1999; Thomas and Huganir, 2004). Considering these established 
notions concerning postsynaptic signalling, the work in this thesis investigated whether 
the cross-talk of signalling cascades with ERK 1,2 could also occur presynaptically, 
using the isolated presynaptic nerve terminal preparation.
The purified presynaptic nerve terminal (synaptosome) is obtained by using 
homogenisation to ‘pinch o ff presynaptic terminals from axons, followed by 
purification of the former using Percoll gradients (Sihra, 1997; Dunkley et al., 1986). 
Synaptosomes prepared in this manner have been shown to have intact membranes 
containing mitochondria and numerous small synaptic vesicles (Maycox et al., 1990).
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• • • 2*j-They are also functionally competent, and able to undergo depolarisation-induced Ca - 
dependent release of neurotransmitter (Sanchez-Prieto et al., 1987). The absence of 
postsynaptic domains, cell somas and nuclei from this preparation are advantageous for 
the examination of the functioning of the presynaptic nerve terminals in isolation, 
eliminating the complications arising from nuclear signalling pathways and postsynaptic 
events which could confound results (Maycox et al., 1990). A recent study, using this 
preparation, has identified a role for ERK 1,2 phosphorylation in enhancing glutamate 
release, downstream of TrkB receptor activation by BDNF (Jovanovic et al., 2000). A 
downstream effector for ERK 1,2 signalling, in this presynaptic preparation, was 
identified as synapsin I, a synaptic vesicle tethering protein involved in regulating 
synaptic vesicle availability (Hilfiker et al., 1999). Could it be that signalling molecules 
that were cross-talking with ERK 1,2 in the postsynaptic domain, could also be cross- 
talking in the presynaptic terminal, with a possible functional role in the regulation of 
glutamate release? If so, could the receptors upstream of these signalling cascades, also 
be identified? This study, has indeed, found that ERK 1,2 activation/phosphorylation is 
a highly regulated phenomenon in presynaptic cerebrocortical nerve terminals, 
integrating multiple signalling cascades involved in regulating glutamate release.
An apparent plethora of signals involved in regulating ERK 1,2 activation in 
cerebrocortical nerve terminals that has been unearthed in this thesis, has complicated 
the unambiguous dissection of interacting pathways. Nevertheless, I have found that
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PKA and Ca , and possibly PKC, are all able to regulate ERK 1,2 phosphorylation 
levels in presynaptic nerve terminals, in a manner dependent on time and incubation 
protocol. In the subsequent sections these pathways are discussed depending on their 
temporal activity, with those affecting basal ERK 1,2 activation levels discussed first, 
followed by acute factors working on top of basal levels, and then pathways which are 
demonstrating tonic cross-talk activity.
Factors Regulating Basal ERK1,2 Phosphorylation
The first temporal delineation made was in examining the regulation of ERK 1,2 
activation/phosphorylation with the exogenous application of receptor antagonists in the 
absence of exogenous agonists. The scientific rationale for this work was to elucidate 
on the involvement of constitutive receptor activity on the basal levels of ERK 1,2 
activation. It was interesting to observe that both p-adrenoceptor inhibition and
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mGluR5 inhibition resulted in the modulation of basal levels of ERK 1,2 activation, 
albeit in opposite directions. I found that basal levels of ERK 1,2 activation were 
reduced following treatment of synaptosomes with the p-adrenoceptor antagonist, 
propranolol, or with the PKA inhibitors, H-89 and KT-5720. This evidence, combined 
with the attenuation of the p-adrenoceptor agonist, isoproterenol, mediated stimulation 
of ERK 1,2 phosphorylation in the presence of PKA inhibitors or p-adrenoceptor 
antagonists, suggests that, in cerebrocortical synaptosomes at least, endogenous 
activation of p-adrenoceptors contributes to the basal levels of ERK 1,2 activation via 
PKA (Figure 7.1). These results are in agreement with other studies which have 
identified inverse agonist properties for propranolol, leading to the inhibition of cAMP 
production (Chidiac et al., 1994; Baker et al., 2003), and with those which have 
demonstrated that p-adrenoceptor stimulation can lead to a PKA-dependent increase in 
ERK 1,2 phosphorylation (Roberson et al., 1999; Schmitt and Stork, 2000). However, 
some of these studies have also suggested that propranolol can act as a dual efficacy 
ligand and stimulate ERK 1,2 activity through a mechanism independent of G-protein 
coupling (Azzi et al., 2003; Baker et al., 2003). It seems unlikely that propranolol is 
acting as a dual efficacy ligand in cerebrocortical synaptosomes as I have shown a 
decrease in ERK 1,2 activation with propranolol and not an increase.
There are several factors within my preparation that could be leading to the observed 
basal activity of P-adrenoceptors. The first is a constitutive activity of the 7- 
transmembrane spanning domain (7-TMD) in the absence of ligand binding to the 
extracellular domain (ECD), recently hypothesised to be a common property of GPCRs 
(Malherbe et al., 2003). The second is that endogenously released/leaked noradrenaline 
from the heterogenous population of synaptosomes is acting as an agonist at the p- 
adrenoceptors. Although the dilution of synaptosomes used in my preparation should 
be such that endogenous ligand cross-talk is kept to a minimum, this looks to be the 
likely explanation for the results I have obtained for ERK 1,2 activation downstream of 
P-adrenoceptors. The reason for this is that the effects downstream of constitutively 
active 7-TMDs are often found to differ from those obtained following agonist 
stimulation (Poisik et al., 2003), whereas I have found a consistent stimulation of ERK
1,2 activation, whether mediated downstream of endogenous activity of the P- 
adrenoceptor or through the exogenous application of an agonist. If this pathway is
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Figure 7.1 Schematic Diagram Illustrating the Possible Pathways, Identified in this 
Thesis, that May be Partly Involved in Controlling Basal Levels of ERK 1,2 
Phosphorylation/Activation in Cerebrocortical Nerve Terminals. Endogenous 
activation of P-adrenoceptors appears to be partially responsible for basal ERK 1,2 
stimulation, via a PKA-dependent pathway. Endogenous activation of mGluR5 appears 
to inhibit mGluR 1 -mediated signalling to ERK 1,2. However, the dependence of this 
signalling pathway on glutamate is yet to be determined. Abbreviations: AC = 
adenylate cyclase, ATP = adenosine triphosphate, cyclicAMP = cyclic adenosine 
monophosphate, PKA = cAMP-dependent protein kinase, ERK 1,2 = extracellular 
signal-regulated protein kinase 1,2, mGluR 1 or 5 = metabotropic glutamate receptor 1 
or 5, ECD = extracellular domain, PLC = phospholipase C, PIP2 = 
phosphatidylinositol-4,5-bisphosphate, DAG = diacylglycerol, IP3 = inositol-1,4,5- 
triphosphate. Pink/Red = stimulatory pathways, Blue = inhibitory pathways.
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being activated by endogenously released/leaked noradrenaline, this increases its 
physiological relevance with regards to the endogenous regulation of ERK 1,2 
activation. However, further experiments would be needed to be conducted to confirm 
this hypothesis, in particular, the addition of a different competitive p-adrenoceptor 
agonist, which should also inhibit downstream ERK 1,2 activation if it was mediated by 
agonist stimulaton of the receptor, but not if the ERK 1,2 activation was due to a basal 
constitutive activity of the 7TMD of the receptor.
Contrary to the p-adrenoceptor antagonist-mediated inhibition of basal levels ERK 1,2 
activation, I found that application of the mGluR5 antagonist, MPEP, enhanced basal 
levels of ERK 1,2 activation. This was particularly intriguing considering that addition 
of the joint mGluRl and mGluR5 agonist, DHPG, also stimulated ERK 1,2 activation, 
whereas application of the two drugs together resulted in no increase in ERK 1,2 
activation in my system. Other studies have shown that MPEP can also act as a positive 
allosteric modulator at mGluR4 receptors which are negatively coupled, through Gi, to 
adenylate cyclase (Mathiesen et al., 2003). Although this MPEP-mediated stimulation 
of mGluR4 may be occurring in synaptosomes, this is unlikely to account for the 
observed enhancement in ERK 1,2 activation, especially considering that I have also 
shown that stimulation of adenylate cyclase enhances ERK 1,2 phosphorylation. As 
discussed in Chapter 6, a possible explanation for the stimulatory effect of MPEP on 
downstream ERK 1,2 activation is that mGluRl is tonically inhibited by mGluR5, 
leading to the attenuation of mGluRl-mediated stimulation of ERK 1,2 phosphorylation 
(see Figure 7.1). This is supported by recent studies which have found that the 7TMD 
portion of the Group I mGluRs may be ‘active’ in the absence of external glutamate 
binding to the extracellular domain (Gasparini et al., 2002; Malherbe et al., 2003). It 
would be interesting to investigate whether the proposed inhibition of mGluRl 
signalling to ERK 1,2 seen here, is as a result of extracellular glutamate binding to 
mGluR5, or of its constitutive activity. It may be possible to further examine this 
phenomenon by utilising the chemical components of the glutamate release assay. The 
addition of the enzyme GDH with NADP would metabolise any ‘leaked’ glutamate 
present in the preparation, therefore allowing the examination of this pathway in the 
absence of any endogenous glutamate-mediated activation of mGluR5. Basal effects of 
the PKC inhibitors were also observed on ERK 1,2 phosphorylation levels however, the
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two inhibitors used, calphostin C and Ro-32-0432, are not entirely specific and had 
opposing effects on ERK 1,2 activation, meaning it was not possible to attribute a 
particular function to PKC (Davies et al., 2000).
The signalling pathways shown to regulate basal ERK 1,2 phosphorylation levels in 
cerebrocortical synaptosomes have been illustrated in Figure 7.1. It should be noted 
that the purified synaptosomes consist of a heterogenous population of presynaptic 
nerve terminals, with only global levels of ERK 1,2 phosphorylation being measured. 
This means that, although represented on the same diagram, these pathways may or may 
not be present within the same nerve terminal.
Factors Regulating Acute ERK1,2 Phosphorylation.
The next section in this discussion examines the signalling pathways involved in 
regulating ERK 1,2 activation/phosphorylation following the application of exogenous 
ligands (Figure 7.2). Again, due to the heterogenous nature of the synaptosome 
preparation, it is not yet known whether all these signalling pathways are occurring 
within the same nerve terminal. The results described in the signalling pathways 
labelled 1-3 in Figure 7.2 suggest that there may be more than one method of 
communicating between cAMP and ERK 1,2 in cerebrocortical nerve terminals. In the 
first pathway, I have shown a p-adrenoceptor-mediated enhancement of ERK 1,2 
activation via a PKA-dependent pathway. This is in agreement with some of the studies 
conducted using different preparations, such as in HEK 293 cells and in slices from the 
hippocampal CA1 region (Roberson et al., 1999; Schmitt and Stork, 2000). However, 
other studies have also shown an ability for P-adrenoceptors to stimulate ERK 1,2 
phosphorylation in a manner independent of PKA, through direct activation of a Rapl- 
GEF by cAMP (de Rooij et al., 1998).
Although it is possible that this could be happening in cerebrocortical nerve terminals, I 
believe this is unlikely to be the main pathway mediating ERK 1,2 activation 
downstream of p-adrenoceptor stimulation as I found that two different PKA inhibitors 
were able to attenuate this signalling between p-adrenoceptor and ERK 1,2. Having 
said this, my results also suggest that the majority of the signalling occurring following 
forskolin/IBMX-mediated stimulation of ERK 1,2 phosphorylation is PKA-independent
221
222
Isoproterenol IBMX BDNF DHPG
eForskolin
p- Adrenoceptor Group I mGluRRECEPTOR
▼
Adenosine Ca24 
eye lie AMP eye lie AMP x  j
j, X .  5 AMP
PDBu
DAG + IP3
B-Raf/Raf-1
MEK
ERK1,2
Site 4/5
t, Synapsin I
Figure 7.2 Schematic Diagram Illustrating the Possible Pathways Involved in Stimulating ERK 1,2 Activation/ 
Phosphorylation in Cerebrocortical Nerve Terminals. Abbreviations: AC = adenylate cyclase, cyclicAMP = cyclic 
adenosine monophosphate, PKA = cAMP-dependent protein kinase, PDE = phosphodiesterase, 5 ’AMP = 5 ’adenosine 
monophosphate, ERK = extracellular signal-regulated protein kinase, MEK = ERK kinase, PIP2 = phosphatidylinositol 
-4,5-bisphosphate, DAG = diacylglycerol, IP3 = inositol-1,4,5-triphosphate, PKC = protein kinase C, BDNF = brain- 
derived neurotrophic factor, PD Bu= phorbol 12,13 dibutyrate , IBMX = 3 - isobutyl- 1-methylxanthine. Blue = 
inhibitory pathways, pink/red = stimulatory influences.
(Figure 7.2 pathways 2 and 3). This supports evidence from other laboratories that have 
found both PKA-dependent and -independent aspects to ERK 1,2 signalling 
downstream of AC activation (Ambrosini et al., 2000; Troadec et al., 2002; Baldassa et 
al., 2003; Lin et al., 2003). Though it is also possible that IBMX-mediated inhibition of
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adenosine A l receptors is leading to disinhibition of Ca channels, resulting in a Ca - 
dependent increase in ERK 1,2 phosphorylation. Postsynaptic studies have 
demonstrated a clear dependency of ERK 1,2 signalling on extracellular Ca2+ (Rosen et 
al., 1994; Walker et al., 2003; Orban et al., 1999), and I have also shown a tonic 
regulation of ERK 1,2 by extracellular Ca2+, suggesting the involvement of Ca2+ influx 
via Ca2+ channels. Further experiments are needed to delineate this PKA-independent 
component ERK 1,2 signalling, to identify the upstream receptors and to dissect the 
specific involvement of phosphodiesterase inhibition versus adenosine A l receptor 
inhibition by IBMX. However, these results suggest that there are more, as yet 
unidentified, receptor signalling cascades involved in regulating ERK 1,2 
phosphorylation levels in cerebrocortical nerve terminals. They also support the 
hypothesis that ERK 1,2 activation in cerebrocortical nerve terminals is a highly 
regulated process. It would also be interesting to investigate whether other receptor- 
linked PKA-dependent signalling pathways can also regulate ERK 1,2 phosphorylation 
in cerebrocortical nerve terminals, such as the Group II mGluRs (Huang et al., 1999).
The PKC signalling cascade has been shown to have many roles in the presynaptic 
regulation of glutamate release (Cousin et al., 1999; Berglund et al., 2002), as well as to 
be able to regulate signalling to ERK 1,2 in various systems (Roberson et al., 1999; Gao 
et al., 1999; Sundaresan et al., 1996). However, the studies conducted in this thesis 
were inconclusive with regards to PKC-dependency o f ERK 1,2 phosphorylation in 
cerebrocortical nerve terminals. Nevertheless, both phorbol esters and Group I mGluR 
agonists, commonly found to stimulate PKC activation, were able to stimulate ERK 1,2 
phosphorylation (Figure 7.2, pathways 5 and 6). Notwithstanding, it remains possible 
that the phorbol ester-mediated stimulation of ERK 1,2 is occurring through the 
activation of a DAG-dependent RasGEF (Lorenzo et al., 2000), and that Group I
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mGluR-mediated stimulation of ERK 1,2 is occurring through the activation of a Ca - 
dependent RasGEF (Farnsworth et al., 1995), especially considering the results obtained 
using the preincubation protocol (Figure 7.3). A potential method for clarifying the role 
of PKC in these situations would be to use another PKC inhibitor (Davies et al., 2000).
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Although the PKC inhibitors that have been used so far, and those that are currently 
available for use with short incubation protocols, are not necessarily completely 
specific, the use of a combination of inhibitors that function through different 
mechanisms could help to elucidate on the role of PKC in this system. For example, 
comparing the effects of the catalytic subunit inhibitors, Ro-32-0432 and calphostin C, 
with the effects of a regulatory subunit inhibitor, such as NPC 15437, could lead to the 
identification of common, and thus likely PKC-dependent, functions (Sullivan et al., 
1992; Davies et al., 2000).
As mentioned above, purified cerebrocortical synaptosomes consist of a heterogenous 
population of nerve terminals. One possible method for identifying the proximity of 
signalling pathways in this system is through the use of additivity studies, in which 
signals utilising the same pool of ERK 1,2 will not have additive effects on ERK 1,2 
phosphorylation when activated in parallel. The TrkB receptor-mediated signalling to 
ERK 1,2 (Figure 7.2, pathway 4) has already been identified as a pathway active in 
glutamatergic nerve terminals (Jovanovic et al., 2000), but was used here as a method of 
clarifying the location of p-adrenoceptor and Group I mGluR signalling to ERK 1,2. 
Additivity studies conducted in chapter 4 and in chapter 6 suggest that signalling from 
TrkB receptors and p-adrenoceptors regulates the same population of ERK 1,2, and that 
signalling from Group I mGluRs and TrkB receptors also regulates the same population 
of ERK 1,2. However, this cannot be extrapolated to say that p-adrenoceptors and 
Group I mGluRs signal to the same population of ERK 1,2, as the possibility that they 
may regulate different subsets of the TrkB regulated ‘pool’ has not been ruled out. It 
would be interesting to investigate whether these two receptors are able to cross-talk 
with the population of ERK 1,2 in cerebrocortical nerve terminals.
Forskolin/IBMX, isoproterenol, PDBu, and DHPG were all shown to enhance ERK 1,2 
phosphorylation levels in cerebrocortical synaptosomes. The functional relevance of 
these signalling pathways was, in part, elucidated by examining a presynaptic 
downstream effector for ERK 1,2 signalling, synapsin I. Although, increases in ERK
1,2 phosphorylation did not always correlate with the enhancement of glutamate release 
from cerebrocortical nerve terminals, increases in the synapsin I phosphorylation sites 
regulated by ERK 1,2, did. It was interesting to observe that, although treatment with
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DHPG enhanced ERK 1,2 phosphorylation levels, it did not enhance downstream 
synapsin I phosphorylation, which was correlated with a lack of effect of DHPG in the 
modulation of glutamate release. This was suggested from current results to be due to 
DHPG-induced increases in intracellular Ca2+ concentration leading to increases in 
Ca2+-dependent phosphatase activity at the synapsin I phosphorylation site stimulated 
by ERK 1,2. The correlation of synapsin I phosphorylation levels at the site regulated 
by ERK 1,2, with the modulation of glutamate release from cerebrocortical nerve 
terminals, suggests that the functional importance of this signalling pathway may lie in 
regulation of the availability of glutamate-containing synaptic vesicle for release 
(Hilfiker et al., 1999). Although levels of ERK 1,2 phosphorylation seem to give a 
fairly good indication of a drugs ability to regulate glutamate release independently of 
Ca2+ channel regulation, they are not definitive, due to the opposing effects of 
phosphatases on site 4/5 synapsin I phosphorylation (Jovanovic et al., 2001). Further 
evidence for the involvement of ERK 1,2 in the regulation of glutamate release from 
nerve terminals has come from preliminary experiments that I have conducted. Results 
have shown that the cannabinoid receptor agonist, WIN 55,212-2, can not only decrease 
glutamate release from purified cerebrocortical nerve terminals, but can also decrease 
ERK 1,2 phosphorylation levels. This is interesting as it suggests that the proposed 
regulation of glutamate release by ERK 1,2 can be bidirectional, assuming a certain 
basal level of phosphorylation is present.
The working hypothesis that ERK 1,2 phosphorylation of site 4/5 on synapsin I, 
combined with the dephosphorylation regulated by calcineurin, contributes to the 
regulation of glutamate release through the tethering of synaptic vesicles, is supported 
by the data obtained in this thesis. However, levels of ERK 1,2 and synapsin I 
phosphorylation have only been correlated with glutamate release, and not directly 
implicated, in these studies. Recent work conducted in other laboratories has identified 
components of the exocytotic machinery that can be directly phosphorylated and 
regulated by PKA (Lonart et al., 2003; Nagy et al., 2004). This begs the question as to 
whether the Ca channel independent regulation of glutamate release mediated by PKA 
and PKC is occurring through direct phosphorylation of the exocytotic machinery, 
rather than through regulation of the tethering of synaptic vesicles by synapsin I. 
Although phosphorylation of RIM la by PKA has been shown to trigger LTP in the 
cerebellar parallel fibre synapse, the overexpression of a construct designed to mimic
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constitutively active RIM la  it was not shown to regulate the EPSP amplitude (Lonart et 
al., 2003), questioning whether this phosphorylation really is sufficient for the induction 
of LTP in this system. PKA has also been shown to phosphorylate SNAP-25a to 
regulate vesicle priming and to possibly regulate the size of the readily releasable pool 
of synaptic vesicle in chromaffin cells (Nagy et al., 2004). However, the variability in 
the requirements for LTP induction and maintenance that has been shown to occur 
between synapses in different regions means that the relative importance of different 
signalling molecules in the modulation of presynaptic plasticity may also be subject to 
spatial regulation (Lonart and Sudhof, 1998). So, the apparent key requirement for 
PKA phosphorylation of RIM la  in cerebellar parallel fibre synapses, or the regulation 
of vesicle pool size by PKA phosphorylation of SNAP-25 in chromaffin cells, may not 
necessarily hold true for cerebrocortical synapses. Having said this, the possibility of 
direct regulation by PKA and PKC on the exocytotic machinery in cerebrocortical 
synaptosomes remains a tenable possibility and the relative contributions of these 
mechanisms, compared to the regulation of synaptic vesicle availability by synapsin I 
remains to be determined. Further experiments need to be conducted to confirm the 
roles of ERK 1,2 and synapsin I in the regulation of glutamate release downstream of (3- 
adrenoceptor activation and phorbol ester treatment. These should perhaps be started by 
investigating the effects of the protein kinase A inhibitors on ionomycin-elicited 
glutamate release, to see if they correlate with the changes in ERK 1,2 phosphorylation 
levels.
The discussion so far has focused on synapsin I phosphorylation downstream of ERK
1,2 activation. However, it is also possible, and even likely, that ERK 1,2 is 
phosphorylating more than one downstream effector in nerve terminals. Studies 
conducted in other labs have suggested that ERK 1,2 can phosphorylate N-type Ca 
channels and in doing so increase the Ca influx into nerve terminals (Fitzgerald,
2002). It would be interesting to examine whether ERK 1,2 can also phosphorylate N- 
type Ca channels in cerebrocortical nerve terminals, as well as to identify whether 
phosphorylation mediated by ERK 1,2 could also be involved in regulating other 
members of the synaptic vesicle exocytosis/endocytosis machinery.
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Figure 7.3 Schematic Diagram Illustrating the Pathways Identified, in this Thesis, that are Involved in Regulating 
Levels of ERK 1,2 Phosphorylation/Activation in Cerebrocortical Nerve Terminals Following P re incubation.
Abbreviations: AC = adenylate cyclase, cyclicAMP = cyclic adenosine monophosphate, ATP = adenosine triphosphate, 
PDE = phosphodiesterase, 5’AMP = 5’adenosine monophosphate, ERK = extracellular signal-regulated protein kinase, 
PIP2 = phosphatidylinosito 1-4,5-bisphosphate, DAG = diacylglycerol, IP3 = inositol-1,4,5-triphosphate, Ca2+ = calcium, 
IBMX = 3-isobutyl- 1-rrethylxanthine, DHPG = dihydroxyphenylglycine. Blue = inhibitory pathways, pink/red = 
stimulatory influences.
Factors Regulating Tonic ERK1,2 Phosphorylation
So far I have been examining the effects of acute cross-talk of signalling pathways. 
However, both p-adrenoceptors and Group I mGluRs have been shown to switch G- 
protein coupling following extended exposure to agonists. Daaka, et al., 1997 showed 
that the Gs-coupled p2-adrenoceptor expressed in HEK 293 cells were phosphorylated 
by PKA in a feedback loop leading to switching of the receptor to Gi-coupling (Daaka 
et al., 1997). In contrast, the typically Gq-coupled Group I mGluRs can be 
phosphorylated by PKC, either in a feedback loop, or through cross-talk with each 
other, resulting in changes in the G-protein coupling (Gereau and Heinemann, 1998; 
Francesconi and Duvoisin, 2000; Poisik et al., 2003). As I have found that both the p- 
adrenoceptor and the Group I mGluRs are able to regulate basal levels of ERK 1,2 
activation in purified cerebrocortical nerve terminals, it begged the question as to 
whether increased exposure to any endogenous ligands would change the nature of the 
exogenous agonist-mediated ERK 1,2 activation, perhaps through the modulation of G- 
protein coupling.
The tonic cross-talking properties of these pathways (as with the preincubation 
protocols) are illustrated in Figure 7.3. An interesting point, highlighted here, is that 
global enhancement of cAMP concentration results in an opposite effect on ERK 1,2 
phosphorylation compared to the supposed localised enhancement following p- 
adrenoceptor stimulation (Figure 7.3, pathways 1 and 2). I found that stimulation of 
synaptosomes with forskolin/IBMX switches from having an acute stimulatory effect on 
ERK 1,2 phosphorylation levels to an inhibitory tonic effect, whereas the tonic p- 
adrenoceptor-mediated stimulation of ERK 1,2 activation remains. These results show 
that p-adrenoceptor signalling to ERK 1,2 in cerebrocortical synaptosomes is not 
subject to temporal regulation within the time points examined, but that the 
forskolin/IBMX-mediated signalling is. Studies conducted in other systems have shown 
that cAMP can regulate ERK 1,2 through more than one signalling pathway 
(Derkinderen et al., 2003; Roberson et al., 1999; Lin et al., 2003), and that PKA 
regulation of ERK 1,2 activation can at times be inhibitory (Konig et al., 2001; Mischak 
et al., 1996). The heterogenous nature of the synaptosome preparation means that these 
signalling pathways may not all be present in the same nerve terminal, and so could be 
dependent on terminal specificity, as has been demonstrated for cell type by Dhillon,
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A.S. et al., (Dhillon et al., 2002). The specific requirements of this ‘switching’ of 
signalling pathways leading to ERK 1,2 regulation need to be examined further to 
determine their PKA- and adenosine-dependency.
The results obtained with the tonic regulation of ERK 1,2 by forskolin/IBMX and p- 
adrenoceptor agonists are in contrast to the phorbol ester and Group I mGluR-mediated 
pathways, which appear to share similar properties regarding their modulation of ERK
1.2 activity. Differences in the temporal regulation of ERK 1,2 activation by 
forskolin/IBMX, has highlighted difficulties with relating results between different 
incubation protocols. So, although the results obtained with Group I mGluR agonists 
and inhibitors of this pathway appear to be consistent between incubation protocols, it is 
perhaps wise to exercise caution in assuming that they really are the same.
Studies conducted using the preincubation protocol have identified roles for
^  I
extracellular Ca , in modulating basal levels of ERK 1,2 phosphorylation, and for 
intracellular Ca , in regulating Group I mGluR signalling to ERK 1,2 (Figure 7.3, 
pathways 3 and 4). It would be interesting to further investigate the locus of the cross­
talk of Ca2+ with the ERK 1,2 signalling cascade. One likely locus for the intracellular 
Ca action is perhaps via a RasGEF, such as RasGRF, which has not only been 
localised to presynaptic nerve terminals, but has also been shown to be involved in 
regulating synaptic plasticity, albeit postsynaptically in this case (Walker et al., 2003). 
As RasGRF knockout mice have been developed (Brambilla et al., 1997), the simplest 
method for elucidating on the RasGRF-dependency of Group I mGluR signalling to
^  I
ERK 1,2 via intracellular Ca stores would be to examine this pathway in 
cerebrocortical nerve terminals from the knockout mice. The Ca2+-dependency of ERK
1.2 activation downstream of Group I mGluR stimulation also provided a mechanism 
for the lack of net change in synapsin I site 4/5 phosphorylation downstream of ERK
i
1.2 activation, as these sites on synapsin I are dephosphorylated by the Ca -dependent 
phosphatase, calcineurin. Experiments using the calcineurin inhibitor, FK506, would be 
needed to confirm the role of this pathway in regulating synapsin I phosphorylation 
downstream of Group I mGluR activation. It would also be interesting to discover at 
what point extracellular Ca is regulating ERK 1,2 basal phosphorylation following a 
preincubation protocol. Considering the ability of p-adrenoceptors to mediate basal
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ERK 1,2 phosphorylation following a standard incubation protocol via a PKA- 
dependent pathway, it is possible that extracellular Ca2+ could be involved in regulating 
the activation of a Ca2+-dependent adenylate cyclase (Mons et al., 1998). Further 
experiments could use the preincubation protocol with BAPTA-AM and EGTA to 
examine the Ca2+-dependency of (3-adrenoceptor signalling to ERK 1,2 in 
cerebrocortical nerve terminals.
Although I have identified (3-adrenoceptors and Group I mGluRs as being upstream of 
ERK 1,2 in cerebrocortical nerve terminals, I have not investigated the specific 
involvement or contribution of Ras and Raf in signalling between these two stages. The 
possible levels through which these signalling cascades could be cross-talking with the 
ERK 1,2 pathway have been discussed in each chapter and so, will not be repeated here. 
However, further elucidation on the levels of interaction could be obtained with future 
experiments using newly developed Raf-1 inhibitors (Lackey et al., 2000) to describe 
whether these receptor-linked signalling cascades require the activation of Raf-1 to 
mediate their stimulation of ERK 1,2 phosphorylation. Investigating the dependency of 
these signalling cascades on Ras activation would be a little more complicated, 
however, as inhibitors are not commonly available. Notwithstanding, it would be 
possible to measure Ras activation in nerve terminals using an immunoprecipitation 
assay, whereby glutathione sepharose beads are primed with Raf binding domains 
which will specifically bind to activated, GTP bound, Ras (de Rooij and Bos, 1997).
In conclusion, the evidence presented in this thesis has identified ERK 1,2 as a highly 
regulated presynaptic nerve terminal protein kinase, with possible roles in regulating 
synaptic transmission. It appears that cross-talk of presynaptic signalling cascades with 
the ERK 1,2 pathway are numerous and are coupled to, though not solely limited to, 
cascades found downstream of p-adrenoceptors or Group I mGluRs. These results 
show that ERK 1,2 is an important presynaptic signalling molecule which, with its 
downstream regulation of synapsin I phosphorylation, has the potential to regulate 
presynaptic plasticity.
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